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ABSTRACT 
Abstract 
New biopolymers are in high demand due to their excellent biocompatibility, biodegradability, 
and natural origin. In this PhD project, water soluble fish sarcoplasmic proteins (FSPs) from the 
North Atlantic cod (Gadus morhua) have been studied as a potential new biopolymer for 
development of nano-micro structures. Two kinds of nano-micro structures have been explored: 
electrospun fibers (Paper I, Paper II, and Paper III) and self-assembled nanocomplexes (NCXs) 
(Paper IV). 
FSP was observed to be highly suitable for electrospinning. The fiber morphology varied 
significantly with FSP concentration, from beads to fibers. Moreover, the morphology within 
one FSP concentration was very diverse, as evident from the fiber diameter ranging from 
nanosized to micronsized (Paper I). The size distribution of the fiber diameter was decreased by 
removal of low molecular weight compounds (< 8 kDa). Despite the water-soluble nature of 
FSP, the fibers were insoluble in aquatic media (except at high sodium dodecyl sulfate 
concentrations) (Paper I, Paper II, and Paper III). Contact angle measurements indicated that the 
FSP fibers were hydrophobic, and incubation with the hydrophobic dye 8-anilino-1-
naphthalenesulfonic acid (ANS), confirmed the presence of hydrophobic pockets inside or at the 
surface of the fibers (Paper III). Interestingly, the physical properties of the fibers significantly 
changed after incubation with surfactants as well as with the surfactant type; the FSP fibers 
were dense after incubation with cationic surfactant, whereas inner porosity of the fibers was 
observed after incubation with anionic or neutral surfactants. Moreover, the contact angle 
changed from being large for anionic surfactants, to being small for neutral and cationic 
surfactants. Lastly, the cationic and neutral surfactants decreased the amount of hydrophobic 
pockets available for dye interaction (Paper III). The inherent property of FSP as consumed 
food made the fibers degradable by proteolytic enzymes, and the degradation products were 
observed to inhibit the diabetes related enzyme dipeptidyl peptidase-4 (Paper I).  
The FSP fibers showed potential as carrier system for delivery of drugs, bioactive agents, and 
nutraceuticals. The dipeptide Ala-Trp, rhodamine B, or insulin was encapsulated into the fibers, 
and the release was studied in biorelevant media (Paper I, Paper II, and Paper III). Release of 
Ala-Trp was slightly decreased in gastric environments compared to pH 6.8, whereas release of 
insulin was independent of pH. Instead, insulin release was affected by the presence of 
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biorelevant compounds, i.e. surfactants and proteins encountered in the intestinal system. 
Anionic surfactants increased the release of insulin from FSP fibers in a dose-dependent 
manner, neutral surfactants had no effect, and cationic surfactants decreased the insulin release 
to negligible amounts (Paper III). Encapsulation of insulin into the FSP fibers provided 
protection against chymotrypsin degradation, and interactions between the fibers and epithelial 
cells led to opening of the tight junction, which promoted an increased transepithelial transport 
of insulin without compromising cellular viability (Paper II).  
The FSPs were also suitable for development of self-assembled NCXs. By gentle bulk mixing 
of FSP and alginate, stable NCXs were formed (Paper IV). The NCXs were 293 ± 3 nm and 
anionic (zeta potential was −42 ± 0.3 mV). The zeta potential as a function of pH revealed that 
the NCX surface was dominated by alginate. The NCXs were stable in biorelevant media, and at 
pH values from 2 to 9, except at pH 3 where the NCXs aggregated. Proteolytic enzymes were 
capable of degrading the NCXs. The viability of HeLa and U2OS cell lines was only decreased 
by high concentrations of NCXs (Paper IV). 
It was concluded that FSP is highly suitable for the production of functional nano-micro 
structures for food and biomedical applications qua the ability of the FSPs to form electrospun 
fibers and self-assembled NCXs. The inherent properties of FSP of being biocompatible, 
biodegradable, and bioactive further promote the use of FSP as a biopolymer. 
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RESUMÉ (DANISH) 
Resumé (Danish) 
Nye biopolymerer er efterspurgte grundet deres biologiske kompatibilitet, nedbrydelighed samt 
naturlige oprindelse. Dette Ph.d-projekt har fokuseret på vandopløselige fiske sarkoplasmiske 
proteiner (FSP’er) fra den nordatlantiske torsks (Gadus morhua) potentiale som ny biopolymer 
til udvikling af nano-mikro strukturer. To typer af strukturer er blevet undersøgt; elektrospundne 
fibre (Paper I, Paper II og Paper III), og selvdannede nanokomplekser (NCX’er) (Paper IV). 
FSP viste sig at være yderst velegnede til elektrospinning. Fibrenes morfologi varierede 
betydeligt, fra partikler til fibre, afhængigt af FSP koncentrationen. Desuden fandtes en stor 
diversitet i fibrenes morfologi inden for den samme FSP koncentration, idet størrelsen på 
fibrenes diameter varierede fra nanometer til micrometer (Paper I). Spredningen på størrelsen af 
fibrenes diameter kunne gøres mindre ved eliminering af stoffer med lav molekylvægt (< 8 
kDa). Til trods for FSP’ernes vandopløselighed, var FSP fibrene uopløselige i vandige medier 
(med undtagelse af ved høje koncentrationer af natriumdodecylsulfat). Kontaktvinkelmålinger 
indikerede at FSP fibrene var hydrofobiske, og inkubation med den hydrofobe farve 8-anilino-1-
naphthalensulfon syre (ANS) bekræftede tilstedeværelsen af hydrofobe lommer i eller på 
overfladen af fibrene (Paper III). Overraskende blev fibrenes fysiske egenskaber signifikant 
ændret efter at fibrene havde inkuberet med surfaktanter, og ændringerne var afhængig af 
surfaktanternes egenskaber; FSP fibrene var kompakte efter at have inkuberet med den 
kationiske surfaktant, hvorimod en indre porøsitet blev observeret efter inkubation med 
anioniske og neutrale surfaktanter. Derudover ændrede kontaktvinklen mellem buffer og FSP 
fibrene sig fra stor for de anioniske surfaktanter, til lille ved de kationiske og neutrale 
surfaktanter. Endelig sænkede de kationiske og neutrale surfaktanter antallet af tilgængelige 
hydrofobe lommer, som ANS kunne interagere med (Paper III). Eftersom FSP er en fødevare, 
blev fibrene nedbrudt af proteolytiske enzymer, og det blev observeret at 
nedbrydningsprodukterne inhiberede det diabetes relaterede enzym dipeptidyl peptidase - IV 
(Paper I). 
FSP fibrene viste potentiale som indkapsuleringssystem for bioaktive stoffer, nutraceuticaler og 
lægemidler. Di-peptidet Ala-Trp, rhodamine B eller insulin blev hver især indkapsuleret i 
fibrene, og deres frigørelse fra fibrene i biologisk relevante medier blev undersøgt (Paper I, 
Paper II og Paper III). Frigørelse af Ala-Trp fra fibrene var marginalt mindre i et gastrisk miljø i 
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forhold til ved pH 6,8, hvorimod frigørelsen af insulin var uafhængig af pH. Til gengæld var 
frigivelsen af insulin påvirket af tilstedeværelsen af biologisk relevante stoffer, såsom 
surfaktanter og proteiner der findes i tarmsystemet. Anioniske surfaktanter forårsagede en 
dosisafhængig øget frigørelse af insulin fra FSP fibrene, neutrale surfaktanter havde ingen 
effekt, og kationiske surfaktanter bevirkede, at kun en forsvindende mængde insulin blev 
frigjort fra fibrene (Paper III). Indkapsulering af insulin i FSP fibrene beskyttede insulin mod 
enzymatisk nedbrydning med chymotrypsin, og vekselvirkninger mellem fibrene og epitelceller 
åbnede cellernes tight junctions, hvilket resulterede i øget transepitel transport af insulin uden at 
indvirke cellernes levedygtighed (Paper II). 
FSP’erne var også anvendelige til udvikling af NCX’er. Ved at blande FSP med alginat blev 
stabile NCX’er dannet (Paper IV). NCX’erne var 293 ± 3 nm og anioniske (zeta potentialet var 
−42 ± 0,3 mV). Zeta potentialets variation som funktion af pH i mediet afslørede at 
NCXoverfladen var domineret af alginat. NCX’erne var stabile i biologisk relevante medier, 
samt ved pH værdier fra 2 til 9, med undtagelse af pH 3 hvor NCX’erne aggregerede. 
Proteolytiske enzymer kunne nedbryde NCX’erne. Levedygtigheden af HeLa og U2OS 
cellelinjer var kun nedsat ved høje koncentrationer af NCX (Paper IV). 
Det blev konkluderet at FSP er højt egnede til produktion af funktionelle nano-mikro strukturer 
til fødevare og biomedicinske anvendelser qua FSP’ernes evne til at danne elektrospundne fibre 
og selvdannede NCX’er. De medfødte egenskaber som FSP besidder, såsom biologisk 
kompatibilitet, bionedbrydelighed og bioaktivitet gør FSP yderligere attraktivt til brug som 
biopolymer. 
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INTRODUCTION 
1 Introduction 
Functional nano-micro structures have gained widespread attention in a large range of research 
areas, and the continuous advancement in material properties causes the range of applications to 
expand equivalently. In the food and pharmaceutical industry nano-micro structures have 
become an essential active in optimizing drug bioavailability, increasing drug stability, 
minimization of side effects, sustainable materials, cost reduction etc. 
Biopolymers are beneficial in the development of new nano-micro structures due to their 
excellent biocompatibility. Moreover, the use of biopolymers is appealing from an economical 
and world wealth point of view. The search for new biopolymers has therefore been reinforced. 
1.1 Aim and outline 
In this PhD project, the potential of using fish sarcoplasmic proteins (FSPs) from the Atlantic 
cod (Gadus morhua) as a new biopolymer for development of nano-micro structures has been 
explored. Since FSP is a food product, special focus has been on evaluating the nano-micro 
structures for oral drug delivery, an administration form that is appealing due to patient 
convenience, compliance, and cost. 
An overview of the PhD projected is illustrated in Figure 1. The flexibility of the FSPs were 
explored by studying two types of nano-micro structures; electrospun FSP fibers and 
nanocomplexes (NCXs) made from electrostatic self-assembly of FSPs and alginate (also a 
biopolymer), but with special focus on the fibers. 
The main results obtained during this PhD project are presented through four papers. In Paper I 
the development and characterization of FSP fibers including morphology, stability, 
encapsulation, and drug release were described. FSP fibers as a drug delivery system was 
further studied in Paper II. A growing amount of new drugs are biopharmaceuticals, which has 
intensified the search for new delivery systems for these biological macromolecules. For that 
reason, insulin was chosen as a model drug in Paper II, and the release of insulin from insulin 
loaded FSP fibers (FSP-Ins fibers) in bio-relevant buffers was studied in addition to the ability 
of the fibers to protect insulin from proteolytic degradation. Moreover, the effect of the FSP 
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fibers on the transepithelial permeation of insulin was studied in vitro. In Paper II, insulin 
release was found to be affected by the presence of bio-relevant compounds. This observation 
led to the study presented in Paper III, where interactions between FSP-Ins fibers and 
surfactants were the main focus; the effect of surfactants on insulin release, porosity, contact 
angle, and surface hydrophobicity were explored. 
In the last paper, Paper IV, the development of NCXs made from electrostatic self-assembly of 
FSP and alginate was described. The NCXs were characterized with respect to size, poly 
dispersity index, zeta potential, stability, and toxicity investigations. 
The four papers provided an insight to how FSP can be used as a biopolymer to develop nano-
micro structures in the food and pharmaceutical industry. The following sections introduce the 
electrospinning process, the NCXs, and lastly the FSPs. 
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Figure 1. Overview of the thesis outline. With point of view in FSPs, two types of nano-micro structures were 
explored; electrospun fibers and NCXs. In Paper I the development of FSP fibers was described, and the potential of 
using the FSP fibers for intestinal delivery of biopharmaceuticals was explored in Paper II. In Paper III interactions 
between FSP-Ins fibers and bio-relevant compounds (surfactants) was studied. The potential of using FSPs together 
with alginate in a self-assembling system to develop NCXs was presented in Paper IV. 
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1.2 Electrospinning 
Electrospinning was first discovered by Rayleigh in 1897, and electrospray was studied in detail 
in 1914 by Zeleny [1]. Formhals patented the technique in 1934 [2] and published patents 
describing the technique that led to the production of polymer fibers, in the years after. In 1969, 
Taylor studied the electrically driven jet [3], which formed the groundwork for electrospinning. 
In the following decades, only few researchers studied and used electrospinning, but in the 
beginning of the 21
th 
century the technique started to gain widespread interest in the research 
community. 
Electrospinning is suitable for production of continuous and functional nano-micro structures 
from a wide range of (bio)polymers [4–6]. A generalized electrospinning setup is shown in 
Figure 2. A high-voltage electrostatic field is used to charge the surface of a polymer solution 
droplet (the Taylor cone), thereby inducing ejection of a liquid jet through a spinneret. On the 
way to the collector, the jet will be subjected to forces that allow the jet to stretch immensely. 
Simultaneously, the jet will solidify through solvent evaporation, and electrically charged nano-
micro fibers will remain, directed by electrical forces towards the collector. 
 
Figure 2. Schematic illustration of the electrospinning setup. The fiber morphology may be controlled by for instance 
the feed rate of the polymer solution (flow), the distance between the needle and the collector plate (d), and the 
voltage applied between the needle and the collector plate. 
Several parameters in the electrospinning process can affect fiber morphology such as 
processing parameters (distance between needle and collector, flowrate, applied voltage, etc.), 
solution parameters (concentration, viscosity, etc.), and ambient parameters (humidity and 
temperature). The effect on the fiber morphology caused by each parameter depends on the 
polymer. For instance, by increasing the humidity, pores on the fiber surface can be created 
(Figure 3 A and B) [7], and by increasing the distance between needle and collector plate, the 
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fiber diameter can be decreased (Figure 3 C and D) [8]. Generalized effects of the main 
processing parameters on fiber morphology are listed in Table 1. The choice of collector 
determines the fiber pattern; a solid collector can provide randomly oriented fibers (Figure 3 D) 
or aligned fibers [9], and in wet electrospinning a liquid is used as a collector [10,11]. 
 
Figure 3. SEM images illustrating how processing parameters can affect fiber morphology. The top images show 
electrospun polystyrene fibers at two different humidities; A) > 25% and B) 50-59% (modified from [7]), and the 
bottom images show electrospun polystyrene fibers made using two different syringe-collector distances (d); C) 5 cm 
and D) 15 cm (modified from [8]). 
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Table 1. Overview of parameters that can affect the fiber morphology [4]. 
Parameter  Change 
Solution parameters  
Increased viscosity Decrease in bead generation, increased fiber diameter 
Increased polymer concentration Increased fiber diameter 
Increased polymer molecular weight Decreased bead generation 
Increased conductivity Decreased fiber diameter 
Increased surface tension Stability of the jet 
Processing parameters  
Increased applied voltage Decreased fiber diameter 
Increased distance There is a minimum distance required. Above/below this 
distance causes bead generation, increased distance may also 
decrease fiber diameter. 
Increased flowrate Increased fiber diameter, however bead generation if the flow 
rate becomes too large. 
Ambient parameters  
Increased humidity Increase in circular pores on the fibers 
Increased temperature Decreased fiber diameter 
 
A large variety of polymers have been electrospun, and many reviews have focused on the 
properties of polymeric fibers, for instance references [6,12–14]. However, many synthetic 
polymers lack the biocompatibility and degradability needed for applications in biological 
systems - properties that characterize many biopolymers. For that reason electrospinning of 
proteins have been explored [15], and electrospun protein fibers will be discussed in the 
following section. 
1.2.1 Electrospinning of proteins 
Dror et al. have investigated some of the underlying mechanisms behind protein 
electrospinning, and how the properties of protein fibers can be controlled. The authors studied 
electrospinning of bovine serum albumin (BSA), and found that the electrospinnability and the 
mechanical properties of the produced nano-micro fibers could be controlled by manipulating 
protein conformation, protein aggregation, and intra/inter-molecular disulfide bonds [16]. 
Woerdemann et al. also considered some of the mechanisms behind electrospinning of proteins. 
The authors studied wheat gluten proteins and found that the highest molecular weight (MW) 
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proteins were responsible for the lower threshold concentration for fiber formation. Moreover, 
the authors found that fiber formation was a result of chain entanglements and reversible 
junctions in the proteins, the breaking and reforming of disulfide bonds in particular [17] – 
which was in agreement with the findings of Dror et al. [16]. In general, proteins must be more 
or less unfolded in order to be electrospinnable - and dependent on the protein of interest - there 
are several ways to fulfill this requirement; choice of solvent, addition of denaturing agents, heat 
etc. Gelatin has shown to be a promising material for tissue engineering, and Sajkiewicz and 
Kolbuk described in a review which solvents and associated ambient parameters that can be 
used for electrospinning of gelatin [18]. Formation of a triple-helix is connected to gelation of 
gelatin, which prevents electrospinnability. Accordingly, combinations of solvents and ambient 
parameters that destabilize triple-helix formation are favorable. Moreover the authors speculated 
if a change in molecular conformation can have an effect on the cellular response [18].  
The morphology of protein fibers can vary similarly to polymer fibers, for which reason each 
biopolymer must be characterized individually. Figure 4 shows examples of electrospun protein 
fibers. Soy protein isolate (SPI)/polyvinyl alcohol (PVA) fibers had bead-like structures (Figure 
4 A). At 11 wt% SPI/PVA  the amount of beads were decreased, and by adding Triton X-100 to 
the electrospinning solution the beads were eliminated [19]. Electrospinning of 15 % gelatin 
provided homogenous fibers (Figure 4 B) [20], and fibers of 10 % BSA or 20% hemoglobin 
resulted in fibers with a ribbon like structure (Figure 4 C and D) [16,21]. In Figure 4 E - G the 
morphology of whey protein isolate (WPI)/poly(ethylene oxide) (PEO) fibers from solutions 
with different pH values are shown, exemplifying how much solution properties can affect fiber 
morphology; from bead-like structures to homogenous fibers [22].  
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Figure 4. SEM images of electrospun fibers with different morphologies. A) 11 wt% SPI/PVA (modified from [19]), 
B) 15 % gelatin (modified from [20]), C) 10% BSA (modified from [16]), D) 20 % hemoglobin (modified from [21]), 
and (E-G) WPI/PEO (10%/0.4%) at pH 1, 7 and 12 (modified from [22]). 
The challenges met during the development of specific protein fibers depends on the application 
of the fibers. Frequent obstacles are related to fiber stability in aqueous media and sufficient 
mechanical strength. The mechanical strength can be improved by crosslinking or by addition of 
polymers to the fiber matrix, and the stability can be improved by crosslinking. An example is 
electrospun gelatin fibers (Figure 5 A), which were degraded upon exposure to water (Figure 5  
B) [23]. To increase the stability of the gelatin fibers in aqueous media, the fibers were 
crosslinked. As evident from Figure 5 C and D, crosslinking resulted in increased fiber diameter 
and smearing of the fiber structure, but the stability was improved [23]. Another example is 
crosslinking of PEO/casein fibers, but in contrast to the gelatin fibers, no large change in 
morphology was observed upon crosslinking (Figure 5 E-F) [24]. In general, electrospun fibers 
made from biopolymers are degradable [15], which is also one of the benefits of these materials. 
The rate by which the fibers degrade (either because of solvent or enzymatic degradation) 
depends on the material and post processing procedures such as crosslinking. For the 
PEO/casein fibers minor degradation was observed after exposure to enzymes (Figure 5  G) 
[24], and for gelatin fibers the stability can vary from a couple of hours [25] to 24 hours [26] or 
longer periods of time [27]. 
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Drawbacks of crosslinking are among others the toxicity related to many crosslinking agents, 
such as glutaraldehyde [28], which is not beneficial especially when the fibers are intended for 
biomedical applications. In fact, the toxicity of some fibers have been proposed to originate 
from residues of unreacted crosslinking agents if the fibers were not rinsed thoroughly enough 
[23]. Alternative non-toxic crosslinking procedures have been pursued. For instance, Erdogan et 
al. recently showed that oleuropein, a major component of olive leaf extract, can be used as a 
natural crosslinker for zein fibers [29]. Noszczyk et al. found that albumin/PEO fibers 
spontaneously crosslinked during 21 days at 37 °C, after which excessive PEO could be washed 
away [30]. The study did not reveal which chemical bonds that were responsible for the 
hardening of the albumin fiber mat. The stability of the fibers depended on the thickness of the 
fiber sheet, however the albumin mats used in the study by Noszczyk et al. were completely 
resorbable within six days after subcutaneous implantation in mice [30].  
Despite the gentler crosslinking methods discovered, the need for crosslinking is a drawback of 
many proteins fibers. Gentle methods are often either expensive or nonexistent, and moreover 
post processing steps may compromise fiber properties such as the 3D structure (Figure 6), and 
increase cost. For that reason, protein fibers that are stable in aquatic media without crosslinking 
are highly appealing such as the laminin fibers developed by Neal et al. [31] or the FSP fibers 
developed in Paper I. 
 10 
 
INTRODUCTION 
 
Figure 5. SEM images showing the effect of crosslinking of gelatin (modified from [23]) and PEO/casein (modified 
from [24]). A) 10% gelatin, B) 10% gelatin after adding a drop of water, C) crosslinked 10% gelatin, D) crosslinked 
10% gelatin after being immersed in 37 °C water for 6 days, E) PEO/Casein fibers, F) crosslinked PEO/Casein fibers, 
and G) crosslinked PEO/Casein fibers after α-chymotrypsin degradation for 25 h. 
Electrospun protein fibers have a large potential for biomedical, biosensing, and food related 
applications. The following paragraph will provide a review of some of the applications that 
have been studied for electrospun protein fibers.  
Gelatin has been widely studied  alone and in combination with synthetic polymers for tissue 
engineering, but also for other applications [20,25,26,32–38]. A series of studies presenting 
semi-interpenetration networks (sIPN) were recently published [25,26,37], where gelatin was 
electrospun and subsequently mixed with a photo-reactive crosslinking agent. Crosslinking of 
the gelatin fibers increased the stability of the gelatin scaffold in aqueous solutions, but the 
morphology of the fibers was interfered after incubation in simulated saliva fluid (Figure 6) 
[37]. The gelatin sPIN were evaluated for wound dressing purposes and transbuccal delivery of 
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insulin. In the latter study, the sPIN promoted increased transbuccal permeability of intact 
insulin in vitro, most likely due to a sustained release and localization of insulin close to the 
buccal mucosal site [25]. Pant et al. studied gelatin/nylon-6 fibers for hard tissue engineering; 
nylon-6 provided good mechanical properties, and the gelatin increased cellular compatibility 
[32]. Similarly, Kuppan et al. studied gelatin/polycaprolactone (PCL) fibers for esophageal 
tissue engineering, and found that cell proliferation on the gelatin/PCL nanofibrous scaffold was 
significantly higher than on the PCL nanofibrous scaffold [35]. Other structural proteins such as 
collagen [39,40] and elastin [41] have also been electrospun into nanofibers for biomedical 
application. For instance, in a study by Wang et al. low molecular weight (LMW) fish scale 
collagen peptides were electrospun together with chito-oligosaccharides, to develop an 
antibacterial wound dressing material. The authors found that the fiber scaffold supported 
proliferation of human skin fibroblast [39].  
 
Figure 6. SEM images of A) sPIN and B) sPIN after 24 h incubation in simulated saliva fluid (12 mM KH2PO4, 40 
mM NaCl, 1.5 mM CaCl2, with NaOH adjusted to pH 6.2). Modified from [37]. 
Electrospinning of silk proteins has also been widely studied [42–48]. The excellent 
biocompatibility of silk fibers makes them appealing for biomedical applications, though sericin 
has to be removed from the protein solution, since sericin has a negative effect on the 
biocompatibility [49]. For instance, Dinis et al. applied silk fibers to promote nerve 
reconstruction. The silk fibers were further functionalized by incorporation of nerve growth 
factor and ciliary neurotrophic factor into the fibers, and the functionalized fibers led to a 3-fold 
increase in neurite length [47]. Soy proteins have also gained widespread interest in an 
electrospinning context [19,50–53]. The popularity of soy proteins is among others caused by its 
use in health food products, and the fact that soy proteins are one of the cheapest and most 
widely grown vegetable products with a wide range of uses. Unfortunately soy proteins cannot 
be electrospun alone, but need a carrier polymer in order to engage in electrospun fiber 
networks. PEO have been explored as a carrier polymer for SPI by Thirugnanaselvam et al., 
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who studied PEO/SPI fibers for wound healing applications. The fibers showed positive results 
with respect to antimicrobial activity and growth of new epithelium in vivo [51]. Zein, gliadin, 
and hordein, prolamine proteins originating from corn, wheat, and barley, respectively, have 
also been electrospun for drug delivery and tissue engineering applications among others [54–
57]. For instance, Brahatheeswaran et al. developed curcumin loaded zein fibers for soft tissue 
engineering. The authors found that curcumin was released in a sustained manner and 
maintained its free radical scavenging ability. The zein fibers also provided an attractive 
structure for attachment and growth of fibroblast in vitro [55]. Moreover, zein fibers have also 
been used to provide oxidative stability of fish oils [58,59]. Moomand et al. showed that omega-
3 fatty acids were less oxidized when encapsulated into zein fibers, compared to 
nonencapsulated omega-3 fatty acids. In a study by Wang et al., hordein and gliadin fibers were 
compared to zein fibers, and the authors found that hordein fibers showed lower cytotoxicity 
than gliadin and zein fibers [56]. Amaranth protein isolates also originate from plants. These 
proteins have been electrospun together with pullulan, to create an encapsulation system that 
maintained the antioxidative properties of quercetin and ferulic acid. Quercetin and ferulic acid 
were released in a sustained manner, and the antioxidative properties were preserved to a greater 
extent than the non-encapsulated compounds [60]. Xie et al. studied PVA and casein/PEO fibers 
with immobilized lipase enzymes. The catalytic activity of lipase was higher in the PVA/lipase 
fibers compared to in the PEO/casein/lipase fibers, and lipase was 6 times more active in the 
PVA/lipase fibers than in the cast membrane from the same solution, most likely due to the 
larger surface area of the fibers, allowing for more lipase enzymes to be accessible [24]. 
Hemoglobin and myoglobin have also been electrospun into bioactive fiber sheets. The idea was 
to utilize the physiological properties of hemoglobin and myoglobin to create a biological 
construct for oxygen delivery in wound healing [21]. The authors characterized the morphology, 
porosity, and mechanical properties, whereas proof of concept was not provided. Another 
bioactive fiber sheet was developed by electrospinning the basement membrane protein laminin 
I, for tissue engineering applications. The fibers maintained their geometry for at least two days 
in culture, without chemical crosslinking, and the authors found that PC12 neuronal cells 
extended their neurites on the fiber scaffolds in vitro without nerve growth factor stimulation 
[31]. The human albumin fibers that were previously described were intended for anti-adhesive 
wound dressings. The fibers were found to have a positive effect on the wound healing, by 
suppressing cell migration, while only provoking limited local inflammatory response [30].   
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1.2.2 Electrospun fibers in drug delivery 
Electrospun fibers have a broad range of biomedical applications, one being drug delivery. 
There exist multiple ways by which a drug can be encapsulated into electrospun fibers. 
Blending the drug into the polymer solution before electrospinning will provide a homogenous 
distribution of the drug throughout the fibers (see Paper I and Paper II), and adsorption of the 
drug on to the fiber surface, will deposit the drug on the surface of the fiber [61]. By using 
coaxial electrospinning the drug can be placed in the core or the shell of the fiber [61], and 
lastly, the fibers can be combined with particulate systems, where the drug is encapsulated in 
the particles [61]. Drug delivery is used in many different applications, and some of them are 
presented in the following sections.  
1.2.2.1 Local drug delivery  
Localized drug delivery is beneficial in for instance tissue engineering and regenerative 
medicine, but also for delivery of chemotherapeutics [61,62]. In cancer therapy a high, local 
concentration of the administered drug is desired in order to treat cancer cells effectively. 
Systematic administration is challenging, among others since many of the therapeutic agents 
suffer from instability in the biological environment, have poor solubility, and cause undesired 
side effects in healthy tissue [63,64]. Several strategies have been investigated to circumvent 
those obstacles, using for instance liposomes, micelles, or hydrogels [65], but despite of 
impressive achievements, the problems have still not been overcome. Drug loaded electrospun 
nanofibers have been proposed as a solution. For solid tumors, the normal strategy to reduce the 
risk of reappearance is a combination between surgical operations to remove the tumor, and 
postsurgical chemotherapy or radiation therapy. In that context, electrospun fibers can deliver 
the anti-cancer drugs locally, as the fibers are easily inserted at the tumor site in connection with 
the tumor removal. The electrospun fibers will subsequently provide a controlled and sustained 
release of multiple drug combinations. Benefits of local delivery are high bioavailability, 
minimization of side effects, and a reduction in the need for frequent administrations, which will 
improve life quality of the patient. The strategy was among others explored by Liu et al., who 
developed doxorubicin-loaded poly-L-lactide (PLLA) electrospun nanofiber for local 
chemotherapy against secondary hepatic carcinoma. The doxorubicin was released from the 
fibers to the fiber-mat-covered area of tissue during the first 24 h in vivo, which resulted in 
inhibition of tumor growth and increased survival time of the mice [66].  Xu et al. developed a 
dual drug delivery system that enabled concomitant delivery of a hydrophobic drug (paclitaxel) 
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and a hydrophilic drug (doxorubicin), by using W/O emulsion electrospinning of the 
amphiphillic PEO–PLLA diblock copolymer. The aqueous phase contained doxorubicin, and 
the oily phase was a chloroform solution of PEO–PLLA and paclitaxel [67]. The authors found 
that the dual drug delivery system showed a higher inhibition and apoptosis against rat glioma 
C6 cells in vitro, compared to when the drugs were in separate drug delivery systems [67]. 
1.2.2.2 Wound dressing 
For severe wounds, such as burns, split-skin graft-donor sites, or diabetic ulcers, a combination 
of wound protection, adjustment of wound moisture, air supply for cell respirations, and 
antibiotics to prevent infections is optimal and necessary for accelerating the wound healing 
process. Bioactive wound dressings such as foams, hydrogels, and films have been developed 
[68], but they do not possess all of the required properties listed above. Electrospun fibers have 
shown great potential for wound healing applications [69]. The fibers can be applied directly to 
the wounded area, where the porosity of the fiber network allows for air supply to the wound, 
and in the same time the small pore size can preserve the wound from bacterial infections. The 
high surface area enables adjustment of moisture, as the fibers easily can absorb exudates. 
Lastly the fibers offer easy incorporation of antibiotics to prevent infections. The antibiotics can 
either be released fast or in a long and sustained manner. Kataria et al. studied PVA/alginate 
fibers loaded with the antibiotic drug ciprofloxacin. The drug loaded fibers were applied to a 
wounded rabbit, and promoted faster wound healing compared to a market product [70]. Thakur 
et al. developed a dual drug delivery system, consisting of PLLA fibers with an anesthetic drug 
(lidocaine) and an antibiotic drug (mupirocin). The authors found that the release kinetics of 
mupirocin was altered by the presence of lidocaine in the same polymer matrix. By using a dual 
spinneret the release profile of mupirocin was optimized, and the dual spinneret technique was 
found to provide the best fiber scaffold for wound healing purposes in vitro [71]. Eriksen et al. 
studied PCL fibers loaded with an antimicrobial peptide, and the drug release and antimicrobial 
activity were compared to tetracycline loaded PCL fibers. Antimicrobial peptides are appealing 
since they have a broad spectrum of antimicrobial activity, in addition to being biocompatible 
which reduces the risk of side-effects. The antimicrobial peptides were most likely affected 
during processing since the peptide loaded fibers did not exhibit sufficient antimicrobial effects 
to prevent bacterial growth, however the potential of using the antimicrobial peptides were 
apparent from the drug release studies: The release of tetracycline from the PCL fibers followed 
an exponentially release profile, whereas the peptides were released linearly. The sustained and 
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prolonged release observed for the peptide is beneficial for long term drug delivery systems, for 
instance in relation with implants [72].  
1.2.2.3 Tissue engineering   
The morphology of electrospun fibers has similarities to the extra cellular matrix. For that 
reason the fibers can provide directed cell growth [73–75], and addition of for instance growth 
factors or DNA will make the fiber scaffold even more effective [74,75]. This makes 
electrospun fibers ideal for tissue engineering applications.  
Electrospun fibers for regenerative medicine or tissue engineering are the sub-categories within 
electrospinning, where encapsulation of biopharmaceuticals has been studied the most [75–78], 
among others since the majority of cell-growth-promoting drugs are biological macromolecules. 
Figure 7 illustrates the effect of encapsulating insulin and epidermal growth factor into 
gelatin/poly(L-lactic acid)-co-poly-(e-caprolactone) (PLLCL) fibers. The images show 
immunocytochemical staining of Ker 10 – a protein specific to epidermal differentiation, and 
the increased expression of Ker 10 in Figure 7 A (expression of Ker 10 on gelatin/PLLCL fibers 
with encapsulated growth factors) compared to Figure 7 B (expression of Ker 10 on 
gelatin/PLLCL fibers) indicated an increased differentiation of ADSCs on fibers with added 
growth factors [78]. 
 
Figure 7. Immunocytochemical analysis of the expression of Ker 10 on A) gelatin/PLLCL fibers with encapsulated 
growth factors and B) gelatin/PLLCL fibers. Modified from [78]. 
1.2.2.4 Oral drug delivery 
Oral drug delivery is the most patient convenient administration form, and drug delivery 
systems that enable oral administration have a huge effect on life quality of patients with high 
needs of medicine. In this PhD project oral drug delivery was the main application studied. 
Accordingly, the introduction to electrospun fibers in oral drug delivery will be more 
elaborated, with a special emphasis on intestinal drug delivery as the foremost target area.  
 16 
 
INTRODUCTION 
The oral cavity 
A large surface area is a key property of electrospun fibers. The large surface are can be utilized 
in obtaining increased dissolution of a compound, which is useful in fast-dissolving drug 
delivery systems, where the target area is the oral cavity. The benefits of using electrospun 
fibers are rapid disintegration, without the need of water. The oral mucosa is an appealing 
delivery site since it is permeable and vascularized. The release and uptake of a drug in the 
mouth will thus enhance bioavailability and provide a fast response [79]. A potential drawback 
of the oral cavity as a target area is the risk of involuntary swallowing of saliva which will wash 
away the active compound before it is absorbed (though omission of water reduces this risk). 
Drug absorption is also challenged by the small surface area of the sublingual mucosa, and it 
may be affected by tongue movements [80,81]. Furthermore, human senses such as taste and 
touch, may affect patient convenience. Delivery through the oral cavity is nevertheless 
appealing for patients with swallowing difficulties such as children [82].  
Drugs that have been incorporated into fast-dissolving drug delivery systems are for instance  
paracetamol [83] and caffeine [83,84]. Encapsulation into electrospun fibers caused the drugs to 
dissolve faster than the pure drugs in vitro. The oral cavity (buccal and sublingual) has also been 
target area for delivery of biopharmaceuticals; insulin [25,85] and nystatin [37]. The 
mucoadhesive properties of the fibers (gelatin and alginate/PVA) were explored [37,85], since 
mucoadhesiveness may favor drug absorption by prolonging the retention time, and release the 
drug in the proximity of the membrane. The gelatin fibers and the alginate/PVA fibers were 
both found to be mucoadhesive; however the effect of the mucoadhesive properties on drug 
absorption was not studied [37,85]. Benefits of mucoadhesive properties in general have been 
explored in several studies [86–90]. 
The intestine 
The small intestine is an obvious target for drug delivery. It is more permeable than the gut and 
the colon, and it is the site for absorption of nutrients as dictated by nature [91]. An increasing 
amount of new drugs are either poorly soluble or biopharmaceuticals, but for these compounds 
intestinal drug delivery are challenging. 
Low solubility of a drug limits drug absorption in the gastrointestinal tract. Different strategies 
such as encapsulation and micronization have been suggested as a way to increase solubility and 
transepithelial permeation [92–94]. As an alternative, the large surface-to-volume ratio of 
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electrospun fibers can aid the dissolution of poorly soluble drugs [95]. This has been explored 
for oral administration of  itraconazole [96], quercetin [97], and diosmin [98], and all 
compounds gained increased solubility upon encapsulation into electrospun fibers. For instance, 
incorporation of diosmin into hydroxypropyl cellulose/PVA/PEO fibers provided approximately 
70% dissolution of diosmin compared to negligible amounts of dissolved diosmin from powder 
and tablet forms (Figure 8) [98]. The increased solubility was first of all due to the increased 
surface-to-volume ration as previously mentioned, but additionally it was the non-crystalline 
form of diosmin that was present inside the fibers. The increased dissolution led to higher initial 
plasma levels, increased maxima plasma concentrations, and increased cumulative absorption in 
vivo [98].  
 
Figure 8. Comparison of in vitro diosmin dissolution from powdered drug, micronized form, and electrospun fibers of 
hydroxypropyl cellulose/PVA/PEO in the ratio of 45:47.5:7.5 [98]. 
Intestinal delivery using electrospun fibers has also been explored for delivery of antibiotics. 
Delivery of antibiotics through the intestine entails obstacles such as permeation through the 
epithelial layer and maintained stability when it passes the low pH in the stomach. To deliver 
the drug in its active form, a carrier material that is stable in the stomach, but releases the cargo 
in the small intestine can be used [99–103]. For instance, Wang et al. encapsulated 
erythromycin into electrospun hydroxypropyl methyl cellulose phthalate (HPMCP) for intestinal 
delivery. The authors found that the release of erythromycin from HPMCP fibers went from a 
slow release in gastric juice to almost 1
st
 order kinetics in intestinal juice [104]. Similarly, 
electrospun eudragit fibers have been studied for intestinal delivery of mebeverine 
hydrochloride [105] and aceclofenac/pantoprazole [106]. In the latter case, aceclofenac loaded 
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zein fibers were electrospun concomitant with pantoprazole loaded eudragit fibers, to develop a 
dual delivery system, where one drug (pantoprazole) minimized the side effects (gastrointestinal 
toxicity) caused by the other drug (aceclofenac). Pantoprazole is unstable in acidic 
environments and accordingly needs protection through the stomach. This was provided by 
eudragit, and the simultaneous administration of aceclofenac and pantoprazole, using zein and 
eudragit fibers, reduced the ulcer inducing tendency of aceclofenac in vivo [106]. Eudragit 
fibers have also been studied for colon targeted drug delivery of diclofenac [101,107] and 
budesonide [108]. For instance, the release of budesonide from ethylcellulose/eudragit S100 
core/shell fibers at pH values < 7.4 was minimal, but when the pH of the release medium was 
increased to 7.4 (pH in the colon), budesonide was released exponentially due to dissolution of 
the eudragit S100 shell (Figure 9) [108]. For the ethylcellulose/eudragit S100 blend fibers the 
release of budesonide was initiated at pH 6.8 (Figure 9). The in vivo release behavior of 
budesonide was studied by analyzing budesonide concentration in the stomach, the intestine, 
and the colon, which showed similar results as the in vitro experiments. The core-shell fibers 
reached 3 fold higher budesonide concentrations in the colon compared to the blend fibers 
[108]. 
 
Figure 9. In vitro release of budesonide from core/shell fibers (black) and bend fibers (red) at varying pH values 
[108].  
Therapeutic proteins and peptides are being increasingly used for treatments of numerous 
diseases, due to their high selectivity and effective drug action among other beneficial effects. 
The biopharmaceuticals deviate from small molecules especially with regards to their larger size 
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and poor enzymatic stability [109], which make it extremely challenging to obtain a therapeutic 
effect, unless the drugs are injected. Some of the challenges associated with oral drug delivery 
of biopharmaceuticals are to ensure sufficient structural and chemical stability, by protection 
against the harsh acidic environment in the stomach and the proteolytic enzymes in the 
gastrointestinal tract. Furthermore, permeation through the mucosa and permeation through the 
intestinal epithelium may be hindered by the size and chemical properties of the 
biopharmaceuticals [110–113]. Several strategies have been proposed to overcome obstacles 
related to delivery of biological macromolecules through the small intestine [112,114–123]; 
examples are hydrogels [124], lipid-based carriers [125], permeation enhancers [123], and 
bioadhesive microspheres [126]. Despite the many promising attempts to develop new oral 
formulations for biopharmaceuticals, none has so far succeeded, and new approaches are 
needed. 
The potential of using electrospun fibers for intestinal delivery of biopharmaceutics has not 
been studied extensively. This matter was therefore explored and evaluated in Paper II, where 
especially obstacles related to small intestinal enzymes (chymotrypsin) and transepithelial 
permeation was addressed.  
The intestine contains a range of physiological compounds such as bile salts, lipids, and 
enzymes, and their interactions with food are crucial in the digestion of a meal. In general, 
physiological compounds are found all over the human body and engage in interactions [127]. 
The physiological compounds may also interact with drug delivery systems and affect e.g. their 
stability and drug release properties, though this is rarely considered when a drug delivery 
system is evaluated [33,42,55,70,105,128–140]. Some studies have taken biorelevant 
compounds into account, and have observed an effect on the drug release from the electrospun 
fibers. Alborzi et al. studied the release of folic acid from alginate/pectin/PEO fibers, and found 
that the in vitro release of folic acid was affected by the presence of a bile extract [99]. 
Sofokleous et al. studied release of amoxicillin from poly(D,L-lactide-co-glycolide) (PLGA) for 
wound healing purposes, and found the drug release from the PLGA fibers to vary between the 
release media (water, simulated body fluid, and phosphate buffered saline) [141]. Moreover, 
Maretschek et al. found that release of cytochrome C from PLLA fibers was increased when 
Tween 20 was present in the release medium [142], and in Paper II insulin release was increased 
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in simulated intestinal fluid (with physiological compounds), compared to release in a buffer 
without physiological compounds.  
The understanding of the interactions between biorelevant compounds and electrospun fibers 
are still inadequate, for which reason the interactions were systematically investigated in Paper 
III.  
1.3 Nanocomplexes 
Interactions between biomacromolecules (DNA, proteins, polysaccharides etc.) are inherent in 
nature and a prerequisite for life. Proteins and polysaccharides perform key functions such as 
providing physical structure, conferring protection against pathogens, performing enzymatic 
reactions, and signaling, in addition to many further specialized functions. Moreover, 
interactions between proteins and polysaccharides can be utilized in technological applications 
to form self-assembled NCXs.  
When oppositely charged compounds interact, they may self-assemble into supramolecular 
organized systems. These ionic complexes are attractive for their simplicity, and since their self- 
assembly is dependent on pH and ionic strength, the complexes can be made sensitive to stimuli 
such as pH, heat, and light [143,144]. In many cases, this response can be utilized as an 
activating effect, where the NCXs respond to stimulation in vivo. When developing stable 
NCXs based on electrostatic self-assembly, it is crucial to assess the conditions in which the 
components are oppositely charged. The physicochemical properties of the constituent 
molecules will subsequently influence the properties of the resulting nano-assembly and the 
supramolecular architecture [145]. The optimal conditions, where aggregation and precipitation 
of the NCXs are avoided, often lie within a narrow range of composition, or external conditions 
[146].  
Polysaccharides have been widely explored for the development of particulate systems 
[147,148].  Interactions between polysaccharides and mucus [149–151] make polysaccharide-
based particles interesting for mucosal delivery, one example being alginate and chitosan based 
carrier systems [152]. Goycoolea et al. developed insulin loaded nanoparticles by ionic gelation 
of chitosan using tripolyphosphate and concomitant complexation of alginate, for transmucosal, 
nasal delivery of insulin. The chitosan-tripolyphosphate-alginate complexes promoted increased 
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systemic absorption of insulin in vivo [153]. In another study Sarmento et al. studied insulin 
loaded nanoparticles made from ionotropic pre-gelation of alginate and subsequent 
complexation with chitosan for oral administration. The particles were found to be 
mucoadhesive, since the particles could be detected in the intestinal mucosa, and the alginate-
chitosan particles increased the bioavailability of insulin in vivo [154].  
Polysaccharides may also engage in colloidal polyelectrolyte complexes together with proteins, 
by spontaneous electrostatic interactions in aqueous medium [146,148,155,156]. The protein-
polysaccharide complexes have been explored for development of biocompatible drug delivery 
carriers or as self-assembled gelling complexes. Combinations such as gelatin/casein [157], 
alginate/casein [158,159], alginate/BSA  [160–162], BSA/fucoidan [163], alginate/lysozyme 
[146,162,164], lactoferrin/gum arabic [165], soybean protein isolate/chitosan [166], 
alginate/WPI [167,168], lysozyme/low methoxyl pectin [169], hyaluronic acid/lysozyme 
[170,171], and β-lactoglobulin/alginate [162,172] have been explored. As an example, 
Fioramonti et al. studied alginate/WPI NCXs [168]. The WPI were heated in order to create 
soluble protein aggregates, and subsequently alginate was deposited onto the surface of the 
protein aggregates. Thermal treatment of WPI at 85 ºC caused a greater exposure of 
hydrophobic patches, which was beneficial since the WPI/alginate NCXs were intended for 
protection of lipophilic bioactive agents [168]. Electrostatic complexation between alginate and 
casein into hydrogel particles has also been studied [158]. The particles remained intact from 
pH 4 to 5, but aggregated or dissociated at lower or higher pH, as indicated by the protein being 
on particle form (pH 5), in solution (pH 7), or aggregated (pH 3) (Figure 10). The authors also 
found that lipid droplets encapsulated in the particles were released in simulated oral conditions, 
which made the particles applicable for oral delivery of lipophilic active ingredients [158]. 
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Figure 10. Influence of pH on the mean particle diameter (d32) of hydrogel particles. Confocal micrographs show the 
hydrogel particles at pH 3, 5, and 7 with the protein phase stained green using FITC [158].  
Particle based systems are being increasingly applied in delivery of nutrients [173,174]. One 
example is delivery of folate, an essential nutrient, which is challenged by the insolubility of the 
oxidized version, folic acid, in acidic environments. To overcome the limited absorption due to 
insolubility, Ding et al. developed folic acid-loaded soy protein/soy polysaccharide nanogels 
that stabilized folic acid under acidic conditions and released it rapidly at neutral pH [175].  
Self-assembled particle systems can also be used for protection of proteins. For instance, Water 
et al. used complexation between hyaluronic acid and lysozyme, a model protein, to increase the 
stability of lysozyme [171]. A similar study was performed by Zhao et al., who studied BSA 
and alginate complexation, and the authors found that the majority of BSA was recovered with 
maintained secondary structure and conformational properties, after dissociation of the protein–
alginate complexes [160].  
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Figure 11. Schematic illustration of NCX formation. The FSPs and alginate were gently mixed, after which NCXs 
were formed spontaneously due to electrostatic self-assembly. 
As indicated by the above and the extensive literature, there is a large interest in exploring 
NCXs made from electrostatic self-assembly between proteins and polysaccharides. The ability 
of FSP to self-assemble with alginate was therefore explored in Paper IV. A schematic 
illustration of the particle processing procedure is shown in Figure 11. Alginate was chosen, due 
to its cyto-compatibility, biocompatibility, and biodegradation [176]. Moreover, the U.S. Food 
and Drug Administration (US-FDA) has recognized alginate as being a “Generally Recognized 
As Save” (GRAS) material. From a commercial point of view, this approval makes alginate 
even more appealing. With the current large emphasis on sustainable research, and since 
biopolymers in general are considered beneficial and sustainable, alginate’s origin from brown 
algae makes it further attracting [177]. 
Alginate is a linear co-polymer composed of homopolymeric (1→4)-linked poly–L– α 
guluronate (poly–G) and poly–D– β mannuronate (poly–M), the chemical structures are shown 
in Figure 12. The physical-chemical, functional, and bioactive properties of alginate are mainly 
determined by the MW and the molar ratio of D–mannuroate to L–guluronate residues (M/G 
ratio). Moreover, the negatively charged glucuronic side chains of alginate have been shown to 
interact with mucin [178], one of the major components in mucus, which gives alginate 
mucoadhesive properties [178,179]. Particle systems with mucoadhesive properties have been 
subject to a lot of interest in drug delivery aspects [180].  As previously mentioned, 
mucoadhesive properties can prolong the retention time in the mucus, and thus extend the time 
for drug absorption. In addition to mucoadhesive properties, alginate has been shown to affect 
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tight junctions in a Caco-2 cell monolayer [181,182], which can lead to increased drug 
permeation and accordingly increased bioavailability.  
The feasibility of using alginate in protein-polysaccharide complexes have already been 
mentioned, and together with the benefits of FSPs described in section 1.4, NCXs composed of 
FSPs and alginate may be highly potential for oral drug delivery purposes. 
 
Figure 12. Chemical structures of alginate showing the homopolymeric (1→4)-linked poly–L– α guluronate (poly–G) 
(top),  poly–D– β mannuronate (poly–M) (middle), and the mixed polymer (bottom).  
1.4 Fish sarcoplasmic proteins 
FSPs are water soluble sarcoplasmic fish proteins from the Atlantic cod (Gadus morhua). A 
one-dimensional gel electrophoresis of the FSPs can be found in Paper I, and a two-dimensional 
gel electrophoresis of the water soluble proteins from a cod muscle is seen Figure 13. The FSPs 
account for 25-30 % of the fish muscle proteins, they are easily accessible, and comprise 
peptides and proteins of up to ~200 kDa in MW. The numerous health benefits and bioactive 
properties of fish make FSPs appealing to use in an oral drug formulation [183–187]. An 
example is inhibitory effects against dipeptidyl peptidase-4 (DPP-IV) [188], an enzyme with an 
essential role in glucose metabolism and linked to type 2 diabetes, and DPP-IV inhibitors have 
been proposed as a potential new treatment for this disease [189,190]. Moreover, dietary cod 
proteins have been shown to improve insulin sensitivity in insulin-resistant subjects [191,192]. 
From an economical and sustainable point of view, FSPs are beneficial since many of the 
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proteins that constitute the FSP mixture also are found in the waste water from the fish industry 
[193–195]. The wastewater originating from the fish industry could thus provide a large and 
cheap source for FSPs. Utilization of wastewater from the fish industry have previously been 
studied [196]. Ferraro et al. characterized the wastewater from salting of codfish, and found that 
the wastewater contained compounds such as free amino acids, peptides, and proteins [195]. 
The intestinal permeability of salt-containing mixtures of amino acids extracted from this 
wastewater was investigated, and the authors found that the amino acids were transported across 
the epithelial cell layer in vitro, and have thus potential in food, feed, cosmetics, and 
pharmaceutical formulations [197].  
FSPs have not been studied for development of nano-micro structures previously. The health 
benefits and economical perspectives make FSPs a very interesting material to explore, for 
which reason it was chosen for this PhD project.   
 
Figure 13. Two-dimensional gel electrophoresis of the water soluble proteins from cod muscle. Immobiline Drystrips 
(GE Healthcare, 18 cm, pI 4-7) were used for the first dimensional protein separation and the second dimensional 
SDS-PAGE was run in a 12 % acrylamide gel. The gel was silver stained (unpublished results, Flemming Jessen). 
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2 Introduction to the methods used 
This section will give a brief introduction to the main methods used in the PhD project. A short 
statement introducing how and in which papers (Paper I, Paper II, Paper III, and Paper IV) the 
given methods have been used is provided. The included methods are; scanning and 
transmission electron microscopy (SEM and TEM), confocal microscopy, assessment of 
hydrophobic surfaces using fluorescence from 8-anilino-1-naphthalenesulfonic acid (ANS), 
attenuated total reflectance - fourier transform infrared spectroscopy (ATR-FTIR), circular 
dichroism (CD), sodium dodecyl sulfate ‐ polyacrylamide gel electrophoresis (SDS-PAGE), 
DPP-IV bioactivity assay, reversed phase – high pressure liquid chromatography (RP-HPLC), 
cell based assays, dynamic light scattering (DLS), contact angle measurements, and critical 
micelle concentration (CMC) determinations.  
2.1 Electron microscopy 
Two types of electron microscopy were used in this PhD project; SEM and TEM. Both are 
widely used to investigate inner and outer structures of electrospun fibers and particles in 
general.  
The electron microscope consists of an electron gun, a system of condenser lenses, a specimen 
holder, and a detector. For both SEM and TEM an electron gun sends electrons towards the 
specimen, and lenses ensure that the beam is focused onto the sample. In TEM another lens 
system is placed after the sample, to collect the beam into the detector. Details about the 
electron gun and lens systems will not be discussed here; instead this section will focus on the 
interactions between sample and electrons. For further information about electron microscopy, 
see references [198,199]. 
The general principle behind electron microscopy is illustrated in Figure 14. Primary electrons 
enter the sample and interact in scattering events, and the same and/or different electrons leave 
the sample to create an image. If the sample and the primary electrons interact elastically, the 
energy of the electron is not changed detectably, whereas in inelastic scattering the electrons 
will transfer some of the energy to the interacting atom. 
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In TEM, where the electron beam passes through a thin specimen, elastic scattering is 
important. When the electron beam hits the specimen, the electrons are scattered through the 
sample, and the spatial distribution of the scattered electrons, the electron diffraction pattern, 
will contain information about the spacious orientation of atoms in the sample. From the 
diffraction pattern, the TEM image can be created. Contrast arises because of interference 
between electrons from different angles, however, for many samples the inherent contrast is 
poor (the NCXs in Paper IV), and in these situations the sample may benefit from negative 
staining. In negative staining, a staining agent is added (often a heavy metal salt, since these 
compounds interact readily with the electrons), which will surround the sample and thus 
increase deflection of the electron beam. The high energy (40-120 kV) of the electrons gives 
TEM microscopes a high resolution (for some TEM instruments sub-50-pm resolution can be 
obtained [200]), and TEM can therefore be used to study very small objects. TEM was utilized 
in Paper IV to study shape and size of the NCXs. 
In SEM the electron beam scans the surface of a sample, and an image is created by monitoring 
the intensity of selected electrons - the secondary or backscattered electrons.  Secondary 
electrons are generated when primary electrons interacts inelastically with an atom in the 
sample, thereby causing emission of an electron, whereas backscattered electrons are reflected 
by the sample after elastic scattering events. As both types of electrons originate from the 
surface of the sample, the field of depth is high in SEM, compared to TEM, which makes SEM 
excellent for morphology studies. SEM was therefore used to study the morphology of 
electrospun fibers in Paper I and Paper II, and it was used to study the fiber porosity in Paper 
III. SEM has a range of other applications such as elementary analysis, but those applications 
will not be discussed here, since they were not utilized in this project. 
When studying biological samples by using SEM, such as protein fibers in Paper I, Paper II, and 
Paper III, the sample must be coated with a metal that reflects the electrons. The coating also 
helps to avoid charging of the surface. In Paper III the porosity of the fibers, was studied by 
freezing fracture the fibers with or without the buffer. In order to obtain a surface structure, the 
sample was sublimated before coating with a metal. The sublimation made the fibers stand out 
from the ice block, thereby enabling porosity analysis.  
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Figure 14. Schematic illustration of electron microscopy. In SEM backscattered and secondary electrons are used to 
create an image of the surface, whereas TEM utilizes transmitted electrons which allows for investigation of the inner 
structure.   
2.2 Confocal microscopy 
In confocal microscopy the property of fluorophores to emit light upon irradiation and the 
microscope’s ability to select between many focal planes are utilized to localize fluorophores in 
a sample. A schematic illustration of a confocal microscope is shown in Figure 15, and a 
detailed introduction to confocal microscopy is found in [201,202]. 
In Paper I the fluorescent molecule rhodamine B was encapsulated into FSP fibers. By studying 
the fibers in the confocal microscope, knowledge about the distribution of rhodamine B inside 
the fibers was obtained. Similar studies were conducted for insulin in Paper II. However, since 
insulin is not intrinsically fluorescent, insulin was labelled with fluorescein isothiocyanate 
(FITC), a well-known fluorescent probe which enabled evaluation of the insulin distribution 
inside the fibers.  
In Paper II, confocal microscopy was also used to study the tight junctions in a Caco-2 cell 
monolayer. As described in section 2.9.1, tight junctions are composed of interacting proteins 
that ensure good connectivity of the monolayer. As with insulin, the tight junction proteins are 
not intrinsically fluorescent, and thus not detectable in a confocal microscope. A labeling 
procedure similar to the one used for insulin was not possible, since the tight junction proteins 
 30 
 
INTRODUCTION TO THE METHODS USED 
are attached to the cells. Instead, fluorescent labeled antibodies were used. Antibodies are 
proteins that interact with specific proteins with high selectivity. By incubating the fluorophore-
labelled antibody with the cells, it was possible to visualize the tight junctions in the confocal 
microscope through fluorescence from the antibody. Lastly, confocal microscopy was utilized in 
Paper III, to study fluorescence from ANS. This will be further elaborated in section 2.3. 
 
Figure 15. Schematic illustration of confocal microscopy. 
2.3 Assessment of hydrophobic regions on the FSP-Ins fibers using ANS 
fluorescence 
In Paper III the hydrophobic nature of the FSP-Ins fibers was investigated using ANS 
fluorescence. When ANS interacts with hydrophobic moieties (for instance hydrophobic regions 
on the FSP-Ins fibers), the fluorescence exhibits a strong blue shift and a significant increased 
fluorescence quantum yield, compared to when ANS is in a hydrophilic environment, where it 
barely fluoresce [203,204]. Accordingly, any fluorescence from ANS after incubation of with 
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the FSP-Ins fibers will reveal the presence of hydrophobic pockets on the fibers (Figure 16). 
The samples were studied by using confocal microscopy. 
 
Figure 16. A) Schematic illustration of how ANS was used to investigate hydrophobic regions on electrospun fibers. 
A) The ANS solution before addition of fibers is not fluorescent. B) When adding a hydrophobic fiber, the ANS 
molecules will adhere to the fiber surface, and the change in the surrounding chemical environment will cause an 
increase in quantum yield and a blue shift of the ANS fluorescence, making the fibers visual in a confocal 
microscope. C) When adding a hydrophilic fiber to the ANS solution, nothing visual happens. 
2.4 ATR-FTIR 
Energetically, molecular vibrations are in the IR-range (e.g. 200 – 4000 cm-1), and can thus be 
studied with IR spectroscopy. IR-absorption of side chains in a protein may deviate from 
absorption of side chains in a dipeptide, for instance as a result of the surrounding environment 
[205]. This was utilized in Paper I, where ATR-FTIR was used to study the encapsulation of a 
dipeptide into FSP fibers. 
ATR is a sampling technique that can be used together with FTIR to study solid or liquid 
samples without sample preparation. ATR is highly suitable to study electrospun fibers, since 
alternative sample preparations such as dissolution or crushing will destroy the fibers.   
The principle behind ATR-FTIR is illustrated in Figure 17. Briefly, in ATR-FTIR the beam 
travels through the ATR crystal until it hits the surface between sample and crystal with an 
angle of incidence (θi). Depending on the size of this angle, a part of the beam will be refracted, 
with an angle of refraction (θR), through the sample, and the rest of the beam will be reflected, 
with an angle of reflectance (θr). When the angle of refraction reaches 90° all light is reflected. 
The critical angle (θc) is the minimum angle of incidence, causing total reflectance and angles 
above θc, will also cause total reflectance. When the beam hits the surface between sample and 
crystal with an angle of incidence that is larger than the critical angle (θi > θc), an evanescent 
wave is created which will extend into the sample, where the light can be absorbed. 
Subsequently the beam travels towards the detector. In FTIR an interferometer enables 
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simultaneous measurements of all frequencies, which results in extremely fast measurements 
compared to the old fashion dispersive instruments. For further introduction to FTIR-ATR see 
references [206,207]. 
The FTIR spectra of FSP fibers were complex due to the mixture of proteins in the fibers. The 
peaks in FTIR spectra are a combination of absorption bands from all compounds in the sample, 
and the presence of many different compounds in one sample will thus decrease the fine 
structure. Furthermore, the signal is sensitive to changes in the immediate environment 
surrounding the vibration; such changes can lead to altered bond polarity, which affects the 
band intensity. In Paper I, the FTIR spectra were therefore only compared, in order to detect 
differences originating from the encapsulated dipeptide.   
 
Figure 17. Illustration of the principles behind ATR-FTIR. When the IR beam hits the surface between the ATR 
crystal and the sample, with an angle larger than the critical angle, an evanescent wave is created, which will extend 
into the sample where the light can be absorbed. Subsequently the beam is send towards the detector. 
2.5 SDS-PAGE 
SDS-PAGE was performed according to the method of Laemmli [208], to analyze the protein 
composition of FSP in Paper I, and to study the degradation of FSP fibers and FSP-Alg NCXs 
in Paper IV. 
The mobility of a protein in a polyacrylamide gel is dependent on MW, charge, and shape. 
Addition of SDS will unfold the protein and create a rod-like protein micellar-structure which, 
together with an excess of negative charge, causes the shape and charge of the protein to have 
no influence on the migration in the gel. Accordingly, the mobility of the proteins is solely 
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determined by the MW. This is utilized in SDS-PAGE, where protein migration in a 
polyacrylamide gel is used for separation of proteins according to their MW. By applying an 
electrical field to the gels, the proteins will migrate through the gel, and by comparing the 
corresponding band pattern with known standards, information about protein MW can be 
obtained.  
2.6 Circular dichroism  
Circularly polarized light arises as a result of two polarized, electrical waves being 
perpendicular to each other and separated with a specific phase shift (Figure 18). The phase shift 
determines if the light is left or right handed. Optically active molecules interact differently with 
right and left handed circular polarized light; this difference is reflected in the extinction 
coefficient, ɛ, and accordingly in the absorbance, A, according to Lambert Beer’s law. In CD 
the difference in absorbance between right (R) and left (L) handed light is measured, from 
which structural information can be obtained: 
∆𝜀 = 𝜀𝐿 − 𝜀𝑅 
∆𝐴 = 𝐴𝐿 − 𝐴𝑅 
Proteins are optically active (for a deeper introduction to the optical activity of biopolymers, the 
reader may refer to [209]), and CD spectroscopy can therefore be used to analyze the secondary 
and tertiary structures of proteins. In far-UV CD (200 – 250 nm) light is absorbed by the protein 
backbone, and especially secondary structure (e.g. α-helix, β-sheet, random coil) can be 
analyzed in this region. In near-UV CD (> 250 nm) the signal is affected by the dipole 
orientation, or the local environment of tyrosine, cysteine, tryptophan, and phenylalanine 
groups. Near-UV CD can therefore be used to analyze changes in the tertiary structure of a 
protein.  
In Paper II the near-UV spectrum of released insulin was compared to the spectrum of 
unprocessed insulin to verify that the tertiary structure of insulin was intact after release from 
the FSP-Ins fibers. Low molecular weight (LMW) compounds were released from the fibers 
simultaneously with insulin, which resulted in noisy far-UV CD spectra. Since the released 
LMW FSPs were mainly small peptides, the amount of tertiary structure was limited, for which 
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reason the near-UV spectrum contained less noise from the LMW compounds, and therefore 
more suited for the investigation. 
 
Figure 18. A) Two electromagnetic waves propagating according to time. B-D) Graphical illustration of the electrical 
field of two electromagnetic waves. The light in this figure will be right handed (clockwise). 
2.7 RP-HPLC 
RP-HPLC is a fast and reliable technique for quantitative analysis of both small and large 
compounds. In Paper II and Paper III RP-HPLC was used for quantification of insulin in release 
and transport experiments.  
In RP-HPLC, the sample is injected into a column, and the time it takes the compound to travel 
through the column (the retention time) is analyzed. The column in RP-HPLC is packed with 
nonpolar, small, and uniformly sized particles (≤ 10 µm), and interactions between nonpolar 
groups in the sample and the stationary phase will affect the retention time, and separate the 
compounds according to their physical-chemical properties.  
The area under the curve (AUC) of a peak in a RP-HPLC chromatogram can be related to the 
amount of analyte in the sample, which allows for quantitative determinations.  
2.8 Dynamic light scattering and zeta potential measurements 
DLS was used in Paper IV to obtain information about the size distribution and homogeneity of 
the NCXs, both key elements in the development of particulate systems.  
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The experimental setup is illustrated in Figure 19 A. Briefly, DLS utilizes the scattering events 
that take place after a monochromatic beam of laser light has impinged on a sample, to calculate 
the size distribution of particles in a sample (Figure 19 B) [210].  
In addition to the mean particle diameter the PDI can be investigated. The PDI is a measure of 
the homogeneity of the sample, and can thus also provide information about the stability of the 
particles.  
 
Figure 19. A) Schematic illustration of a DLS experiment. B) Example of a particle size distribution diagram. 
The zeta potential is a physical measure of the charge of a compound. In solution, charged 
particles are surrounded by oppositely charged ions, the inner part being strongly attached to the 
particle, and the outer layer being more diffuse. The zeta potential is defined as the potential at 
the slipping plane, see Figure 20. 
Zeta potential measurements had several applications in Paper IV. Firstly, the optimal pH for 
electrostatic self-assembly of positively charged FSP and negatively charged alginate was 
investigated using zeta potential measurements. The average pI of FSPs and pKa of alginate 
were determined as the pH at which the net charge of the solution was zero. The optimal pH for 
self-assembly was in between those pH values. Secondly, the zeta potential of the particles was 
used for evaluating the stability of the NCXs. Particles with a positive or negative net charge of 
30 mV is considered a stable system, since repulsive forces between the particles will prevent 
the particles from aggregating [211]. When the net charge of the particles approaches 0 mV, the 
particles will have a greater ability to aggregate [211]. Lastly, the zeta potential measurements 
were used to speculate about the architecture of the NCXs. Since the charges of the two 
constituents in the NCXs were known (alginate was negatively charged and FSPs was positively 
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charged), the zeta potential could be used to hypothesize about the distribution of the two 
compounds inside the NCXs. 
 
Figure 20. Illustration of a charged particle (grey) in solution, surrounded by a layer of strongly attached oppositely 
charged ions (dark blue), and an outer layer being more diffuse (light blue). The zeta potential is defined as the 
potential at the slipping plane. 
2.9 Cell models 
2.9.1 Caco-2 cell model – the oral route 
The intestinal epithelium consists of a monolayer of cells, mainly absorptive enterocytes, but 
also goblet cells, M-cells, and endocrine cells are present [212]. The cells are polarized, which 
refers to the asymmetric orientation of different aspects of the cells, e.g. the surface of the cells. 
The apical side denotes the surface of the cells, and the basolateral side is opposite to the apical 
side (see Figure 21). Epithelial cells are connected through junctions on the lateral side of the 
cells: tight junctions, desmosomes, and adherent junctions. Tight junctions are multi protein 
complexes placed close to the apical side, and they ensure close contact between two cells, and 
serve as an absorption barrier for molecules. Drugs and nutraceuticals can be absorbed across 
the epithelia through the cells (transcellular pathway (Figure 21)) by passive diffusion or via 
receptor-mediated internalization pathways followed by transcytosis [213–215]. Alternatively, 
drugs and nutraceuticals can be absorbed between two cells (paracellular pathway (Figure 21)) 
by passive diffusion, however, paracellular transport may also involve signaling pathways, 
regulation of proteins, and alternations in cytoskeletal organization, which result in opening of 
the junctions and allows for permeation of the respective molecule [216,217].  
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Figure 21. Illustration the intestinal epithelium and the paracellular and transcellular route of permeation. The tight 
junctions, desmosomes, and adherent junctions are highlighted, in addition to the ZO-1 and claudin proteins. 
The Caco-2 cell model is frequently used to mimic the epithelial layer in the small intestine in 
vitro, to study intestinal permeability [218]. The Caco-2 cells originate from a colon cell line, 
but when cultured under specific conditions, the Caco-2 cells can polarize and express receptors 
that resemble the adsorptive enterocyte cells found in the small intestine [219]. Figure 22 shows 
an illustration of the setup employed for the cell-based experiments in Paper II, where 
transepithelial permeation of insulin was studied. From the accumulated amount of transported 
insulin, the apparent permeability coefficient (Papp) can be calculated and used as a measure for 
the permeability of the monolayer: 
𝑃𝑎𝑝𝑝 =
𝑑𝑄
𝑑𝑡
⋅
1
A𝐶0
 
Where dQ/dt is the linear rate of appearance of the compound on the basolateral side of the 
monolayer, A denotes the surface area of the monolayer (1.12 cm
2
), and C0 is the initial 
concentration on the apical side of the monolayer. 
Changes in the integrity of the monolayer may originate from modulations of tight junctions or 
cell death. The integrity can be investigated by studying the transepithelial electrical resistance 
(TEER), which is a measure of the flux of ions across the monolayer. Variations in TEER 
during an experiment can thus provide information about the mechanism by which a molecule is 
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transported; a decreased TEER often indicates paracellular transport facilitated by opening of 
the tight junctions - provided that the cell viability is not compromised. In Paper II TEER 
investigations were employed to explore the mechanism behind the transepithelial permeation 
of insulin. 
Tight junction protein complexes are composed of proteins such as claudins, which are 
associated with cytoplasmic proteins like ZO-1 [212] (see zoom in in Figure 21). In Paper II 
claudin-4 and ZO-1 were stained by using fluorophore-labelled antibodies (cf. section 2.2), to 
study the structural state of the tight junctions after incubation with FSP-Ins fibers.  
The viability of the Caco-2 cells can be investigated by measuring the relative metabolism of 
treated cells, in relation to untreated cells. In Paper II, this was done by the MTS/PMS (3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium/phenazine methosulfate) assay [220]. The MTS/PMS assay is a colorimetric assay, 
where the cell viability is assessed by monitoring a reduction of MTS, to a colored formazan 
product using absorbance spectroscopy. The reduction of MTS is only possible by viable cells, 
and the relative viability can therefore be quantified by comparison to a positive control.  
 
Figure 22. Illustration of a Transwell® setup with seeded Caco-2 cells. A sheet of fiber with an encapsulated 
compound was placed on top of the cells. The compound was released and permeated the monolayer. The 
accumulated amount of permeated compounds was determined by taking out samples from the basolateral side and 
analyzing them using RP-HPLC. 
The Caco-2 cell model does not take the mucus layer into account. Mucus is a viscoelastic non-
Newtonian gel that covers the epithelial layer and thus serves as a protection barrier for the cells 
[221,222]. The major components of mucus are water and mucins, but small amounts of 
proteins, lipids, DNA, and electrolytes are also present [223]. Mucins are large, glycosylated 
proteins produced by goblet cells found in the epithelial layer [224], and disulfide bonds and 
numerous of non-covalent bonds build up the highly entangled network of mucus [224]. Co-
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culture cell models comprising Caco-2 cells and mucus-secreting cells have been developed to 
obtain an in vitro cell model that resembles the intestine more than the Caco-2 cell model [225–
228]. Alternatively, Boegh et al. have developed a biosimilar mucus that resembles the 
properties of the native mucus without being toxic (native mucus exerts a cytotoxic effect on the 
cells and can therefore not be applied), thus allowing for investigations of the steric  and 
interactive barriers of the mucus layer [223,229]. Investigation of the performance of the FSP-
Ins fibers in mucus containing cell models was beyond the scope of this PhD project.  
2.9.2 HeLa and U2OS cell lines 
In Paper IV, the toxicity of the NCXs was studied in HeLa and U2OS cell lines. The cell 
viability after incubation with the NCXs, FSPs, or alginate was monitored using the MTS/PMS 
assay, as described above.  
2.10 Contact angle measurements 
In Paper III, interactions between surfactants and FSP-Ins fibers were investigated by using 
contact angle measurements. Absorption of a liquid by electrospun fibers is also referred to as 
wetting, and the contact angle can be used as a quantitative measure for this process [230]. The 
contact angle also provides information about the strength of the solid/liquid interactions; a 
small contact angle indicates strong interactions, exemplified by the contact angle between 
water and a hydrophilic surface. A change in the contact angle can thus be regarded as a change 
in interactions between the solid and the liquid. In Paper III, changes in contact angles were 
used as an indication of interactions between surfactants in a buffer and electrospun fibers. In 
specific, any difference between the contact angle for buffer A (with surfactants) and the contact 
angle for buffer B (without surfactants), when deposited on FSP-Ins fibers, was ascribed to 
interactions between surfactants and the fibers.  
To determine the contact angle between the buffer and the FSP-Ins fibers, a static mode was 
used where a single drop of buffer was deposited on the fiber surface, and a high speed camera 
subsequently monitored the absorption of the liquid. The contact angle was deduced from the 
resulting images (Figure 23 A), and the Young/Laplace fitting procedure was used to determine 
the contact angles [231,232]. The average value between the left and the right contact angle was 
used.  
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Immediately after deposition of the drop on the fiber surface the drop was unstable. To account 
for this instability, the first linear part of the (time, contact angle)-graph is extrapolated, and the 
intersection with the y-axis was used as the measure for the contact angle (Figure 23 B). 
 
Figure 23. A) Example of an image recorded with the high speed camera in a contact angle experiment. The image 
shows a drop of buffer on the fiber surface, and the contact angle is highlighted with red. B) Contact angle plotted as 
a function of time. Due to instabilities in the drop immediately after deposition, the contact angle will fluctuate. In 
order to find the initial contact angle, the first linear part of the graph is therefore extrapolated, and the intersection 
with the y-axis is defined as the contact angle. 
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2.11 Critical micelle concentration determinations 
Surfactants in solution will at a given surfactant concentration start to form micellar structures 
(Figure 24 B); this concentration is known as the CMC. In Paper III, the CMC of the surfactants 
was determined to investigate if there was any relation between the CMC and the observations 
made from fiber-surfactant interactions.  
A colorimetric assay that utilizes the tautomerism of benzoylacetone (BZA) was used to study 
the CMC of the surfactants [233]. BZA exists in two tautomeric forms: the ketone and the enol 
form (Figure 24 A). The cis-enolic form is more stable in nonpolar environments, where 
intermolecular hydrogen bonds with the solvent are less pronounced. Formation of micelles will 
provide a less polar environment for BZA, and the enolic BZA will accordingly engage in the 
micellar network (Figure 24 B), and the concentration of enolic BZA will increase with 
increasing amounts of micelles. Enolic BZA absorbs light at 312 nm, which allows for 
quantification by monitoring the increase in absorbance using UV-VIS spectroscopy.   
 
Figure 24. A) The two tautomeric forms of BZA; ketone (left) and enol (right). B) Illustration of formation of a 
micelle. The enolic form of BZA will engage in the micellar network and become detectable by using UV absorption 
spectroscopy. 
2.12 DPP-IV assay 
DPP-IV is a peptidase that selectively removes N-terminal dipeptides from oligopeptides, with a 
strong preference for proline > alanine > serine as the penultimate amino acid [234]. DPP-IV 
degrades glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 
(GLP-1) [235], enzymes that stimulate insulin-secretion [236]. Degradation of GIP and GLP-1 
will therefore result in a decreased insulin secretion, for which reason DPP-IV inhibitors are 
interesting materials in diabetes treatments [190,237].  The ability if the FSP degradation 
products to inhibit DDP-IV was investigated in Paper I by using the DPP-IV assay. The DPP-IV 
assay is a colorimetric assay, where Gly-Pro-ρ-nitroanilide is cleaved into a chromophore by 
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DPP-IV (Figure 25), and the DPP-IV activity is quantified by monitoring the increase in 
absorbance over time [188,238]. The potency of an inhibitor can be deduced from a dose-
response curve which is constructed by plotting the DPP-IV activity as a function of inhibitor 
concentrations.  
 
Figure 25. The principle behind the DPP-IV assay. When DPP-IV cleaves the bond between proline and ρ-nitroanilid, 
ρ-nitroanilid can absorb light and the concentration can thus be determined with absorption spectroscopy. 
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3 Results and discussion 
This section has been divided into two parts; part A concerns electrospinning of FSP, and is 
composed of three subsections constituted by Paper I, Paper II, and Paper III. Part B concerns 
the self-assembly of FSP and alginate into NCXs, and is composed of one subsection 
constituted by Paper IV. 
The results and discussions will thus be presented throughout the subsections, which each are 
composed of the abstract from the given paper (for the full papers see Appendix I-IV), a 
comments section that describes observations and challenges related to the project, and future 
work. 
Part A and part B are each ended with concluding remarks about the feasibility of using the 
given preparation technique for preparation of FSP nano-micro structures. 
3.1 Part A - electrospinning 
3.1.1 Development of protein nanofibers 
3.1.1.1 Paper I 
Abstract from the paper: 
Nano-microfibers were made from cod (Gadus morhua) sarcoplasmic proteins (FSPs) (Mw < 
200 kDa) using the electrospinning technique. The FSP fibers were studied by scanning 
electron microscopy, and the fiber morphology was found to be strongly dependent on FSP 
concentration. Interestingly, the FSP fibers were insoluble in water. However, when exposed to 
proteolytic enzymes, the fibers were degraded. The degradation products of the FSP fibers 
proved to be inhibitors of the diabetes-related enzyme DPP-IV. The FSP fibers may have 
biomedical applications, among others as a delivery system. To demonstrate this, a dipeptide 
(Ala-Trp) was encapsulated into the FSP fibers, and the release properties were investigated in 
gastric buffer and in intestinal buffer. The release profile showed an initial burst release, where 
30% of the compound was released within the first minute, after which an additional 40% was 
released (still exponential) within the next 30 min (gastric buffer) or 15 min (intestinal buffer). 
The remaining 30% was not released in the timespan of the experiment. 
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For the full paper “Bioactive electrospun fish sarcoplasmic proteins as a drug delivery system”, 
see Appendix I. 
3.1.1.2 Comments to the study 
Paper I concerns the development of electrospun FSP fibers. The proteins were extracted from 
centrifuged tissue fluid without further purification, and consequently compounds such as salts 
and nucleotides were also present in the final material. Despite the complexity of the FSP 
mixture, no variation in electrospinning, fiber morphology, or fiber properties were observed 
throughout the PhD study, where FSP from three different cods was used arbitrarily. Instead 
difficulties occurred due to ambient parameters; temperature and humidity, with humidity being 
the more influential factor (low humidity was preferred). It was unfortunately not possible to 
explore the influence of the ambient parameters with the setup available, nor was it possible to 
optimize the process accordingly.   
One of the benefits of using FSP is the very few processing steps it takes to obtain the material. 
However, purification is possible, and this was briefly touched upon in preliminary studies, 
where the effect of LMW proteins, salts, etc., on electrospinning of FSP was investigated by 
dialyzing the centrifuged tissue fluid prior to freeze drying (D-FSPs). The dialysis removed 
compounds with MW up to 8 kDa. The viscosity of the D-FSPs was increased compared to the 
same concentration of FSP, and as expected the diameter of the resulting electrospun fibers was 
also increased (Figure 26). The morphology of the D-FSP fibers was more homogenous than the 
FSP fibers with negligible amounts of bead-like structures. The increased viscosity of the D-
FSP solution may result from i) removal of charged LMW compounds that have an effect on the 
molecular interactions in the solution, or ii) by removing the LMW compounds the 
concentration of high MW proteins was increased, and this led to an increased degree of chain 
entanglements and thus an increased viscosity. Purification or selection of specific protein 
fractions of the FSPs were not explored further in this thesis.   
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Figure 26. SEM images of A) dialyzed-FSP-Ins fibers ([FSP] = 100 mg/ml and [insulin] = 20 mg/ml), and B) regular 
FSP-Ins fibers ([FSP] = 125 mg/ml and [insulin] = 20 mg/ml) (Paper II). 
3.1.1.3 Future work 
Electrospinning of FSPs has shown promising results. Further exploring the electrospinnability 
of different protein fractions with different MW ranges, and investigating the morphology and 
properties of the fibers, will provide a detailed knowledge about electrospinning of fish proteins. 
It will also elucidate which proteins that enable electrospinning, and which proteins that has an 
effect on the morphology of the fibers. Special emphasis on proteins that are found in the 
wastewater from the fish industry will make the FSP fibers further appealing for industrial 
applications.  
In this PhD project hexafluoro-2-propanol (HFIP) was used to facilitate electrospinning of FSP. 
HFIP is a well-known solvent for electrospinning, since its ionic strength can facilitate 
electrospinning of troublesome materials. Drawbacks of HFIP are the cost and organic origin, 
which encourage the search for alternative GRAS solvents. Exploring the electrospinnability of 
the FSPs as described in the above paragraph will also enable solvent optimization, which 
should focus on GRAS solvents.  
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3.1.2 FSP-Ins fibers as an intestinal drug delivery system 
3.1.2.1 Paper II 
Abstract from the paper: 
In the present study the potential of using bioactive electrospun fish proteins (FSPs) as a carrier 
matrix for small therapeutic proteins was demonstrated especially focusing on the challenges 
with oral delivery. The inherent structural and chemical properties of FSPs as a biopolymer 
facilitated interactions with cells and enzymes found in the gastrointestinal tract and displayed 
excellent biocompatibility. More specifically, insulin was efficiently encapsulated into FSP 
fibers maintaining its conformation, and subsequent controlled release was obtained in 
simulated intestinal fluid. The encapsulation of insulin into FSP fibers provided protection 
against chymotrypsin degradation, and resulted in an increase in insulin transport to around 
12% without compromising the cellular viability. This increased transport was driven by 
interactions upon contact between the nanofibers and the Caco-2 cell monolayer leading to the 
opening of the tight junction proteins. Overall, electrospun FSPs may constitute a novel 
material for oral delivery of biopharmaceuticals. 
For the full paper “Bioactive protein-based nanofibers promote transepithelial permeation of 
intact therapeutic protein by interactions with biological components”, see Appendix II. 
3.1.2.2 Comments to the study 
In Paper II the potential of using FSP fibers for oral delivery of biopharmaceuticals was 
explored. The nature of FSP as consumed food together with the benefits of oral delivery 
provided the rationale for studying this route of administration. Biopharmaceuticals is a hot 
topic, and much attention has been drawn towards the development of new approaches for 
delivery of these biological macromolecules. The central role of insulin in diabetes has 
motivated extensive studies of this compound, and as a result, in vitro methods for accurate and 
effective evaluation and quantification of insulin have been optimized, which makes insulin an 
ideal model compound. In vivo, insulin is easily monitored via blood glucose, and the 
bioavailability can be assessed quantitatively by determination of insulin concentrations in the 
blood. For those reasons insulin was chosen as model drug in Paper II. 
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In Paper II the potential of using FSP-Ins fibers for delivery on insulin via the intestine was 
explored by using in vitro methods. The performance of the fibers in vivo was studied in rats 
(unpublished data), however these studies entailed challenges. For the fibers to have an effect in 
vivo they must reach the intestine in a controllable manner, and for that reason the fibers were 
added to a capsule which subsequently was coated with eudragit. However the capsules were 
too large to exit the stomach of the rat, and accordingly the capsules were degraded in the 
stomach, and the fate of the FSP-Ins fibers were unknown. In Paper I it was found that the FSP 
fibers were degraded in pepsin, but dependent on the degradation time, the fibers may be able to 
reach the intestine and tricker a response. Such studies were, however, out of scope for this 
thesis.  
3.1.2.3 Future work 
Insulin permeation was promoted by interactions between the FSP-Ins fibers and the Caco-2 
cells. Since mucus covers the intestinal epithelium, it would be interesting to explore the effect 
of mucus on the interactions beteen FSP-Ins and the Caco-2 cells, by using an in vitro model 
that takes the mucus into account. It will also be valuable to perform additional in vivo studies 
with an animal model applicable for intestinal evaluation such as a rat where the stomach is 
bypassed. Alternatively the FSP-Ins fibers must be further characterized and developed, or 
formulated, to ensure that the fibers reach the small intestine. 
The benefits of mucoadhesiveness have previously been described, and due to the nature of FSP 
as a complex protein mixture, it could be interesting to explore the mucoadhesive properties of 
the FSP fibers. The fiber properties may be optimized by addition of mucoadhesive compounds, 
or by addition of compounds that alter the protein network inside the fibers and thus creates new 
properties. In continuation, hybrid delivery systems could be developed, where mucus 
penetrating particles are combined with mucoadhesive fibers. Furthermore compounds such as 
permeation enhancers and mucolytics may be added to further increase drug absorption.  
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3.1.3 Interactions between surfactants and FSP fibers 
3.1.3.1 Paper III 
Abstract from the paper: 
Interactions between compounds found in the human body such as proteins, bile salts, etc. and 
electrospun compounds has hitherto been an unstudied phenomena, despite the exposure of 
fibers to such biorelevant compounds in many biomedical applications such as tissue 
engineering, wound healing and drug delivery. In this study we present a systematic 
investigation of how surfactants and proteins, as physiological relevant components, interact 
with insulin loaded fish sarcoplasmic protein (FSP) electrospun fibers (FSP-Ins fibers) and 
thereby affect fiber properties such as hydrophilicity, stability and release characteristics of an 
encapsulated drug. Interactions between insulin-loaded protein fibers and five anionic 
surfactants (the bile salts sodium taurocholate, sodium taurodeoxycholate, sodium glycocholate 
and sodium glycodeoxycholate, and sodium dodecyl sulfate), a cationic surfactant 
(benzalkonium chloride) and a neutral surfactant (Triton X-100) were studied. The anionic 
surfactants increased the insulin release in a concentration-dependent manner, whereas the 
neutral surfactant did not have a significant effect on the release. Interestingly, almost no 
insulin was released from the fibers when benzalkonium chloride was present. The FSP-Ins 
fibers were dense after incubation with this cationic surfactant, whereas high fiber porosity was 
observed after incubation with anionic or neutral surfactants. Contact angle measurements and 
staining with the hydrophobic dye 8-anilino-1-naphthalenesulfonic acid indicated that the FSP-
Ins fibers where hydrophobic, and showed that the fiber surface properties were affected 
differently by the surfactants. Bovine serum albumin also affected insulin release in vitro, 
indicating that also proteins can affect the fiber performance.  
For the full paper “Interactions between surfactants in solution and electrospun protein fibers - 
Effects on release behavior and fiber properties”, see Appendix III. 
3.1.3.2 Comments to the study 
The release studies presented in Paper II revealed that biorelevant compounds can affect fiber 
properties which thereby motivated the study presented in Paper III. Physiologically relevant 
compounds are rarely taken into account when investigating fiber properties, but as 
demonstrated in Paper III, the presence of such compounds can have a huge influence on the 
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behavior of the fibers. The surfactants included in Paper III were chosen because of 
physiological relevance (taurocholate (TC), taurodeoxycholate (TDC), glycocholate (GC), 
glycodeoxycholate (GDC), and BSA) or to cover a broad spectrum of surfactants; anionic 
(SDS), cationic (benzalkonium chloride (BC)), and neutral (Triton X-100). This range of 
different surfactants enabled a thorough investigation of interactions between fibers and 
surfactants.   
A theoretical investigation of the release mechanism behind release of a drug from electrospun 
fibers is not trivial. Srikar et al. developed a model that described the release of water-soluble 
compounds from nondegradable fibers [129]. This model was used by Khansari et al. to 
describe the release of rhodamine B and riboflavin from soy-protein-containing hydrophilic and 
hydrophobic fibers. Khansari et al. furthermore studied the effect of porogens on the release 
profile, however since the proteins and porogens were soluble materials, the fibers were no 
longer completely nondegradable, which caused Srikar’s model to deviate from the 
experimental data [128]. In Paper III, the variations in insulin release from the fibers, and the 
variations in inner porosity of the fibers, were both dependent on which surfactant that was 
present in the buffer. This indicated that i) the FSP-Ins fibers were partly degradable, as evident 
from the porosity, ii) the degradability was affected by the presence of surfactants, and iii) the 
release of insulin was strongly affected by the presence of surfactants. Accordingly, in order to 
perform a theoretical analysis of the mechanism behind insulin release from FSP-Ins fibers in 
the absence and presence of surfactants, a mathematical model that takes the above mentioned 
observations into account must be developed. Development of such a model was beyond the 
scope of this PhD project. 
Release of rhodamine B from rhodamine B loaded FSP fibers was studied in a similar manner as 
insulin (0 mM, 3 mM and 6 mM surfactant concentrations) to investigate if the effects of the 
surfactants were similar on other drug delivery systems (unpublished data). Encapsulation of 
rhodamine B into FSP fibers was briefly touched upon in Paper I, where the encapsulation and 
distribution was analyzed. Rhodamine B release from the fibers in MES-HBSS in the presence 
and absence of surfactants are shown in Figure 27. From these data it was evident that the 
release of rhodamine B was different from the release of insulin; release of rhodamine B in 
MES-HBSS reached 70 % within 3 h, compared to approximately 50 % for insulin. Release of 
rhodamine B was increased in 6 mM TC, whereas no significant change was observed in 3 mM 
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TC. The trend of rhodamine B release in the presence of SDS was similar to that of TC, except 
that the effect in 6 mM SDS was more pronounced compared 6 mM TC. BC had no effect on 
rhodamine B release, compared to almost no release of insulin when BC was added to the 
release media. The presence of Triton X-100 only caused minor effects on rhodmine B release, 
which was similar to the effects observed for insulin release.  
The release data presented in Figure 27 clearly indicated that the rhodamine B release was 
affected by the surfactants, however differently compared to their effects on the insulin release. 
Variations in the way the surfactants affected the drug delivery systems may be due to different 
release behaviors of insulin and rhodamine B, or due to the fiber properties being modified by 
encapsulation of the respective compound. The high maximum release for rhodamine B in 
MES-HBSS made it difficult to make similar concentration-dependency analysis for rhodamine 
B, as for insulin, where maximum release was lower and thus, where the span between 
maximum release and 100% release was larger. For that reason, the study presented in Paper III 
was limited to insulin. 
 
Figure 27. In vitro rhodamine B release from FSP fibers in MES-HBSS with varying concentrations of surfactants. A) 
MES-HBSS (black), 3 mM TC (red), 6 mM TC (yellow), 3 mM SDS (green) and 6 mM SDS (blue). B) MES-HBSS 
(black), 3 mM BC (red), 6 mM BC (yellow), 3 mM Triton (green) and 6 mM Triton X-100 (blue). Data represent 
mean ± SD, n ≥ 3. After 300 min trypsin was added to the solution which allowed for quantification. Unpublished 
data.  
3.1.3.3 Future work 
The study in Paper III included seven surfactants, and BSA was briefly touched upon. In order 
to further explore the mechanism behind surfactant-fiber interactions, for instance by a 
structure-activity analysis, more surfactants should be included in the study. Moreover, the 
effect of other physiological compounds such as protein, mucin, DNA etc. should also be 
explored. In continuation, inclusion of other electrospun fibers and other cargo will also be 
highly relevant. 
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The investigations presented in Paper III were all indirect and qualitative indications of the 
interactions that take place between surfactants and FSP-Ins fibers in solution. Direct and 
quantitative measurements of the surfactant-fiber interaction would also contribute to elucidate 
and understand the mechanisms behind the interactions.   
3.1.4 Conclusion and outlook 
The studies presented in Paper I, Paper II, and Paper III showed that the FSPs were highly 
suitable for the production of electrospun fibers: 
Electrospinning of FSPs were found to be stable, since no variation in electrospinning or fiber 
properties were observed throughout the three studies (Paper I, Paper II, and Paper III), where 
FSPs from three different cods were used arbitrarily.  
The morphology of the FSP fibers was diverse, as evident from the fiber diameter ranging from 
nanometer to micrometer scale, dependent on both FSP concentration and FSP composition 
(Paper I). The adjustable morphology of the fibers allows for optimization of the fibers 
according to the application. 
LMW compounds were released from the FSP fibers upon contact with aquatic media, however 
the FSP fibers remained insoluble (Paper I), except at high SDS concentrations (Paper II and 
Paper III). Most fibers made from biopolymers are water soluble and need crosslinking in order 
to become insoluble. The inherent stability of the FSP fibers makes them appealing cf. section 
1.2.   
The FSP fibers were degraded into small peptides by proteolytic enzymes (Paper I). The 
residual degradation products were shown to inhibit the diabetes related DPP-IV (Paper I), 
which can be considered an added advantage when selecting appropriate carrier matrices, 
depending on the target. 
The carrier potential of the FSP fibers was explored by encapsulating Ala-Trp (Paper I), 
rhodamine B (Paper I and Paper III), or insulin (Paper II and Paper III) into the fibers. The 
compounds were uniformly distributed throughout the fibers (Paper I and Paper II). 
Encapsulation of insulin did not have a significant effect on fiber morphology, and high loading 
capacities with high loading efficiency was successfully obtained (Paper II). High loading 
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capacity and high loading efficiency are both key properties for drug delivery systems in order 
to increase the amount of drug available for absorption into the bloodstream. 
Encapsulation of insulin into the FSP fibers caused insulin to be detectable in α-chymotrypsin-
containing buffer for up to 8 h as compared to 1 h when insulin was not embedded in the fibers 
(Paper II). The protective effects of the FSP fibers are beneficial for oral drug delivery of 
biopharmaceuticals, where enzymatic degradation of the drug is a major challenge. 
The release of insulin from FSP-Ins fibers was increased in the presence of anionic surfactants. 
The neutral surfactant did not have an effect on the release, and the cationic surfactant limited 
the release to negligible amounts (Paper III). Cryo-SEM images of the FSP-Ins fibers after 
incubation with the surfactants showed a correlation between release of cargo and increased 
porosity; when insulin was released, porosity was observed (Paper III).   
Contact angle measurements revealed that the surfactants had a significant influence on wetting 
of the fibers; for anionic surfactants large contact angles were observed, whereas the presence of 
the cationic surfactant and especially the neutral surfactant decreased the contact angle 
considerably (Paper III).  
Interactions between fibers and surfactants were further illustrated with ANS fluorescence, 
where a decrease in the fluorescence was observed after incubation with neutral or cationic 
surfactants compared to incubation with anionic or no surfactants (Paper III). 
The FSP fibers interacted with intestinal Caco-2 cells and caused an effect on the tight 
junctions, demonstrated by a decrease in integrity, which promoted increased transepithelial 
permeation of insulin without compromising cellular viability (Paper II). The interactions 
between electrospun fibers and the epithelial cells may be used to promote increased uptake of 
biopharmaceuticals in general.  
3.2 Part B - Nanocomplexes 
3.2.1 Nano-microstructures as nanocomplexes made from electrostatic self-assembly 
3.2.1.1 Paper IV 
Abstract from the paper: 
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Macrostructures based on natural polymers are subject to large attention, as the application 
range is wide within the food and pharmaceutical industries. In this study we present 
nanocomplexes (NCXs) made from electrostatic self-assembly between negatively charged 
alginate and positively charged fish sarcoplasmic proteins (FSPs), prepared by bulk mixing. A 
concentration screening revealed that there was a range of alginate and FSP concentrations 
where stable NCXs with similar properties were formed, rather than two exact concentrations. 
The size of the NCXs was 293 ± 3 nm, and the zeta potential was −42 ± 0.3 mV. The NCXs were 
stable in water, gastric buffer, intestinal buffer and HEPES buffered glycose, and at all pH 
values from 2 to 9 except pH 3, where they aggregated. When proteolytic enzymes were present 
in the buffer, the NCXs were degraded. Only at high concentrations the NCXs caused a 
decreased viability in HeLa and U2OS cell lines. The simple processing procedure and the high 
stability of the NCXs, makes them excellent candidates for use in the food and pharmaceutical 
industry 
For the full paper “Design and characterization of self-assembled fish sarcoplasmic protein-
alginate nanocomplexes”, see Appendix IV. 
3.2.1.2 Comments to the study 
In Paper IV NCXs made from self-assembly of FSP and alginate were described. Throughout 
the NCX studies, FSP originating from three cods was used arbitrarily, and despite the very 
complex protein mixture, the properties of NCXs did not exhibit large variations. 
3.2.1.3 Future work 
NCXs composed of alginate and FSP have potential as drug carriers, and accordingly the next 
step will be to encapsulate an active ingredient and study the ability of the NCXs to act as a 
drug carrier. The FSP fibers protected insulin against proteolytic degradation, and the NCXs 
could have similar properties. Alginate has been shown to be mucoadhesive, for which reason 
the mucoadhesive properties of the NCXs should be explored, in order to obtain full benefit 
from the NCXs. Moreover, alginate has been shown to affect tight junction permeability. 
Modulations of the tight junctions can facilitate increased bioavailability of a drug; hence the 
ability of the NCXs to increase transepithelial permeation must be studied, and potentially 
utilized to transport active ingredients across the epithelial layer.  
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From a particle development point of view, it would be interesting to explore selected FSP 
fractions as counter material to alginate. This may increase the homogeneity of the NCXs and 
also provide further details about the NCXs such as the structural network.  
3.2.2 Conclusion and outlook 
The NCXs developed from electrostatic self-assembly of alginate and FSP were easily formed 
by bulk mixing of the two constituents. Combining different concentrations of alginate and 
FSPs revealed optimal processing conditions, however it also showed that formation of NCXs is 
flexible in terms of processing concentrations since small changes in alginate or FSP 
concentrations did not alter NCX properties. 
The NCXs were stable in water, in biorelevant media, and at different pH values, except at pH 3 
where the NCXs aggregated. The zeta potential of the NCXs at the processing conditions was 
−42 ± 0.3 mV, which indicated that the shell of the NCXs was dominated by alginate. Changes 
in the zeta potential of the NCXs as a function of pH revealed that the electrostatic interactions 
holding the particles together varied with pH. 
As separate compounds alginate and FSPs did not reduce cell viability, and only at high 
concentrations of NCXs was the cell viability in HeLa and U2OS cell lines affected. 
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4 Conclusion 
The potential of using FSP as a new biopolymer for development of nano-micro structures using 
either electrospinning or electrostatic self-assembly was evaluated in Paper I, Paper II, Paper III, 
and Paper IV. Overall the four studies showed that FSP is highly applicable as a biopolymer, 
since the FSPs accommodate many of the properties that are sought for in such components. 
These properties were shown to also be present in the fabricated nano-micro structures: 
One of the benefits of the majority of biopolymers is their inherent biocompatibility. The 
biocompatibility of FSP was illustrated by cell based studies, where no decrease in viability was 
observed in Caco-2 cells, HeLa cells, or U2OS cells, except at high NCX concentrations, where 
minor toxicity was introduced in HeLa and U2OS cells. 
Another advantage of using biopolymers is their natural ability to interact with biological 
systems. The FSP fibers interacted with enzymes and were degraded, and they interacted with 
Caco-2 cells and promoted increased transepithelial permeation of insulin. Moreover, the fibers 
interacted with biorelevant compounds, which affected the physical properties of the fibers. 
Interactions between the FSPs and alginate led to stable NCXs, and interactions between the 
FSPs in the electrospun fiber matrix caused the FSP fibers to be stable in aquatic media, despite 
the water soluble nature of the FSPs. 
Nano-micro structures are often developed from pure materials. One of the benefits of using a 
complex mixture of proteins was the diverse morphology observed for the FSP fibers. However, 
the fiber morphology could also be made more homogenous by using selected protein fractions, 
as evident from the morphology of the electrospun D-FSPs. 
The findings in this PhD study illustrate that FSP shows great potential as a novel biopolymer. 
The inherent compatible nature of the FSPs and their versatility in applications emphasize the 
prospects of this natural material. Excitingly, many applications and possibilities are yet to be 
explored. 
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a  b  s  t  r  a  c  t
Nano-microﬁbers  were  made  from  cod  (Gadus  morhua)  sarcoplasmic  proteins  (FSP)  (Mw < 200  kDa)  using
the  electrospinning  technique.  The  FSP  ﬁbers  were  studied  by  scanning  electron  microscopy,  and  the
ﬁber  morphology  was found  to be  strongly  dependent  on  FSP  concentration.  Interestingly,  the  FSP ﬁbers
were  insoluble  in  water.  However,  when  exposed  to proteolytic  enzymes,  the  ﬁbers  were  degraded.  The
degradation  products  of the  FSP  ﬁbers  proved  to be inhibitors  of  the  diabetes-related  enzyme  DPP-IV.  The
FSP ﬁbers  may  have  biomedical  applications,  among  others  as  a delivery  system.  To  demonstrate  this,  a
dipeptide (Ala-Trp)  was  encapsulated  into  the  FSP  ﬁbers,  and  the  release  properties  were  investigated
in  gastric  buffer  and  in intestinal  buffer.  The  release  proﬁle  showed  an  initial  burst  release,  where 30%
of  the compound  was  released  within  the ﬁrst minute,  after  which  an  additional  40% was  released  (still
exponential)  within  the  next  30  min  (gastric  buffer)  or 15  min  (intestinal  buffer).  The  remaining  30%  was
not  released  in  the  timespan  of the  experiment.
©  2014  Elsevier  B.V.  All  rights  reserved.
Introduction
Electrospinning processing is a straightforward technique
suitable for the production of continuous and functional nano-
microﬁbers from a wide range of (bio)polymers [1–3]. This
electrostatic technique involves the use of a high-voltage electro-
static ﬁeld to charge the surface of a polymer solution droplet,
thereby inducing ejection of a liquid jet through a spinneret. On the
way to the collector, the jet will be subjected to forces that allow it
to stretch immensely. Simultaneously, the jet will solidify through
solvent evaporation, and electrically charged nano-microﬁbers will
remain, directed by electrical forces toward the collector.
Several proteins have been electrospun [4]. To name a few, the
structural proteins collagen and gelatin were electrospun, among
others, in an attempt to mimic  the extra cellular matrix [5–7]. Dror
et al. presented a study in which the globular protein bovine serum
albumin was electrospun into nano-microﬁbers [8], and Barnes
et al. have electrospun two other globular proteins, hemoglobin
and myoglobin, aiming at the development of a biologic construct
with the potential of being used as an oxygen delivery system [9].
In a study by Neal et al., laminin proteins were electrospun in order
to mimic  the basement membranes [10], and Woerderman et al.
∗ Corresponding author. Tel.: +45 45 25 27 73.
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demonstrated that it was possible to electrospin a heterogeneous
protein mixture, such as the commercial wheat gluten [11]. More-
over, electrospun silk proteins have been studied, especially for
biomedical applications [12–15]. In many cases, however, proteins
need a carrier system in order to be electrospun, and crosslink-
ing to achieve, for instance, the desired mechanical properties, or
to become insoluble. For example, crosslinking of hemoglobin and
myoglobin ﬁbers as well as collagen and gelatin have been studied
[9,16,17]. Poly vinyl alcohol (PVA) has been used as a carrier system
to achieve egg albumin spinnability [18], and poly(ethylene oxide)
(PEO) facilitate electrospinning of whey proteins [19]. In a study by
Jiang et al., poly (-caprolactone) (PCL) was co-axially electrospun
together with zein proteins (PCL as the core material and zein as the
shell), to increase the mechanical strength of the zein ﬁbers [20].
Fish sarcoplasmic proteins account for 25–30% of the ﬁsh mus-
cle proteins. They are easily accessible, and comprise peptides
and proteins of up to ∼200 kDa in molecular weight. Fish protein
hydrolysates have been shown to comprise bioactive proper-
ties [21–23]. One example is inhibitory effects against dipeptidyl
peptidase-4 (DPP-IV) [24], an enzyme with an essential role in
glucose metabolism and linked to type 2 diabetes, and DPP-IV
inhibitors may  be used as a potential new treatment for type 2 dia-
betes [25,26]. Additionally, dietary cod proteins have been shown
to improve insulin sensitivity in insulin-resistant subjects [27,28].
The usage of electrospun nano-microﬁbers for biomedical
application has gained widespread interest [29–31], and more
speciﬁc in the drug delivery ﬁelds of bio-functional scaffolds for
http://dx.doi.org/10.1016/j.colsurfb.2014.06.053
0927-7765/© 2014 Elsevier B.V. All rights reserved.
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regenerative medicine [32,33], wound dressing [34,35], as well
as sublingual drug delivery systems [36]. Electrospun nano-
microﬁbers can be used to enhance the solubility and release
of poorly soluble drugs, due to the large aspect ratio of ﬁbers.
For instance the poorly water soluble drug nabumetone has been
encapsulated into polyethylene oxide nano-microﬁbers [37], while
itraconazole has been encapsulated into hydroxypropyl methyl
cellulose [38]. Likewise, lipophilic drugs such as rifampicin and
paclitaxel have also been encapsulated into polymeric nano-
microﬁbers [39].
Few studies have been published on the application of drug-
loaded nano-microﬁbers as oral drug delivery systems, which is the
desired route of administration from a patient convenience point
of view. These systems are mainly polymer-based matrices, such
as the system described by Shen et al., where Eudragit® L 100-55
nano-microﬁbers were loaded with diclofenac sodium for colon-
targeted delivery [40], or the loading of caffeine and riboﬂavin into
polyvinyl-alcohol ﬁbers, as described by Li et al. [41].
In this study, FSP were electrospun into nano-microﬁbers and
characterized with respect to ﬁber morphology, protein composi-
tion, ﬁber solubility, ﬁber degradability and bioactivity. To illustrate
how the FSP ﬁbers may  be used as a delivery system, a dipeptide
(Ala-Trp) was encapsulated into the ﬁbers and the release proper-
ties were investigated. Rhodamine B (RhdB) was also encapsulated
to study the distribution of an encapsulated compound in the FSP
ﬁbers.
Experimental
Materials
Cod (Gadus morhua) from the North Sea was obtained
from Hanstholm Fisk, Denmark. 1,1,1,3,3,3-Hexaﬂuoro-2-propanol
(HFIP), pepsin (activity of 3.260 units/mg protein), pancreatin
(activity of 8× U.S.P. speciﬁcations), DPP-IV, diprotin, Gly-
Pro-Nitroanilid and Ala-Trp were obtained from Sigma-Aldrich
Company, St. Louis, USA. The remaining reagents were obtained
from Sigma-Aldrich Company, St. Louis, USA, and used without
further puriﬁcation.
Methods
Preparation of FSP
FSP extract: fresh cod was ﬁlleted and frozen at −30 ◦C. The
frozen ﬁllet was defrosted, chopped, placed into centrifuge tubes
and centrifuged for 15 min, 18,000 × g, 5 ◦C (4K15, Sigma Labora-
tory centrifuges, Germany).
FSP: FSP extract was transferred to a petri dish, frozen, freeze-
dried (FD) and stored at −60 ◦C.
Electrospinning
FSP was dissolved in HFIP, added to a syringe and placed in a
syringe pump (New Era Pump Systems, Inc., USA). A 22 G needle
(Proto Advantage, Canada) was used. The syringe pump delivered
the FSP solution with a ﬂow rate of 0.02 ml/min. Using a high volt-
age power supply (Gamma  High Voltage Research, USA), an electric
ﬁeld of 20 kV was applied between the spinneret of the syringe and
a 5 × 5 cm collector plate made of stainless steel with alumina foil
wrapped around it. The distance between the syringe tip and the
collector plate was 15 cm.  The electrospinning was  conducted at
room temperature, and samples were stored in an exicator until
further analysis.
Protein composition of FSP
Sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) was performed according to the method of Laemmli
[42] using pre-cast 4–20% acrylamide Tris–glycine Novex gels (Life
Technologies, USA). FSP extract: 0.5 ml  FSP extract was added to
a 1.5 ml  Eppendorf tube, centrifuged, and the supernatant was
saved. FD FSP in water: 27.5 mg  FD FSP was added to an Eppendorf
tube together with 0.5 ml  demineralized water, dissolved and cen-
trifuged. This amount was chosen to obtain a FSP concentration of
55 mg/ml, which is the approximate protein concentration in the
FSP extract. The supernatant was saved. FD FSP in HFIP: 27.5 mg
FD FSP was added to an Eppendorf tube together with 0.5 ml  HFIP,
dissolved and centrifuged. The supernatant was  saved.
10 l of each sample was  added to Eppendorf tubes together
with 60 l of SDS sample buffer (4.8% SDS, 1 mM EDTA, 0.1 M DTT,
20% (v/v) Glycerol, 125 mM Tris–HCl pH 6.8, 0.05% (w/v) Brom Phe-
nol Blue) and heated for 2 min  at 95 ◦C. 10 l was loaded on the gel.
In addition to the samples, 10 l Mark12TM (Life Technologies, USA)
was loaded. The gel was run at 125 V, 200 mA and 150 W.
Microscopy analysis
Fiber morphology was  analyzed with scanning electron
microscopy (SEM) (FEI Inspect, USA). A small area of the samples
was cut out, placed on carbon tape and sputter coated with gold,
10 s, 40 mA.  The diameters of 60 FSP ﬁbers were analyzed with
ImageJ [43]. For clarity reasons only images containing few ﬁbers
are reported. The polymer jet was  stable and continuous, and the
ﬁbers shown here represent the collection of ﬁbers obtained after
further electrospinning.
The RhdB distribution in FSP ﬁbers was analyzed with confo-
cal microscopy (Zeiss LSM 780, Germany). FSP ﬁbers with 0.05 wt%
RhdB were prepared by mixing RhdB into the protein solution
(125 mg/ml  FSP) prior to electrospinning. The electrospinning was
carried out as previously described. Rhodamine ﬂuorescence was
detected at 626 nm after excitation with 543 nm, and FSP ﬁber auto
ﬂuorescence was detected at 481 nm after excitation with 405 nm.
The images were processed with the ZEN microscopy software
(Zeiss, Germany).
Solubility and degradation of FSP ﬁbers
1 ± 0.2 mg  ﬁber was added to 4 × 7 Eppendorf tubes. 250 l
solvent (gastric buffer (2 mg/ml  NaCl, 84 mM HCl), simulated gas-
tric ﬂuid (gastric buffer with 0.32% (w/v) pepsin), intestinal buffer
(6.8 mg/ml  KH2PO4, 15.4 mM NaOH, pH 6.8), or simulated intesti-
nal ﬂuid (intestinal buffer with 1% (w/v) pancreatin) was added
to Eppendorf tubes and placed on an orbital shaker (90 RPM). At
the times 1 min, 30 min, 1 h and 4 h after the addition of solvent,
the tubes were centrifuged and supernatants were transferred to
another Eppendorf tube containing SDS sample buffer. The samples
were treated and SDS-PAGE was performed as described above.
The degradation of FSP ﬁbers by enzymes was  studied further
in a similar set-up; with low activity simulated ﬂuids (low activity
simulated gastric ﬂuid (gastric buffer with 0.0032% (w/v) pepsin)
and low activity simulated intestinal ﬂuid (intestinal buffer with
0.01% (w/v) pancreatin).
The degradation pattern of FD FSP was studied as in the case of
the FSP ﬁbers, except that the time point at 10 h was omitted and
a control consisting of solvent without enzyme was added.
Bioactivity of the FSP ﬁbers
Inhibitor dilution series: 60 mg  of FSP ﬁbers was added to an
Eppendorf tube together with 1 ml  simulated gastric ﬂuid or simu-
lated intestinal ﬂuid. The Eppendorf tubes were placed on an orbital
shaker (90 RPM). After 3 h, the Eppendorf tubes were centrifuged
and the supernatants were transferred to another 1.5 ml tube and
heated at 95 ◦C for 4 min. The Eppendorf tubes were subsequently
centrifuged and the supernatants were saved. In parallel, samples
containing only simulated ﬂuids were prepared for control. From
the samples, 3-fold dilution series were made using water. The
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Fig. 1. SEM images of FSP ﬁbers. (A)–(E) [FSP] = 50 mg/ml, 75 mg/ml, 100 mg/ml, 125 mg/ml, and 150 mg/ml, respectively. Magniﬁcation: ×5000, scale bar: 5 m.  (F) Size
histogram of FSP ﬁbers; 50 mg/ml  (red), 75 mg/ml  (green), 100 mg/ml (blue), 125 mg/ml (black) and 150 mg/ml (yellow). (For interpretation of the references to color in this
ﬁgure  legend, the reader is referred to the web  version of this article.)
samples were pH adjusted to ∼8. In parallel, a 3-fold dilution series
of the well-known DPP-IV inhibitor diprotin was prepared.
DPP-IV assay: the assay was conducted as described by Li-Chan
et al. [24]. In short, 25 l of the inhibitor solution was added to the
wells in a transparent ﬂat bottom 96 well microtiter plate (Greiner
bio-one, Switzerland) together with 50 l DPP-IV (0.01 unit/ml in
100 mM TRIS). The plate was pre-incubated at 37 ◦C for 10 min. The
substrate, 2.4 mM Gly-Pro-Nitroanilid in 100 mM TRIS, was  pre-
incubated (37 ◦C for 10 min) and 25 l was transferred to the wells.
Absorption at 405 nm was detected over time using a plate reader
(Synergy 2 multi-mode microplate reader, Biotek, USA). In parallel,
the known DPP-IV inhibitor, diprotin, was run.
All experiments (except the buffer control which were car-
ried out in singlets) were carried out in triplicate; the mean
values ± SDare reported.
FT-IR spectroscopy
Fourier-transform infrared (FT-IR) spectra were obtained on a
Spectrum Two IR Spectrometers (PerkinElmer, USA). Washed ﬁbers
were obtained by adding the ﬁbers to a 100 ml  beaker with 50 ml
demineralized water and stirring gently for 1 min. The samples
were dried overnight in an exicator. The spectra were scanned from
4000 cm−1 to 550 cm−1 (only data from 1600 cm−1 to 1000 cm−1
were reported, as the spectra outside this region did not show any-
thing of relevance), with 1 cm−1 resolution, and an average of 28
scans are reported.
Release of Ala-Trp from FSP ﬁbers
FSP-(Ala-Trp) ﬁber: 1.7 mg  Ala-Trp was dissolved in 1 ml  HFIP
together with 125 mg  FSP. The solution was  spun with similar con-
ditions to the one described for FSP ﬁber formation.
FSP-(Ala-Trp) ﬁber and solvent were added to an Eppendorf
tube to achieve 4 mg  FSP ﬁber/ml and placed on an orbital shaker
(90 RPM). At the times 1, 5, 10, 15, 30, 60, 120 and 180 min, the
supernatant was  transferred to another 1.5 ml  tube, heated (95 ◦C
for 4 min) and centrifuged. The supernatant was  saved. 50 l of
sample was  added to a black ﬂat bottom 96 well microtiter plate
(Corning Incorporated, USA) together with 50 l of solvent, and ﬂu-
orescence at 360 nm upon excitation with 280 nm was measured
in a plate reader (Spectra Max  Gemini, Molecular Devices, USA).
Samples containing FSP-(Ala-Trp) ﬁbers, FSP ﬁbers and the sol-
vent without any ﬁbers were made for gastric buffer and intestinal
buffer.
All experiments were carried out in triplicate, and the mean
value ± SD are reported.
Results and discussion
Morphology of electrospun FSP ﬁbers
The morphology of the electrospun ﬁbers as a function of FSP
concentration was  investigated with SEM, Fig. 1A–E. At 50 mg/ml,
the majority of the observed structures were particles. When
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Fig. 2. SDS-PAGE showing the protein composition in FSP extract (lane 1), FD FSP
dissolved in water (lane 2), FD FSP dissolved in HFIP (lane 3) and a marker (lane 4).
the FSP concentration was increased to 75 mg/ml  and 100 mg/ml,
respectively, a larger tendency toward ﬁber formation versus par-
ticle formation was observed, although beads and particle-like
structures were still present. At a FSP concentration of 125 mg/ml,
beads and particles were approximately eliminated, and there was
an increased ﬁber diameter. Increasing the FSP concentration fur-
ther had no large inﬂuence on the ﬁber morphology (data not
shown). Fig. 1F shows the size distribution of the FSP ﬁber diameter
(excluding particles). At low FSP concentrations, the ﬁber diam-
eters were in the nano scale, e.g. for 75 mg/ml, ﬁber diameters
were between 100 and 700 nm.  At 125 mg/ml, the dominant ﬁber
diameter was approximately 1000 nm (though still varying from
hundreds of nm to several m)  and, at larger FSP concentrations,
the ﬁber diameter increased further. Although most pronounced
for low FSP concentration ﬁbers, a large size distribution and irreg-
ularities were observed. This may  originate as a result of low chain
entanglement between the proteins. The solvent may  also have
an impact on the morphology (e.g. the double, spindle like ﬁbers),
which may  arise as a result of solvent polarity and volatility. Since
ﬁbers made with an FSP concentration of 125 mg/ml were with-
out beads or particles and the ﬁber diameters had the smallest
variations, FSP ﬁbers made from FSP at 125 mg/ml were chosen
for further characterization. No attempts were made to modify the
diameter of uniform FSP ﬁbers by using surfactants and salts, for
instance, as this was not the main focus of this study.
Analysis of FSP protein composition by SDS-PAGE
To investigate any potential loss of material during process-
ing, FSP composition during the processing steps; FSP before FD
(FSP), FSP after FD (FD FSP/water), and FD FSP dissolved in HFIP (FD
FSP/HFIP), were analyzed with SDS-PAGE (Fig. 2). The band pat-
terns for the three samples were alike, suggesting that the protein
composition in the three solutions was similar. This indicates that
the protein composition of FSP was preserved during freeze drying
and dissolution in HFIP; hence, all water soluble proteins normally
found in the cod muscle will also be present in the FSP ﬁbers. This
was supported by amino acid analysis, which showed very similar
amino acid compositions for FSP, FD FSP and FSP ﬁbers (data not
shown).
Solubility and enzymatic degradation of FSP ﬁber
The solubility and enzymatic degradation of FSP ﬁbers and FD
FSP for a period of 4 h in gastric buffer, simulated gastric ﬂuid,
intestinal buffer and simulated intestinal ﬂuid was investigated.
Fig. 3A and E shows SDS-PAGE analyses of compounds released
from the FSP ﬁbers in gastric buffer and intestinal buffer. After
a short amount of time, low molecular weight (MW) compounds
were released in both systems. These compounds may  have been
attached to the ﬁbers, however not as a part of the ﬁber network,
and therefore they will be detached upon contact with water. Very
weak bands corresponding to compounds with larger Mw (∼25 kDa)
were observed after 4 h in gastric buffer, Fig. 3A. Similar to the low
Mw compounds released immediately, these compounds may  be
partially engaged in the ﬁber network; however, due to the larger
size, they have more electrostatic interactions with the ﬁber and
will consequently be released after a longer amount of time. Despite
this minimal release of compounds from the ﬁbers, the ﬁbers were
not solubilized over a period of 24 h in the enzyme free solutions
(data not shown). Characteristic drawbacks of many electrospun
nano-microﬁbers developed using natural biopolymers are their
high dissolution and degradation rates in aqueous (thus also physi-
ologically) environments. Hence they need thorough modiﬁcations
(often with very toxic agents) to become insoluble. The FSP ﬁbers
stand out in this context, being insoluble in aqueous solutions, and
can thus be used without further treatment. Another ﬁber system
that has been reported to be insoluble in water without crosslink-
ing is ﬁbers made of the basement membrane protein laminin I [9].
The omission of crosslinkers resulted in maintained bioactivity of
the laminin ﬁbers, which enabled the use of laminin ﬁbers to mimic
the basement membranes.
When pepsin or pancreatin was  present in the simulated ﬂuids,
it was observed by the naked eye that the ﬁbers were degraded.
Fig. 3B and F show SDS-PAGE analyses of the degradation frag-
ments for ﬁber degradation in simulated gastric ﬂuid or simulated
intestinal ﬂuid, respectively. In both situations all lanes contained
the same band pattern, including the solvent control, and hence all
bands in all lanes originated from the enzyme(s) in the solvent.
To further investigate the mechanism by which the ﬁbers were
enzymatically degraded, the amounts of enzymes were decreased
100 fold. SDS-PAGE analyses of the degradation fragments are seen
in Fig. 3C and G. Again, by observing the ﬁbers in the solvents by
eye, it was evident that the ﬁbers were degraded, though much
more slowly; ﬁbers in low activity simulated gastric ﬂuid were
not degraded completely until after 24 h (compared to after 30 min
with the higher amount of pepsin), and ﬁbers in low activity simu-
lated intestinal ﬂuid were only ∼50% degraded after 24 h (compared
to 100% with the higher amount of pancreatin). In Fig. 3C and
G no bands corresponding to large degradation fragments were
observed. However, the bands corresponding to compounds with
Mw around 6 kDa in Fig. 3C and G, lanes 1–7, were not observed in
the corresponding lanes in Fig. 3A and E; they may  originate from
degraded ﬁber.
Fig. 3D and H SDS-PAGE show analyses of degradation pattern
of FD FSP in low activity simulated gastric ﬂuid or low activity
simulated intestinal ﬂuid. In low activity simulated gastric ﬂuid,
proteins were partially degraded into larger fragments before being
completely degraded. In low activity simulated intestinal ﬂuid,
compounds were partially degraded into rather stabile fragments,
and after 4 h there was  still a signiﬁcant amount of compounds
that were not degraded. The differences between degradation pat-
terns for FD FSP and FSP ﬁbers suggest that electrospun FSP does
not follow the same degradation mechanism as FD FSP in solution.
In the ﬁbers, the proteins were most likely kept in an unfolded
state (in contrast to FD FSP in solution, where the proteins may
have been in a folded state), and therefore all cleavage sites were
available for the enzymes. Consequently, the FSP proteins in the
ﬁbers were more prone to degradation, and complete degradation
was thus possible. The fact that only small FSP ﬁber degradation
products were observed indicates that the ﬁbers were degraded
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Fig. 3. Solubility and degradation of FSP ﬁbers ((A)–(G)) and FD FSP ((D) and (H)) in gastric buffer (A), simulated gastric ﬂuid (B), low activity simulated gastric ﬂuid ((C)
and  (D)), intestinal buffer (E), simulated intestinal ﬂuid (F) and low activity simulated intestinal ﬂuid(G) and (H). (A)–(H) lanes 1–4 represent the protein composition in the
supernatant after 1 min, 30 min, 1 h and 4 h, respectively. (A)–(C) and (E)–(F) lane 5: solvent and lane 6: marker. (D) and (H) lane 5: FD FSP in buffer without enzyme (control),
lane  6: solvent and lane 7: marker.
directly into small fragments, rather than by initial degradation
into large fragments, followed by sequential degradation to smaller
fragments—as observed for the FD FSP.
To rule out that compounds (such as salts, small peptides,
nucleotides etc.) other than the FSP proteins were causing the insol-
uble nature of the FSP ﬁbers, the FSP extract was dialyzed (cut-off
6–8 kDa) prior to freeze drying. The dialyzed FD FSP was electro-
spun into ﬁbers, and the ﬁber solubility in gastric buffer or intestinal
buffer was investigated. These ﬁbers were also found to be insoluble
in the simulated ﬂuids (data not shown). As the dialysis eliminated
the majority of salts, small peptides, nucleotides etc., the majority
of the remaining compounds in the FSP were proteins: hence the
insoluble nature of the FSP ﬁbers in aqueous solutions pertains to
the proteins. The fact that the water soluble FSP became insolu-
ble after electrospinning may  be due to the proteins being in an
unfolded state when turned into ﬁbers. Unfolding may  be caused
either by the solvent or by the electrospinning process; however
this was not further investigated in this study.
Bioactivity of the FSP ﬁbers
Degradation products from FSP ﬁbers degraded by pepsin or
pancreatin were investigated for inhibitory properties against DPP-
IV. Dose-response curves for FSP ﬁbers degraded in simulated
gastric ﬂuid, simulated gastric ﬂuid, FSP ﬁbers degraded in sim-
ulated intestinal ﬂuid, simulated intestinal ﬂuid, and diprotin, a
known DPP-IV inhibitor, are shown in Fig. 4. The dose–response
curves show that the DPP-IV activity decreases with increasing
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Fig. 4. Dose–response curves for FSP ﬁbers degraded in simulated gastric ﬂuid (),
FSP ﬁbers degraded in simulated intestinal ﬂuid (), simulated gastric ﬂuid (x), sim-
ulated intestinal ﬂuid (x) and diprotin (©), against DPP-IV. Mean ± SD is reported,
n  = 3. The buffer controls were carried out in singlets.
amount of inhibitor, indicating that the degraded FSP ﬁbers contain
inhibitory properties against DPP-IV. The origin of the bioactiv-
ity may  be peptides containing proline (the proline content in the
FSP ﬁbers was ∼4%), as peptides containing proline are known to
have an inhibitory effect toward DPP-IV [44]. As the plots illustrate,
the degradation products of FSP ﬁbers, collectively, were not as
potent inhibitors as diprotin. This was expected, as diprotin is a pure
antagonist, whereas it is highly unlikely that all FSP ﬁber degrada-
tion products have inhibitory activity against DPP-IV, instead FSP
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degradation products were a mixture of inhibitory peptides and
peptides without any inﬂuence on DPP-IV activity.
FSP ﬁbers as a carrier system
A large range of peptides contain bioactive properties. As the FSP
ﬁbers may  be utilized as a carrier system for such bioactive pep-
tides, a model system was set up to simulate the release proﬁle of a
peptide from the FSP ﬁbers. Ala-Trp was chosen to simulate a bioac-
tive peptide due to its inherent ﬂuorescent properties, enabling the
release of Ala-Trp from FSP ﬁbers to be investigated by ﬂuorescence.
The following sections present the encapsulation of Ala-Trp into FSP
ﬁbers and the release of Ala-Trp from FSP-(Ala-Trp) ﬁbers. In addi-
tion, RhdB was encapsulated into the FSP to visually demonstrate
the distribution of an encapsulated compound in the FSP ﬁber.
Encapsulation of Ala-Trp into FSP ﬁbers
The absorption of side chains in a protein may  deviate from the
absorption of side chains in a dipeptide as a result of, for instance,
the surrounding environment [45]. This was utilized to verify that
Ala-Trp was encapsulated into the FSP ﬁbers, by recording FTIR
spectra of Ala-Trp, FSP ﬁbers and FSP-(Ala-Trp) ﬁbers (Fig. 5).
The spectrum for Ala-Trp (Fig. 5C) contained a large degree of
ﬁne structure, and was simpler to analyze as it only represented
one molecule. The spectra for FSP and FSP-Ala-Trp (Fig. 5A and B)
were more complicated, as they were a combination of absorption
spectra from many different compounds. The observed peaks may
thus be a combination of several absorption bands from different
compounds, leading to a decrease in ﬁne structure. As all samples
contained peptides, similar peak patterns were expected (espe-
cially for FSP and FSP-Ala-Trp). Comparing the spectra for FSP and
FSP-Ala-Trp, large similarities were observed, however two peaks
stand out (indicated with arrows), being present in the spectrum
for FSP-Ala-Trp but not in the spectrum for FSP, most likely aris-
ing because of Ala-Trp. Comparing the peak patterns in the region
where the spectrum for FSP-Ala-Trp deviates from FSP, with the
peak pattern for Ala-Trp alone, the peak at 1098 cm−1 have shifted
to 1090 cm−1 in Ala-Trp’s spectrum. This peak is one of the char-
acteristic peaks for the indole IR spectrum. The peak at 1192 cm−1
also stands out in the FSP-Ala-Trp spectrum. Compared to the Ala-
Trp spectrum, several peaks are present in this region, and the peak
in the FSP-Ala-Trp spectrum may  arise as a result of a shift in the
relative intensity of the overlapped bands, due to changes in the
surrounding environment.
A washing procedure was carried out to reduce dipeptides
located on the outside of the ﬁber; thus only Ala-Trp encapsulated
into the ﬁber network was present. Fig. 5B shows spectra of the
ﬁbers after a washing procedure. The peak patterns did not change
signiﬁcantly, though the intensities were affected by washing. Nev-
ertheless, the spectrum still contained peaks that could be ascribed
to Ala-Trp, indicating that some amount of the dipeptide was still
present inside the ﬁber network.
Release of Ala-Trp from the FSP ﬁbers
Release proﬁles of Ala-Trp from FSP ﬁbers in gastric buffer or
intestinal buffer, without enzymes, are seen in Fig. 6. The inset
ﬁgure is a zoom in on the release within the ﬁrst 20 min. Within
the ﬁrst minute, the Ala-Trp concentration increased to ∼30 M
in both solvents. In gastric buffer the maximum release (∼60 M)
was obtained after ∼30 min, whereas maximum release (∼70 M)
in intestinal buffer was obtained after ∼15 min. The reason for the
extended release time in gastric buffer may  have to do with the
acidic environment, which leads to protonation of all protonation
sites in the ﬁbers. If Ala-Trp is released by diffusion, the rate of
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Fig. 5. FT-IR spectra of (A) FSP-(Ala-Trp) ﬁbers (full line) and FSP ﬁbers (dashed
line), (B) FSP-(Ala-Trp) (full line) ﬁbers and FSP ﬁbers (dashed line) after a washing
procedure and (C) Ala-Trp. The arrows highlight signiﬁcant peaks for Ala-Trp and
Ala-Trp in FSP-(Ala-Trp) ﬁbers.
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Fig. 6. Release proﬁles of Ala-Trp from FSP-(Ala-Trp) ﬁbers in gastric buffer () or
intestinal buffer (). The inset ﬁgure is a zoom in on the release proﬁle for the ﬁrst
60  min. Mean ± SD, n = 3 is reported.
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Fig. 7. Confocal images of FSP–RhdB ﬁbers. (A) 3D representation of FSP–RhdB ﬁbers constructed from multiple 2D images. (B) and (C) Scans at height x + 300 nm (A) and x
(B).
release will depend on chemical interactions between Ala-Trp and
the ﬁber network. Increased protonation of the FSP ﬁbers will lead
to increased chemical interactions and thus a prolonged release
rate. The theoretical Ala-Trp concentration upon total release of
Ala-Trp from the FSP ﬁber was 97.5 M.  Hence, ∼30% of the encap-
sulated Ala-Trp dipeptide was potentially trapped inside the ﬁbers
and would not be released unless the ﬁbers were degraded. In an
attempt to release the remaining 30%, enzymes (pepsin or pan-
creatin) were added. Unfortunately, the background ﬂuorescence
from the enzymes made it impossible to distinguish the signal from
Ala-Trp from the background signal. The release properties of the
system may  be tuned (e.g. prolonged release, continuous release,
delayed release), for instance by post treatments of the ﬁbers, or by
changing the composition of the FSP solution, however this study
focuses solely on the properties of the unmodiﬁed FSP ﬁbers.
As a surrogate for Ala-Trp, RhdB, which is readily detectable in
the presence of enzymes, was encapsulated into the FSP ﬁbers (data
not shown). Although RhdB is not a peptide, it is somewhat similar
in size (Mw(RhdB) = 479 g/mol versus Mw(Ala-Trp) = 275 g/mol) and
it contains some of the same functional groups. Moreover, RhdB
is known to interact well with proteins (it is used as a staining
agent for proteins). It was therefore hypothesized to mimic  Ala-Trp
with respect to encapsulation in the ﬁber network. When FSP ﬁbers
with RhdB were placed in gastric buffer or intestinal buffer, without
enzymes being added, ∼70% of the RhdB was released, compared
to when enzymes were present. This corresponded very well to the
behavior of Ala-Trp, and it can be assumed that the remaining 30%
Ala-Trp may  be released upon ﬁber degradation.
Distribution of compounds encapsulated in the FSP ﬁbers
Encapsulation of Ala-Trp and RhdB was carried out by mixing
the respective compound together with the FSP protein solution
prior to electrospinning. FSP–RhdB ﬁbers were studied with confo-
cal microscopy to verify that the RhdB was uniformly distributed
throughout the ﬁber. The steady RhdB ﬂuorescence observed from
the cross sections of the ﬁbers indicates that RhdB was  distributed
throughout the ﬁber, Fig. 7A. This was further supported by looking
at the RhdB ﬂuorescence in two different planes of the FSP–RhdB
ﬁber, Fig. 7B and C. Here similar ﬂuorescence was  observed in
both planes, indicating that RhdB was distributed throughout the
ﬁber. Studying the auto ﬂuorescence from unloaded FSP ﬁbers (data
not shown), showed small areas around in the sample with an
increased autoﬂuorescence, which may  be a result of increased pro-
tein density. In FSP–RhdB ﬁbers comparable areas were observed
as dark spots—areas with decreased RhdB ﬂuorescence. These
observations may  be explained by a dense FSP network, with corre-
spondingly limited RhdB. The dense FSP network causes increased
autoﬂuorescence, decreased amount of RhdB causes decreased
RhdB ﬂuorescene, and thus dark spots.
Conclusion
Nano-microﬁbers were made from FSP using the electrospin-
ning process. The FSP concentration had a large inﬂuence on the
morphology of the electrospun FSP ﬁbers. The FSP ﬁbers were insol-
uble in gastric buffer and intestinal buffer, but the ﬁbers were
degraded when enzymes were present. The enzymes degraded the
ﬁbers into small peptides rather than into large fragments that
were subsequently degraded to small peptides. The residual FSP
ﬁber degradation products were inhibitors of the diabetes related
DPP-IV, providing an inherent bioactivity to the FSP ﬁbers. When
encapsulating a compound into the FSP ﬁbers, the compound was
distributed uniformly throughout the ﬁber, except for small areas
where the protein network was densely packed. The release pro-
ﬁle of a dipeptide from the FSP ﬁbers was composed of a burst
release within one minute followed by a slower, although still fast,
release. In gastric buffer, the maximum release of the dipeptide was
released within 30 min, and in intestinal buffer maximum release
was obtained after 15 min. ∼30% of the encapsulated compound
was not released in the timespan of the experiment.
Acknowledgements
This study was funded by the Danish Strategic Research Coun-
cil (DSF-10-93456, FENAMI Project). The authors would also like
to thank Prof. Klaus Qvotrup (the Core Facility for Integrated
Microscopy, University of Copenhagen), for assistance with con-
focal imaging.
References
[1] N. Bhardwaj, S.C. Kundu, Electrospinning: a fascinating ﬁber fabrication tech-
nique, Biotechnol. Adv. 28 (2010) 325–347.
[2] P. Supaphol, O. Suwantong, P. Sangsanoh, S. Srinivasan, R. Jayakumar, S.V. Nair,
Electrospinning of biocompatible polymers and their potentials in biomedical
applications, Biomed. Appl. 246 (2012) 213–240.
[3] A. Frenot, I.S. Chronakis, Polymer nanoﬁbers assembled by electrospinning,
Curr. Opin. Colloid Interface Sci. 8 (2003) 64–75.
[4] D.B. Khadka, D.T. Haynie, Protein- and peptide-based electrospun nanoﬁbers
in  medical biomaterials, Nanomedicine 8 (2012) 1242–1262.
[5] Z.-M. Huang, Y. Zhang, S. Ramakrishna, C. Lim, Electrospinning and mechan-
ical characterization of gelatin nanoﬁbers, Polymer (Guildford) 45 (2004)
5361–5368.
[6] J.A. Matthews, G.E. Wnek, D.G. Simpson, G.L. Bowlin, Electrospinning of collagen
nanoﬁbers, Biomacromolecules 3 (2002) 232–238.
[7] P. Songchotikunpan, J. Tattiyakul, P. Supaphol, Extraction and electrospinning
of  gelatin from ﬁsh skin, Int. J. Biol. Macromol. 42 (2008) 247–255.
[8] Y. Dror, T. Ziv, V. Makarov, H. Wolf, A. Admon, E. Zussman, Nanoﬁbers made of
globular proteins, Biomacromolecules 9 (2008) 2749–2754.
K. Stephansen et al. / Colloids and Surfaces B: Biointerfaces 122 (2014) 158–165 165
[9] C.P. Barnes, M.J. Smith, G.L. Bowlin, S.A. Sell, J.A. Matthews, D.G. Simpson, et al.,
Feasibility of electrospinning the globular proteins hemoglobin and myoglobin,
J.  Eng. Fibers Fabr. 1 (2006) 16–29.
[10] R.A. Neal, S.G. McClugage, M.C. Link, L.S. Sefcik, R.C. Ogle, E.A. Botchwey,
Laminin nanoﬁber meshes that mimic  morphological properties and bioactivity
of  basement membranes, Tissue Eng., C: Methods 15 (2009) 11–21.
[11] D.L. Woerdeman, P. Ye, S. Shenoy, R.S. Parnas, G.E. Wnek, O. Troﬁmova, Elec-
trospun ﬁbers from wheat protein: investigation of the interplay between
molecular structure and the ﬂuid dynamics of the electrospinning process,
Biomacromolecules 6 (2005) 707–712.
[12] R. Machado, A. da Costa, V. Sencadas, C. Garcia-Arévalo, C.M. Costa, J. Padrão,
et  al., Electrospun silk-elastin-like ﬁbre mats for tissue engineering applica-
tions, Biomed. Mater. 8 (2013) 065009.
[13] F. Zhang, B. Zuo, Z. Fan, Z. Xie, Q. Lu, X. Zhang, et al., Mechanisms and control
of  silk-based electrospinning, Biomacromolecules 13 (2012) 798–804.
[14] T. Elakkiya, G. Malarvizhi, S. Rajiv, T.S. Natarajan, Curcumin loaded electrospun
Bombyx mori silk nanoﬁbers for drug delivery, Polym. Int. 63 (2014) 100–105.
[15] J. Chutipakdeevong, U.R. Ruktanonchai, P. Supaphol, Process optimization of
electrospun silk ﬁbroin ﬁber mat  for accelerated wound healing, J. Appl. Polym.
Sci.  130 (2013) 3634–3644.
[16] S. Baiguera, C. Del Gaudio, E. Lucatelli, E. Kuevda, M.  Boieri, B. Mazzanti, et al.,
Electrospun gelatin scaffolds incorporating rat decellularized brain extracellu-
lar  matrix for neural tissue engineering, Biomaterials 35 (2014) 1205–1214.
[17] Y.Z. Zhang, J. Venugopal, Z.-M. Huang, C.T. Lim, S. Ramakrishna, Crosslinking of
the electrospun gelatin nanoﬁbers, Polymer (Guildford) 47 (2006) 2911–2917.
[18] X. Liu, X. Wang, J. Zhang, X. Wang, Y. Lu, H. Tu, et al., Electrospun poly(vinyl alco-
hol)/albumin egg/rectorite composite nanoﬁbrous mats and their cytotoxicity,
RSC Adv. 4 (2014) 8867–8873, http://dx.doi.org/10.1039/c3ra45344h.
[19] A.-C. Vega-Lugo, L.-T. Lim, Effects of poly(ethylene oxide) and pH on the elec-
trospinning of whey protein isolate, J. Polym. Sci., Part B: Polym. Phys. 50 (2012)
1188–1197.
[20] H. Jiang, P. Zhao, K. Zhu, Fabrication and characterization of zein-based nanoﬁ-
brous scaffolds by an electrospinning method, Macromol. Biosci. 7 (2007)
517–525.
[21] S.W.a. Himaya, D.-H. Ngo, B. Ryu, S.-K. Kim, An active peptide puriﬁed from
gastrointestinal enzyme hydrolysate of Paciﬁc cod skin gelatin attenuates
angiotensin-1 converting enzyme (ACE) activity and cellular oxidative stress,
Food Chem. 132 (2012) 1872–1882.
[22] G. Pilon, J. Ruzzin, L.-E. Rioux, C. Lavigne, P.J. White, L. Frøyland, et al., Dif-
ferential effects of various ﬁsh proteins in altering body weight, adiposity,
inﬂammatory status, and insulin sensitivity in high-fat-fed rats, Metabolism
60 (2011) 1122–1130.
[23] H.S. Ewart, D. Dennis, M.  Potvin, C. Tiller, L. Fang, R. Zhang, et al., Development
of a salmon protein hydrolysate that lowers blood pressure, Eur. Food Res.
Technol. 229 (2009) 561–569.
[24] E.C.Y. Li-Chan, S. Hunag, C. Jao, K. Ho, K. Hsu, Peptides derived from Atlantic
salmon skin gelatin as dipeptidyl-peptidase IV inhibitors, J. Agric. Food Chem.
60 (2012) 973–978.
[25] K.B. Moore, C.D. Saudek, Therapeutic potential of dipeptidyl peptidase-IV
inhibitors in patients with diabetes mellitus, Am.  J. Ther. 15 (2008) 484–491.
[26] M.  Lehrke, N. Marx, New antidiabetic therapies: innovative strategies for an old
problem, Curr. Opin. Lipidol. 23 (2012) 569–575.
[27] V. Ouellet, J. Marois, S.J. Weisnagel, H. Jacques, Dietary cod protein improves
insulin sensitivity in insulin-resistant men and women: a randomized con-
trolled trial, Diabetes Care 30 (2007) 2816–2821.
[28] V. Ouellet, S.J. Weisnagel, J. Marois, J. Bergeron, P. Julien, R. Gougeon, et al.,
Dietary cod protein reduces plasma C-reactive protein in insulin-resistant men
and women, J. Nutr. 138 (2008) 2386–2391.
[29] Q.P. Pham, U. Sharma, A.G. Mikos, Electrospinning of polymeric nanoﬁbers
for  tissue engineering applications: a review, Tissue Eng. 12 (2006)
1197–1211.
[30] T.J. Sill, H. a von Recum, Electrospinning: applications in drug delivery and
tissue engineering, Biomaterials 29 (2008) 1989–2006.
[31] M.  Zamani, M.P. Prabhakaran, S. Ramakrishna, Advances in drug delivery
via  electrospun and electrosprayed nanomaterials, Int. J. Nanomed. 8 (2013)
2997–3017.
[32] Y.-F. Goh, I. Shakir, R. Hussain, Electrospun ﬁbers for tissue engineering, drug
delivery, and wound dressing, J. Mater. Sci. 48 (2013) 3027–3054.
[33] H. Liu, X. Ding, G. Zhou, P. Li, X. Wei, Y. Fan, Electrospinning of nanoﬁbers for
tissue engineering applications, J. Nanomater. 2013 (2013) 1–11.
[34] L.K. Macri, L. Sheihet, A.J. Singer, J. Kohn, R.a.F. Clark, Ultrafast and fast bio-
erodible electrospun ﬁber mats for topical delivery of a hydrophilic peptide, J.
Controlled Release 161 (2012) 813–820.
[35] M.  Jannesari, J. Varshosaz, M.  Morshed, M.  Zamani, Composite poly(vinyl
alcohol)/poly(vinyl acetate) electrospun nanoﬁbrous mats as a novel wound
dressing matrix for controlled release of drugs, Int. J. Nanomed. 6 (2011)
993–1003.
[36] P. Vrbata, P. Berka, D. Stránská, P. Dolezˇal, M.  Musilová, L. Cizˇinská, Electro-
spun drug loaded membranes for sublingual administration of sumatriptan
and naproxen, Int. J. Pharm. 457 (2013) 168–176.
[37] F. Ignatious, L. Sun, C.-P. Lee, J. Baldoni, Electrospun nanoﬁbers in oral drug
delivery, Pharm. Res. 27 (2010) 576–588.
[38] G. Verreck, I. Chun, J. Peeters, J. Rosenblatt, M.E. Brewster, Preparation and char-
acterization of nanoﬁbers containing amorphous drug dispersions generated
by  electrostatic spinning, Pharm. Res. 20 (2003) 810–817.
[39] J. Zeng, X. Xu, X. Chen, Q. Liang, X. Bian, L. Yang, et al., Biodegradable electrospun
ﬁbers for drug delivery, J. Controlled Release 92 (2003) 227–231.
[40] X. Shen, D. Yu, L. Zhu, C. Branford-White, K. White, N.P. Chatterton, Electrospun
diclofenac sodium loaded Eudragit® L 100-55 nanoﬁbers for colon-targeted
drug delivery, Int. J. Pharm. 408 (2011) 200–207.
[41] X. Li, M.  a Kanjwal, L. Lin, I.S. Chronakis, Electrospun polyvinyl-alcohol
nanoﬁbers as oral fast-dissolving delivery system of caffeine and riboﬂavin,
Colloids Surf., B: Biointerfaces 103 (2013) 182–188.
[42] U.K. Laemmli, Cleavage of structural proteins during the assembly of the head
of  bacteriophage T4, Nature 227 (1970) 680–685.
[43] C. a Schneider, W.S. Rasband, K.W. Eliceiri, NIH Image to ImageJ: 25 years of
image analysis, Nat. Methods 9 (2012) 671–675.
[44] K. Augustyns, P. Van der Veken, A. Haemers, Inhibitors of proline-speciﬁc dipep-
tidyl peptidases: DPP IV inhibitors as a novel approach for the treatment of Type
2  diabetes, Expert Opin. Ther. Pat. 15 (2005) 1387–1407.
[45] A. Barth, The infrared absorption of amino acid side chains, Prog. Biophys. Mol.
Biol.  74 (2000) 141–173.
  
 
 
Appendix II – Paper II 
Paper II 
Bioactive protein-based nanofibers promotes transepithelial permeation of intact therapeutic 
protein by interactions with biological components 
K. Stephansen, M. García-Díaz, F. Jessen, I.S. Chronakis, H.M. Nielsen 
Macromolecular Bioscience (in revision) 
1 
 
Bioactive protein-based nanofibers promotes transepithelial permeation of intact therapeutic 
protein by interactions with biological components 
 
Karen Stephansen
1,2
, María García-Díaz
2
, Flemming Jessen
1
, Ioannis S. Chronakis
1*
, Hanne 
Mørck Nielsen
2*
 
1
 National Food Institute, Technical University of Denmark, Søltofts Plads 227, DK-2800 Kgs. 
Lyngby, Denmark. 
2
 Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, 
Universitetsparken 2, DK-2100 Copenhagen, Denmark. 
 
*Corresponding authors:  
Hanne Mørck Nielsen; mail: hanne.morck@sund.ku.dk, phone: +45 35 33 63 46, address: 
Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, 
Universitetsparken 2, DK-2100 Copenhagen, Denmark. 
Ioannis S. Chronakis; mail: ioach@food.dtu.dk, phone: +45 45 25 27 16, address: National Food 
Institute, Technical University of Denmark, Søltofts Plads 227, DK-2800 Kgs. Lyngby, Denmark 
  
2 
 
Abstract 
In the present study the potential of using bioactive electrospun fish proteins (FSP) as a carrier 
matrix for small therapeutic proteins was demonstrated especially focusing on the challenges 
with oral delivery. The inherent structural and chemical properties of FSP as a biomaterial 
facilitated interactions with cells and enzymes found in the gastrointestinal tract and displayed 
excellent biocompatibility. More specifically, insulin was efficiently encapsulated into FSP 
fibers maintaining its conformation, and subsequent controlled release was obtained in simulated 
intestinal fluid. The encapsulation of insulin into FSP fibers provided protection against 
chymotrypsin degradation, and resulted in an increase in insulin transport to around 12% without 
compromising the cellular viability. This increased transport was driven by interactions upon 
contact between the nanofibers and the Caco-2 cell monolayer leading to the opening of the tight 
junction proteins. Overall, electrospun FSP may constitute a novel material for oral delivery of 
biopharmaceuticals. 
 
Introduction 
The interest in exploring the potential of oral delivery for biopharmaceuticals, mainly peptides 
and small proteins, becomes increasingly clear both from a therapeutic and from a patient 
convenience point of view. These compounds deviates from small molecules especially with 
regards to their larger size and vulnerability towards enzymatic degradation
[1]
, which make it 
extremely challenging to obtain a therapeutic effect after non-injectable administration. Delivery 
via the oral route implies a series of challenges; such as ensuring sufficient structural and 
chemical stability of the drug by protection against the harsh acidic environment in the stomach 
and the enzymes in the gastrointestinal (GI) tract. Further, permeation through the mucosa may 
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be hindered by the properties of these drugs
[2,3]
. Despite many promising attempts to develop 
new oral formulations for biopharmaceuticals, especially focused on particle-based drug delivery 
systems, none has so far succeeded and new biomaterials and approaches are needed
[4–10]
. 
During the last decade, electrospinning has gained increasing interest as a promising technique 
for biomedical applications. This straightforward and scalable technique is suitable for the 
production of continuous and functional nano- and microfibers from a wide range of 
(bio)polymers
[11–13]
. Due to their similarity to the extracellular matrix, electrospun fibers have 
been extensively studied for tissue engineering, wound healing, and nerve and bone 
regeneration
[14–17]
. The large surface to volume ratio of the fibers can also be exploited to 
enhance the solubility and release of poorly soluble drugs and thus increase the dissolution 
rate
[18–20]
. 
For therapeutically active macromolecules, a number of reports have arisen regarding the 
encapsulation of proteins into electrospun polymer fibers
[15,17,21]
. Administration of 
macromolecules through the oral cavity using nanofibers has been investigated recently
[22–24]
 
showing promising results for electrospun scaffolds as non-injectable and non-invasive drug 
delivery systems. But despite of the associated challenges, oral delivery is still the most preferred 
route of administration - a route already utilized by nature for delivery nutrients. However, 
intestinal delivery of macromolecules using nanofibers has not yet been explored.  
The homogeneity and elongated structure make polymers an excellent material for 
electrospinning. However, only few are biodegradable and biocompatible; properties that are 
essential for use in biomedical systems. To address the need for such properties, attention has 
been drawn towards some of nature’s own materials, proteins, as they are biocompatible, as well 
as degradable by proteolytic enzymes. They are easy accessible in large quantities either from 
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natural sources or from biological expression, and several proteins have been successfully 
electrospun
[25]
. In a previous study, we introduced electrospinning of water soluble cod 
sarcoplasmic proteins (FSP)
[26]
. FSP is a heterogeneous mixture of proteins, containing up to 200 
kDa large proteins. As a result, the FSP fibers displayed an interesting morphology; containing 
fiber diameters from hundreds of nanometers to few microns. The fibers were insoluble in 
aqueous media, but degraded by proteolytic enzymes – even more degraded than FSP in solution. 
These properties make the FSP fibers a very interesting carrier material, as various post 
electrospinning treatments (e.g. crosslinking of the fibers) normally are required for obtaining 
insolubility of fibers made from water soluble materials
[27,28]
. The numerous health benefits of 
consuming fish
[29–31]
 make FSP fibers appealing carriers for oral drug formulations. Further, the 
inhibitory effects of FSP on dipeptidyl peptidase-4 (DPP-IV)
[32]
, an enzyme with an essential 
role in glucose metabolism and linked to type 2 diabetes, makes FSP fibers an attractive platform 
for the delivery of antidiabetic drugs like insulin
[33,34]
.  From an economical and sustainable point 
of view, many of the proteins that comprise the FSP are also found in waste water from the fish 
industry
[35]
, which can thus provide a large and cheap FSP source. Despite the heterogeneity of 
the FSP, the material has proven to be very stable, and no variation in eletrospinning or fiber 
properties have been observed between different batches. Proteins are ideal candidate 
components to develop new “soft” materials for biomedical, food and biotechnological 
applications, particularly, when they, like FSP, already are common constituents of food. 
It is our hypothesis that the FSP will serve as an excellent material for, among others, oral 
delivery applications. The inherent chemical properties of the proteins, together with the 
structural properties of the nanofibers, will ensure good interactions with the biological 
components comprising the barrier for obtaining efficient delivery of labile drugs. Additionally, 
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the FSP fibers will serve to physically protect and thus minimizing the degradation of insulin. To 
the best of our knowledge, no attempt has been made to utilize the properties of protein nano-
microfibers for insulin encapsulation, and evaluate such for oral administration. 
 
Materials and Methods 
Materials 
Cod (Gadus morhua) from the North Sea was obtained from Hanstholm Fisk (Hanstholm, 
Denmark). Human insulin was kindly provided by Sanofi-Aventis Deutschland (Frankfurt, 
Germany). Soy-bean phosphatidylcholine (SPC, purity 98%) was purchased from Lipoid 
(Ludwigshafen, Germany). 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES) was 
acquired from AppliChem (Darmstadt, Germany). 1,1,1,3,3,3-Hexafluoro-2-propanol (HFIP), 2-
(N-morpholino)ethane sulfonic acid (MES), Hank´s balanced salt solution (HBSS), sodium 
taurocholate hydrate (purity > 97%), -chymotrypsin (Type II, from bovine pancreas, ≥ 40 
units/mg protein) and phenazine methosulfate (PMS), fluorescein isothiocyanate (FITC), 
dimethylsulfoxide (DMSO) and DPX Mountant for histology were obtained from Sigma-Aldrich 
(St. Louis, MO, USA). 3-(4,5-Dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium (MTS) was purchased from Promega (Madison, WI, USA). Anti-
ZO-1 monoclonal antibody (mouse, AlexaFluor 594 conjugate) and anti-Claudin-4 monoclonal 
antibody (mouse, AlexaFluor 488 conjugate) were purchased from Invitrogen (Carlsbad, CA, 
USA). 
All the other reagents were obtained commercially at analytical grade and used without further 
purification, and the chromatographic solvents were of HPLC grade. Ultrapure water from 
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Barnstead NanoPure Systems (Thermo Scientific, Waltham, MA, USA) was used throughout the 
studies. 
 
Preparation of FSP-Ins Fibers  
FSP were isolated from fresh cod and fibers were prepared as previously described
[26]
 (see 
Supplementary data S1, S2). A concentration of 125 mg/mL FSP was used together with 20 
mg/mL insulin. The electrospinning was conducted at room temperature, and samples were 
stored at -20°C until further analysis. Prior to experiments fiber mats were cut into 3×6 mm 
sheets. For some cell experiments fiber sheets of 3×3 mm, 3×6 mm or 6×6 mm were also used. 
To evaluate the distribution of insulin in the fibers, insulin was labeled with FITC similar to the 
method described by Clausen et al.
[36]
 (Supplementary data S3) and encapsulated into the FSP 
fibers together with unlabeled insulin at a ratio of 1:4 (w/w) following the standard procedure.  
 
Characterization of Electrospun Fibers  
The morphology of the fibers was investigated using scanning electron microscopy (SEM) 
(FEI Inspect, Hillsboro, OR, USA). Approximately 0.5×0.5 cm of the fiber sheet was placed on 
carbon tape and sputter coated with gold, 10 s, 40 mA utilizing a Cressington 208HR Sputter 
Coater (Cressington Scientific Instruments, Watford, England). The diameters of 60 fibers were 
measured with the imaging processing software ImageJ
[37]
. The localization of FITC-insulin was 
analyzed with laser scanning confocal microscopy (LSCM) (Zeiss LSM 780, Jena, Germany) 
detected at 519 nm after excitation with 495 nm, and compared to the bright field image of the 
fibers. The images were processed using ZEN 2012 lite software (Zeiss, Jena, Germany). 
 
7 
 
Analysis of Insulin by RP-HPLC 
Insulin concentrations were analyzed by reverse phase high-pressure liquid chromatography 
(RP-HPLC) using a Prominence system (Shimadzu, Kyoto, Japan) equipped with an Aeris 
WIDEPORE XB-C18 column (100×2.10 mm, 3.6 m) (Phenomenex, Allerød, Denmark) and a 
PDA detector (SPD-M20A, Shimadzu). The mobile phase A consisted of 95% H2O/5% 
acetonitrile (AcCN)/0.1% trifluoroacetic acid (TFA) (vol%) and mobile phase B consisted of 
95% AcCN/5% H2O/0.1% TFA (vol%). The autosampler temperature was 4°C. Insulin was 
eluted using a linear gradient of mobile phase B from 20-50% over 3.5 min at a constant flow of 
0.8 mL/min and 40°C. Insulin was quantified using automatic integration of the peak at 218 nm 
(retention time 2.7 min). Limit of detection (LOD) and limit of quantification (LOQ) were 0.2 
g/mL and 0.8 g/mL (n=3), respectively.   
 
Release of Insulin From FSP-Ins Fibers 
In vitro release of insulin from the fibers was performed in 10 mM HEPES-HBSS buffer (pH 
7.4), 10 mM MES-HBSS buffer (pH 6.5) or simulated small intestine fluid SSIF-HBSS (10 mM 
MES, 3 mM sodium taurocholate and 0.2 mM SPC in HBSS, pH 6.5) during 8 h at 37°C with 
continuous orbital mixing. FSP-Ins fibers were placed in the pre-warmed buffers at a 
concentration of 3.5 mg/mL. Aliquots of 100 l of the supernatant were taken at regular time 
points and replaced with fresh buffer. The samples were analyzed with RP-HPLC as previously 
described. The experiment was carried out in triplicates. 
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Quantification of Encapsulation Efficiency 
A concentration of 3.5 mg/mL FSP-Ins fibers were added to 18 mM SDS in 10 mM MES-HBSS 
buffer and incubated at 37°C with continuous orbital mixing. After 2 h the fibers were fully 
degraded, and the insulin concentration was quantified by using RP-HPLC, as previously 
described. The experiment was carried out in triplicates. 
Conformational Stability of Insulin 
The tertiary structure of insulin after release from the fibers was analyzed using circular 
dichroism (CD). A concentration of 3.5 mg/mL FSP-Ins or FSP fibers were incubated for 4 h at 
37°C in 10 mM HEPES buffer (pH 7.4). The supernatants were analyzed on a J-815 Jasco CD 
spectrometer (Jasco, Tokyo, Japan). A 0.5 mg/mL insulin solution was used as control. Near-UV 
spectra (250-350 nm) were recorded with a 0.5 nm step size, and an average of 5 repeats was 
reported. A quartz cell (l = 0.5 cm) was used. CD spectra of the appropriate reference were 
recorded and subtracted. All spectra were normalized according to the insulin concentration and 
2
nd
 order smoothing was performed.  
 
Enzymatic Degradation Studies 
A concentration of 3.5 mg/mL FSP-Ins fibers or 0.5 mg/mL insulin solution was incubated 
with SSIF-HBSS buffer (pH 6.5) in the presence of -chymotrypsin (0.05 U/mL) at 37°C with 
continuous orbital mixing. Aliquots of 30 l were taken at regular time points and added to ice 
cold HPLC vials to stop the enzymatic degradation. The samples were analyzed immediately on 
RP-HPLC as previously described. The experiment was carried out in triplicates. 
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Cell Culture 
Caco-2 cells (DSMZ, Braunschweig, Germany) were cultured in DMEM supplemented with 
10% (vol%) FBS, penicillin/streptomycin (100 U/mL and 100 μg/mL), 1% (vol%) L-glutamine 
and 1% (vol%) non-essential amino acids at 37 °C in an atmosphere of 5% CO2. Cells grown in 
T75 culture flasks were passaged weekly. The cells were seeded at a density of 1 x 10
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cells/insert onto 12-well polycarbonate Transwell
®
 filter inserts (1.12 cm
2
 growth area, 0.4 μm 
pore size) (Corning Costar, Tewksbury, MA, USA). The apical and basolateral media were 
replaced every other day and the cells were used after 20 days of culturing. All experiments were 
performed within a range of 11 successive passages.  
 
Permeability Studies 
Insulin transport across Caco-2 cell monolayers was studied during 4 h at 37 °C on a Max Q 
200 horizontal shaker (Thermo Scientific, Waltham, MA, USA),  (75 rpm). Culture media was 
removed and Caco-2 cell monolayers were washed with 10 mM HEPES-HBSS buffer (pH 7.4). 
For insulin permeability studies, sheets of FSP-Ins fibers were added to the apical side together 
with 0.5 mL buffer (HEPES-HBSS, MES-HBSS or SSIF-HBSS). The concentrations obtained 
were normalized according to the weight of the fibers. As controls, 0.5 mg/mL insulin solutions 
in the different buffers were used. In all cases, 1 mL HEPES-HBSS was added to the basolateral 
side. Samples of 100 l were withdrawn from the basolateral side at fixed time points and 
replaced with pre-heated buffer. The samples were stored at -20 ˚C until analysis with RP-HPLC. 
All experiments were carried out in triplicates or more and in at least 3 different cell passage 
numbers.  
The apparent permeability coefficient (Papp) was calculated according to Equation (1): 
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𝑃𝑎𝑝𝑝 = (𝜕𝑄 𝜕𝑡⁄ ) 𝑥 1 (𝐴 𝑥 𝐶0)⁄   (1) 
where 𝜕𝑄 𝜕𝑡⁄  is the steady state rate of permeation, A is the diffusion area, and C0 the initial 
donor concentration.  
 
Epithelial Integrity  
The transepithelial electrical resistance (TEER) of Caco-2 cell monolayers was monitored 
before and after the permeability experiments using an Endohm
TM
 chamber connected to an 
EVOM voltohmmeter (World Precision Instruments, Berlin, Germany). Additionally, TEER was 
monitored before and after 4 h incubation with fiber sheets of sizes 3×3 mm, 3×6 mm and 6×6 
mm, 3×6 mm fiber sheets placed in baskets or low molecular weight (LMW) compounds 
released from FSP fibers. TEER measurements were performed before and after the experiment 
in HEPES-HBSS buffer upon equilibration to room temperature. The initial TEER value was 465 
± 63 ×cm2 (n = 231).  
TEER recovery experiments were performed after the permeability studies with FSP-Ins fibers. 
After the 4 h permeability study, the epithelium was washed, the test medium was changed to 
DMEM supplemented with 10% FBS and the cells were incubated at 37 °C in an atmosphere of 
5% CO2. Recovery of TEER values was followed over 24 h.  
 
Cellular Compatibility 
The cell viability was determined by the dehydrogenase activity in the Caco-2 cells in 
monolayers after treatment using the MTS/PMS assay. After 4 h incubation with the test 
solutions, the cells were gently washed twice with HEPES-HBSS buffer and incubated with 320 
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µl of freshly prepared MTS/PMS reagent. The cells were incubated at 37 °C for 2 h on a 
horizontal shaker (75 rpm). A volume of 100 µl of the supernatant was transferred to a 96-well 
plate and the absorbance was measured at 492 nm on a FLUOstar OPTIMA plate reader (BMG 
Labtech, Offenburg, Germany). Cells incubated with insulin in HEPES-HBSS were used as 
positive control, and MTS/PMS solution was used as negative control. 
 
Tight Junction Protein Connectivity 
Caco-2 cell monolayers were incubated with FSP-Ins fibers for 4 h in HEPES-HBSS buffer. 
After incubation, cells were washed with Dulbecco´s phosphate buffered saline and fixed with 
4% (vol%) paraformaldehyde. Cells were permeabilized with 0.5% (vol%) Triton-X100 for 5 
min and blocked with 2% (wt%) bovine serum albumin (BSA) for 30 min at room temperature. 
Anti-ZO-1 monoclonal antibody or anti-Claudin-4 monoclonal antibody was incubated with the 
cell monolayer for 45 min at the concentration 5 g/mL in PBS. Cells were then washed with 
PBS and the filter material was carefully removed from the plastic support with a scalpel, 
transferred to a microscope slide and mounted in DPX Mountant for histology. The samples 
were analyzed on a confocal microscopy (Zeiss LSM 780, Jena, Germany) equipped with Intune 
excitation laser system. For analysis of Claudin-4, a 490 nm laser was used, and for analysis of 
ZO-1, a 595 nm laser was used.  
 
Statistics 
Statistical analysis was performed using GraphPad (GraphPad, La Jolla, CA, USA). Unpaired 
Student’s t test was used for assessment of statistically significant differences. 
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Results and Discussion 
Successful Encapsulation of Insulin Into FSP Fibers 
Water soluble FSP was successfully electrospun together with insulin into solid nanofibers. In 
general, encapsulation by mixing prior to electrospinning is very effective. Sharma et al.
[24]
 
reported 99% encapsulation efficiency when encapsulating insulin into polymeric composite 
nanofibers, and in this study the encapsulation efficiency was found to be 98.6 ± 2.9 %. The 
loading capacity of insulin into FSP fibers was 14% under the tested conditions. No difference in 
the morphology was observed between fibers obtained from electrospinning of FSP without 
insulin (Figure 1A) and FSP together with insulin (Figure 1B) indicating that the presence of 
insulin did not have an effect on the macroscopic structure of the fibers or on the fiber average 
diameter (349 ± 23 nm for FSP fibers and 360 ± 37 nm for FSP-Ins fibers). The effect of 
different insulin loadings up to 33% on the fiber morphology was also investigated. Interestingly, 
the macroscopic morphology revealed no significant dependency on the loaded amount of insulin 
within the investigated range (see Supplementary data S4). This revealed a possibility of a very 
high loading of therapeutic protein into the fibers, and even higher loadings may be explored.  
In order to visualize the distribution of insulin throughout the fibers, FITC-labeled insulin was 
electrospun with FSP, and the fibers were evaluated by confocal microscopy (Figure 1C-E). The 
fluorescence from the FITC-insulin co-localized with the fiber structure obtained from the 
brightfield image, and the z-stack fluorescence images of FITC-insulin in the fibers 
demonstrated a uniform distribution throughout the whole fiber (data not shown).  
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Figure 1. Representative scanning electron microscopy images of electrospun FSP fibers (A) 
and FSP-Ins fibers (B). LSCM representative images of FITC-insulin loaded FSP fibers, with 
bright-field image (C), confocal image (D), and overlay of confocal and bright field images (E). 
 
The Tertiary Structure of Insulin is Preserved after Encapsulation and Release from FSP 
Fibers  
Insulin release from FSP-Ins fibers was studied at 37 °C in three different buffers: HEPES-
HBSS (pH 7.4), MES-HBSS (pH 6.5) and SSIF-HBSS (pH 6.5) (Figure 2A). Insulin was 
released gradually reaching a plateau after 2 h in SSIF-HBSS and after 3 h in MES-HBSS and 
HEPES-HBSS. The release profiles in HEPES-HBSS and MES-HBSS showed very similar 
kinetics with rate constants of 2.7 ± 0.5 × 10
-4
 s
-1
 and 2.4 ± 0.1 × 10
-4
 s
-1
, respectively. In total, 
45 ± 6% insulin was released from FSP-Ins in HEPES-HBSS buffer and 50 ± 13% was released 
in MES-HBSS buffer. Surprisingly, the release kinetic rate constant was increased to 3.7 ± 0.4 × 
10
-4
 s
-1
 in SSIF-HBSS as well as the maximum amount of released insulin that was increased up 
to 75 ± 6%. Uncompleted release of an encapsulated compound from the nanofibers has 
previously been observed for other insoluble fibers, and the maximum possible release was 
explained to depend on the porosity of the fibers
[38,39]
. They also showed that the release was 
facilitated by a two-step mechanism; a rate limiting step being desorption of the compound from 
the nanoporous surface of the fibers, followed by diffusion into the buffer. As a result, only 
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compounds situated at the surface of the fibers will be released, as long as the fibers are intact. 
Addition of for instance porogens such as poly(ethylene glycol) or varying the polymer nature, 
concentration or molecular weight, will modulate the porosity, and thus the surface area, of the 
fibers, modifying the maximum release and also the release profile of the compound
[39–41]
. The 
increased insulin release in SSIF-HBSS was most likely due to interactions between the fibers 
with the mixed-micelles formed with sodium taurocholate and phosphatidylcholine. A similar 
interaction between micelles and polymeric films was shown in a study by Sett et al.
[42]
. For all 
buffers, maximum release was achieved after 3 h of incubation, which is convenient for 
achieving absorption from the small intestine as the transit time is 3-4 h.  
 
 
Figure 2. In vitro insulin release profiles of insulin from FSP-Ins fibers in HEPES-HBSS (solid 
line), MES-HBSS (dashed line) and SSIF-HBSS (dotted line). Data represent mean ± SD, n = 3 
(A). Near-UV CD spectra of unprocessed insulin (solid line) and insulin released from FSP-Ins 
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fibers (dashed line). An average of 5 scans is reported. The spectra were normalized according to 
the insulin concentration, and the curves submitted to 2
nd
 order smoothing (B). 
 
Proteins are generally sensitive towards stressful processing conditions. In fact, one of the 
main concerns about incorporating proteins into electrospun fibers is the loss of bioactivity of the 
biomolecules after blend electrospinning
[43]
. Since maintaining the native structure of the protein 
is crucial for preservation of the activity, the effect of electrospinning on the insulin structure 
was investigated by collection of near-UV CD spectra of unprocessed insulin and insulin 
released from FSP-Ins fibers (Figure 2B). The spectrum for released insulin was similar to the 
spectrum for unprocessed insulin, indicating that the tertiary structure of insulin was similar to 
the native form of insulin after release from FSP-Ins fibers. Since the tertiary structure does not 
necessarily correlate with the bioactivity of a protein, the presence of intact insulin was further 
supported using ELISA and RP-HPLC analysis (data not shown). Previous studies of insulin in 
electrospun fibers
[23,44]
, and insulin that have been exposed to HFIP
[45]
, also found that insulin 
activity was not compromised during processing, which further emphasized that the combination 
of electrospinning and HFIP would not affect the activity of insulin.  
 
Ins-FSP Fibers Demonstrate Enhanced Stability of Insulin Against Enzymatic Degradation 
A significant challenge for delivering biopharmaceuticals by the oral route of administration is 
sufficient protection against degradation by intestinal proteases; mainly chymotrypsin and 
trypsin. To investigate whether the encapsulation of insulin into FSP fibers implied also 
protective effects against enzymatic degradation, the concentration of monomeric insulin during 
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the study of release from FSP-Ins fibers was monitored in SSIF-HBSS in the presence of 0.05 
U/mL -chymotrypsin (Figure 3) to which the insulin is most labile[46]. The insulin concentration 
as a function of time followed the expected rise-and-decay shape kinetics of an intermediate 
product of irreversible consecutive reactions (equations in Supplementary data S5). The kinetic 
analysis of the data yielded rate constants of k1 = 4 ± 1 ×10
-4
 s
-1
 for the insulin release and k2 = 2 
± 1 × 10
-4
 s
-1
 for the degradation. In order to assess the protective effect of the fibers, enzymatic 
degradation studies were also performed with insulin in solution (Firgure 3). As previous studies 
showed that LMW compounds were released from the fibers upon contact with a buffer
[26]
, the 
degradation of insulin in solution was studied with the LMW compounds. In this case, the 
degradation happened fast with a degradation rate constant of k = 11 ± 1 × 10
-4
 s
-1
, and after 1 h, 
all the insulin was degraded. When encapsulated in the fibers, insulin could be detected in 
solution for up to 8 h. The degradation of insulin by chymotrypsin was also studied without the 
LMW compounds, however no effect of the LMW compounds was observed. These results 
clearly show a protecting effect from enzymatic degradation when insulin is encapsulated in the 
FSP fibers, and that the protection comes from the encapsulation of insulin into the fibers and not 
from a competition of the LMW compounds previously reported to be released from the fibers. 
In addition to protection against intestinal enzymes, protection against acidic pH and pepsin in 
the stomach are essential for the effectiveness of an oral delivery system. Current methods to 
overcome these barriers rely on e.g. enteric coating; however this has not been implemented in 
the current study. 
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Figure 3. Enzymatic degradation profiles of insulin in solution (solid line) and insulin released 
from FSP-Ins fibers (dashed line). Data represent mean ± SD, n = 6. 
 
Enhanced Transport of Insulin across Caco-2 Cell Monolayers upon Interaction with FSP-
Ins Fibers 
The influence of 3×6 mm sheets of FSP-Ins fibers on the transport of insulin across a Caco-2 
cell monolayer was studied in HEPES-HBSS (Figure 4A), MES-HBSS and SSIF-HBSS. When 
encapsulated in fibers, insulin permeated through the Caco-2 monolayer after dosing in all three 
buffers HEPES-HBSS, MES-HBSS and SSIF-HBSS (Figure 4B), whereas the amount of 
transported insulin was below the LOD of the analytical method when a comparable amount (0.5 
mg/mL) of insulin was applied as a solution. In HEPES-HBSS the amount of transported insulin 
reached 12 ± 4% within 4 h. There was no significant difference between the insulin transport in 
MES-HBSS and SSIF-HBSS (both pH 6.5), however in HEPES-HBSS (pH 7.4) the Papp value 
was increased, indicating that pH had a significant influence on the permeation across the 
membrane. Interestingly, the increased insulin release from FSP-Ins fibers observed in SSIF-
HBSS did not result in an overall increased insulin transport. No degradation of insulin was 
observed during the transport experiments (data not shown), and the structural retention and 
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binding affinity after permeation across the Caco-2 cell monolayer of insulin was confirmed by 
RP-HPLC and ELISA (data not shown).  
 
 
Figure 4. Permeation of insulin across a Caco-2 cell monolayer after release from FSP-Ins fibers 
in HEPES-HBSS (A). Data represent mean ± SD, n > 6. Apparent permeability (Papp) values for 
transport of insulin released from FSP-Ins fibers in HEPES-HBSS, MES-HBSS and SSIF-HBSS 
(B). Data represent mean ± SD, n > 3 (* p < 0.05, ** p < 0.01). 
 
FSP-Ins fibers were placed close to the monolayer, hence when released from the fibers a 
relatively high concentration of insulin is exposed to the monolayer, resulting in an increased 
insulin transport across the epithelium due to a concentration gradient-driven flux. Alterations in 
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the tight junction structure, as reflected by changes in the TEER of the monolayer, may also be 
the reason for increased permeation of insulin. The FSP-Ins fibers (3×6 mm) caused an 
approximate two-fold decrease in the TEER values after incubation for 4 h in the different 
buffers (Figure 5A), however the effect seemed to be the least pronounced in SSIF-HBSS buffer. 
In order to evaluate whether the contact area between the fibers and the cells was crucial for the 
effect on TEER, three different sizes of fiber sheets (3×3 mm, 3×6 mm, 6×6 mm) were applied 
to the cell monolayer (Figure 5B). An area-dependent decrease in the TEER was observed 
(Figure 5B) suggesting that contact between the fibers and the cell monolayer is necessary to 
obtain an effect.  
 
 
Figure 5. The relative change in TEER after incubation with insulin or 3×6 mm FSP-Ins sheets 
in HEPES-HBSS, MES-HBSS and SSIF-HBSS (A). The relative change in the TEER after 
incubation for 4 h in HEPES-HBSS with insulin in solution, supernatant after incubation with 
FSP fibers for 4 h, FSP-Ins fibers placed in baskets ensuring no direct contact to the cell 
monolayer, FSP-Ins size 3×3 mm, FSP-Ins size 3×6 mm and FSP-Ins size 6×6 mm (B). Mean ± 
SD, n > 6 (*** p<0.001). 
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To evaluate if the LMW compounds released from the fibers in solution had any influence on the 
integrity of the monolayer and thus the permeation of insulin, the effect of compounds released 
from FSP fibers in buffer during 4 h, and subsequently applied to the cell monolayer was 
investigated. It is shown that the compounds released from FSP fibers to a solution did not 
decrease the TEER of the monolayer (denoted “FSP” in Firgure 5B), emphasizing that it was the 
interaction between the fibers and the monolayer that induced a decrease in TEER. This 
conclusion was further supported by the fact that no decrease in TEER was observed when the 
fibers were placed in a basket above the monolayer, in a similar set-up as the one described by 
Sander et al.
[47]
 (denoted “baskets” in Figure 5B). As the increased permeation was induced by 
close proximity of the fibers to the monolayer, the transient drop in TEER and thus increase in 
Papp values for insulin permeation was sensitive to variations in the FSP-Ins positioning on the 
monolayer, which to some extent may account for the observed SD. Future studies will focus on 
developing a material with more distinct contact to the cell monolayer. To investigate if the 
change in integrity was reversible, the TEER was monitored after the permeability experiment 
(see Supplementary data SI 6). After 24 h recovery, 50 ± 35% (n = 9) of the integrity that was 
lost during direct contact with the fibers, was regained, which indicated that the change in 
monolayer integrity was reversible. To rule out that the decrease in TEER was associated with 
detrimental effects on the cells, the viability of the cells in the presence of the FSP-Ins fiber 
sheets of different sizes was investigated. The MTS/PMS assay was applied to assess the effect 
after 4 h incubation with 3×3 mm, 3×6 mm and 6×6 mm FSP-Ins sheets in HEPES-HBSS, 3×6 
mm sheets placed in baskets or in MES-HBSS or SSIF-HBSS (Figure 6). For all treatments the 
cell viability was > 90% and not significantly different from the control, except for exposure to 
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the 6×6 mm sheet where the cell viability decreased to 74 ± 4% after 4 h of exposure. 
Additionally, the cell viability 24 h after the 4 h incubation, corresponding to the TEER 
recovery, was higher than 90% (data not shown). The generally high cellular compatibility 
observed after incubation with FSP-Ins fibers substantiates that the decrease in TEER was not 
due to cell death. 
 
 
Figure 6. The relative biocompatibility after incubation for 4 h in HEPES-HBSS with insulin in 
solution, supernatant after incubation with FSP fibers for 4 h, FSP-Ins fibers placed in baskets 
ensuring no direct contact to the cell monolayer, FSP-Ins size 3×3 mm, FSP-Ins size 3×6 mm 
and FSP-Ins size 6×6 mm, 3×6 mm FSP-Ins sheets in MES-HBSS, MES-HBSS with insulin in 
solution, 3×6 mm FSP-Ins sheets in SSIF-HBSS or SSIF-HBSS with insulin in solution. Data 
show mean ± SD, n > 6. 
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Some of the main proteins responsible for the junction tightness are the transmembrane 
proteins (e.g. claudins) and cytoplasmic plaque proteins (e.g. zonula occludens proteins). To 
further investigate if the observed increase in insulin permeation was related to modifications of 
the tight junctions, the Caco-2 cell monolayer was incubated with FSP-Ins fiber sheets, stained 
with anti zonula occludens-1 (ZO-1) and claudin-4 (CL-4) antibodies labeled with a fluorophore 
and studied with confocal microscopy. Untreated Caco-2 monolayers contained continuous and 
circumferential ZO-1 and CL-4 distribution indicating intact tight junctions (Figure 7). After 
incubation for 4 h with FSP-Ins fibers different scenarios were observed when scanning the 
monolayer; one displaying a similar ZO-1 and CL-4 distribution as compared to the control 
(FSP-Ins A, Figure 7), and one that displayed less distinct cellular boarders, indicating that the 
tight junctions were affected by FSP-Ins (FSP-Ins B, Figure 7). These differences show that only 
a certain part of the monolayer was affected by the presence of FSP-Ins fibers, and support the 
hypothesis that direct contact between the fibers and the cell monolayer is important to mediate 
an effect. It is thus in line with the correlation between the area of the fiber sheets and the 
decrease in TEER, and substantiate the conclusion that the direct interaction between the fibers 
and the monolayer induces changes in the tight junctions and thus an increase in permeation at 
local hot spots on the epithelial barrier.  
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Figure 7. Confocal images of Caco-2 cell monolayers stained with Alexa-598 labeled anti ZO-1 
and Alexa-488 labelled anti CL-4. FSP-Ins A and B represent two different scenarios on the 
same filter insert with a Caco-2 cell monolayer after incubation with FSP-Ins fibers in HEPES-
HBSS. 
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Conclusion 
Insulin was successfully encapsulated into water soluble FSP nanofibers without affecting the 
structure of the insulin. Interactions between the fibers and mixed micelles of bile salts present in 
the simulated intestinal release medium resulted in an increase in insulin release, as 75 ± 6% was 
released in SSIF-HBSS, compared to only 45 ± 6% in HEPES-HBSS and 50 ± 13% in MES-
HBSS buffer. By encapsulation into the FSP fibers, insulin was detected in α-chymotrypsin-
containing buffer for up to 8 h as compared to 1 h when insulin was not embedded in the fibers. 
Overall, the permeation of insulin across Caco-2 cell monolayers was increased to 12 ± 4% by 
applying FSP-Ins in HEPES-HBSS to the apical surface of the cells, evidently by exerting a 
specific effect on the tight junctions as shown by a decrease in integrity. Further, it was found 
that FSP-Ins fibers induced tight junction modulations dependent on the direct contact to the cell 
monolayer, as the tight junction proteins ZO-1 and CL-4 was disturbed only in specific regions.  
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Text for the table of contents 
This study presents new and promising properties of electrospun fibers, here applied to an 
intestinal delivery system for biomacromolecules. Inherent fiber properties facilitated protection 
of the model protein, insulin, from enzymatic degradation, and increased transepithelial 
permeation of intact therapeutic protein – two critical barriers within intestinal delivery. This 
study promotes electrospun fibers for delivery of biopharmaceuticals through the small intestine. 
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S1: Preparation of FSP 
Fresh cod (Gadus morhua) was filleted and frozen at -30˚C. The frozen fillet was defrosted, chopped 
into approximately 1x1x2 mm sized pieces, placed into centrifuge tubes and centrifuged for 15 min, 
18,000 g, 5˚C (4K15, Sigma Laboratory centrifuges, Osterode am Harz, Germany). The supernatant 
was transferred to a petri dish, frozen, freeze dried and stored at -60˚C. 
 
S2: Preparation of FSP-Ins fibers  
FSP (125 mg/mL) and insulin (20 mg/mL) were dissolved in HFIP, added to a syringe and placed in a 
syringe pump (New Era Pump Systems, Farmingdale, NY, USA). A 30 G needle (Proto Advantage, 
Ancaster, ON, Canada) was used. The syringe pump delivered the FSP-Ins solution with a flow rate of 
0.04 mL/min. Using a high voltage power supply (Gamma High Voltage Research, Ormond Beach, FL, 
USA), an electric field of 25 kV was applied between the spinneret of the syringe and a the 5×5 cm 
collector plate made of stainless steel covered by alumina foil. The distance between the syringe tip and 
the collector plate was 15 cm. For control experiments, FSP (125 mg/mL) was dissolved in HFIP, and 
electrospun under the same conditions. 
 
S3: Labeling of insulin with FITC 
FITC (2 mg/mL) was dissolved in DMSO and gradually added in aliquot volumes of 5 µl to 5 mg/mL 
insulin dissolved in 0.1 M NaHCO3. After 8 h of incubation at 4 °C, NH4Cl was added to a final 
concentration of 50 mM to stop the coupling reaction. The resulting conjugates were incubated for 2 h 
at 4 °C, dialyzed for 24 h at 4 °C against ultrapure water (Slide-A-Lyzer® Dialysis Cassette (3,500 
MWCO), Thermo Scientific, Waltham, MA, USA), and lyophilized (-20°C, 0,1 mbar) using a Christ 
Epsilon 2-4 LSC freezedryer (Martin Christ, Osterode am Harz, Germany).  
 S4: SEM images of FSP-Ins  
Fig. SI 4 
Fig. SI 4. Representative SEM images of insulin encapsulated into fibers of dialyzed FSP, containing 
0% (A), 9% (B), 20% (C) and 33% (D) insulin. 
 
S5: Equations describing the kinetics of insulin degradation 
𝐹𝑆𝑃 − 𝐼𝑛𝑠 
𝑘1
→  𝐼𝑛𝑠 
𝑘2
→  𝐼𝑛𝑠𝑑𝑒𝑔𝑟𝑎𝑑𝑒𝑑         
where  
[𝐼𝑛𝑠] =
𝑘1∙𝐹𝑆𝑃−𝐼𝑛𝑠0
𝑘2−𝑘1
∙ (𝑒−𝑘1𝑡 − 𝑒−𝑘2𝑡)      
S6: TEER recovery 
 
Fig. SI 6  
Fig. SI 6. TEER values before incubation with FSP-Ins fibers (T = 0 h), after incubation with FSP-Ins 
fibers (T = 4 h) and after 24 h recovery (T = 24 h). 
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Abstract 
Interactions between compounds found in the human body such as proteins, bile salts, etc. and 
electrospun compounds has hitherto been an unstudied phenomena, dispite the exposure of fibers to 
such biorelevant compounds in many biomedical applications such as tissue engineering, wound 
healing and drug delivery. In this study we present a systematic investigation of how surfactants and 
proteins, as physiological relevant components, interact with insulin loaded fish sarcoplasmic protein 
(FSP) electrospun fibers (FSP-Ins fibers) and thereby affect fiber properties such as hydrophilicity, 
stability and release characteristics of an encapsulated drug. Interactions between insulin-loaded protein 
fibers and five anionic surfactants (the bile salts sodium taurocholate, sodium taurodeoxycholate, 
sodium glycocholate and sodium glycodeoxycholate, and sodium dodecyl sulfate), a cationic surfactant 
(benzalkonium chloride) and a neutral surfactant (Triton X-100) were studied. The anionic surfactants 
increased the insulin release in a concentration-dependent manner, whereas the neutral surfactant did 
not have a significant effect on the release. Interestingly, almost no insulin was released from the fibers 
when benzalkonium chloride was present. The FSP-Ins fibers were dense after incubation with this 
cationic surfactant, whereas high fiber porosity was observed after incubation with anionic or neutral 
surfactants. Contact angle measurements and staining with the hydrophobic dye 8-anilino-1-
naphthalenesulfonic acid indiated that the FSP-Ins fibers where hydrophobic, and showed that the fiber 
surface properties were affected differently by the surfactants. Bovine serum albumin also affected 
insulin release in vitro, indicating that also proteins can affect the fiber performance.  
 
Keywords: Electrospinning, proteins, surfactants, drug delivery, tissue engineering  
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Introduction 
Electrospun nanofibers have a large range of biomedical applications within e.g tissue engineering, 
regenerative medicine and drug delivery
1–5
. The nanofibers can be functionalized in order to improve 
the performance in vivo, for example by addition of proteins to increase biocompatibility
6,7
, addition of 
a polymer to strengthen the mechanical properties
7
, addition of drugs such as antibiotics in wound 
dressing
8–10
 or growth factors or DNA in tissue engineering
11–15
. Even cells can be electrospun to 
promote regeneration of new tissue
16–18
. During optimization of the fiber properties, special attention is 
given to the hydrophilicity of the fibers, fiber stability and drug release profiles (in case of encapsulated 
compounds)
12
. Drug release and stability properties are often studied in vitro in water
19,20
, phosphate 
buffer
21
, phosphate buffered saline
8,22–33
 or other similar buffers not containing specific physiological 
compounds
34,35
. Depending on the application of the electrospun fibers, they will be exposed to 
different physiological environments, which contain compounds such as bile salts, proteins, salts, etc. 
However, the effects of physiological components on fiber stability and drug release characteristics are 
rarely taken into account, eventhough any deviation in fiber performance in vivo, from what was 
expected based on in vitro evaluation, may be critical. In our previous study we found that release of 
insulin from protein fibers was increased in simulated small intestinal fluid containing lipids and 
sodium taurocholate
36
. The study also showed that transport of insulin across a Caco-2 cells monolayer 
was increased, due to interactions between the cells and fibers. In a study by Alborzi et al., release of 
folic acid from alginate-pectin/polyethylene oxide electrospun fibers was studied in a simulated 
intestinal fluid with a bile extract added, and the authors found that the release was decreased in the 
presence of bile extract
37
. Sofokleous et al. studied release of amoxicillin from poly(D,L-lactide-co-
glycolide) (PLGA) for wound healing purposes, and found the drug release from the PLGA dressings 
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to be different in the tested media (water, simulated body fluid and phosphate buffered saline)
10
. 
Moreover, Maretschek et al. found release of cytochrome C from poly(L-lactide) fibers to be increased 
when Tween 20 was present in the release medium
38
. Despite of those observations, no study has been 
dedicated to further investigate the potential effects on the performance of electrospun fiber scaffolds 
caused by interactions with biorelevant compounds. In the current study we investigated how 
biorelevant compounds can have an effect on electrospun fibers, by systematically studying the 
interactions between insulin-loaded electrospun protein fibers and four different bile salts present in the 
human intestinal fluid (sodium taurocholate (TC), sodium taurodeoxycholate (TDC), sodium 
glycocholate (GC) and sodium glycodeoxycholate (GDC)). In order to further elucidate the mechanism 
accounting for the drug release induced by biological surfactants, different synthetic surfactants were 
also included in the study: the anionic sodium dodecyl sulfate (SDS), the cationic benzalkonium 
chloride (BC) and the neutral Triton X-100. The effect of the different surfactants on the insulin release 
profile, fiber porosity and fiber surface properties were studied  
Materials and methods 
Materials 
Cod (Gadus morhua) from the North Sea was obtained from Hanstholm Fisk (Hanstholm, Denmark). 
Human insulin was kindly provided by Sanofi-Aventis Deutschland (Frankfurt, Germany). 4-(2-
Hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES) was acquired from AppliChem (Darmstadt, 
Germany). 1,1,1,3,3,3-Hexafluoro-2-propanol (HFIP), 2-(N-morpholino)ethane sulfonic acid (MES), 
Hank´s balanced salt solution (HBSS), TC, TDO, GC, GDO, Triton X-100,  SDS, and 8-
anilinonaphtalene-1-sulfonic acid (ANS) and benzoylacetone (BZA) were obtained from Sigma-
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Aldrich (St. Louis, MO, USA), and BC was obtained from Nomeco (Copenhagen, Denmark). All the 
other reagents were obtained commercially at analytical grade and used without further purification, 
and the chromatographic solvents were of HPLC grade. Ultrapure water from Barnstead NanoPure 
Systems (Thermo Scientific, Waltham, MA, USA) was used throughout the studies. 
Preparation of FSP-Ins fibers  
Fish sarcoplasmic proteins (FSP) were isolated from fresh cod and fibers were prepared as previously 
described
39
 (Supplementary data S1, S2). A concentration of 125 mg/mL FSP was used together with 
20 mg/mL insulin (Ins) for production of the FSP-Ins fibers. Electrospinning was conducted at room 
temperature, and samples were stored at -20°C until further analysis. 
In vitro release studies 
The in vitro release of insulin from FSP-Ins fibers was performed in 10 mM MES-HBSS buffer (pH 
6.5) containing varying amounts (1.5 mM, 3 mM or 6 mM) of surfactant (TC, TDC, GC, GDC, Triton 
X-100, SDS or BC) during 5 h at 37°C with continuous orbital mixing. FSP-Ins fibers were placed in 
the pre-warmed buffers at a concentration of 3.5 mg/mL. Aliquots of 30 l were taken from the 
supernatant at regular time points and replaced with fresh buffer. The samples were analyzed for 
contenct of insulin by using reverse phase high-pressure liquid chromatography (RP-HPLC) as 
described below. The experiment was carried out at least in triplicates.  
Insulin quantification 
Insulin concentrations were analyzed by RP-HPLC using a Prominence system (Shimadzu, Kyoto, 
Japan) equipped with an Aeris WIDEPORE XB-C18 column (100×2.10 mm, 3.6 m) (Phenomenex, 
Allerød, Denmark) and a PDA detector (SPD-M20A, Shimadzu). The mobile phase A consisted of 
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95% H2O/5% acetonitrile (AcCN)/0.1% trifluoroacetic acid (TFA) (v/v/v) and mobile phase B 
consisted of 95% AcCN/5% H2O/0.1% TFA (v/v/v). The autosampler temperature was 4°C. Insulin 
was eluted using a linear gradient of mobile phase B from 20-50% over 3.5 min at a constant flow of 
0.8 mL/min and with a column temperature of 40°C. Insulin was quantified as the peak area obtained at 
218 nm (retention time 2.7 min). Limit of detection and limit of quantification were 0.2 g/mL and 0.8 
g/mL (n=3), respectively.   
Internal fiber porosity  
The internal porosity of FSP-Ins fibers was studied by using cryo-scanning electron microscopy (cryo-
SEM) using a Quanta FEG 3D (FEI, Hillsboro, OR, USA) system equipped with a Leica cryo stage and 
the EM VCT100 Cryo transport system, in combination with the MED020 freeze fracture and 
Platinum/Carbon or Carbon coating unit (Leica, Wetzlar, Germany). The samples were incubated in 10 
mM MES-HBSS pH 6.5 with 6 mM surfactant (TC, SDS, Triton X-100, BC), and subsequently put on 
a aluminum stub, that was mounted on a transport shuttle, and fixed to the stub with Carbon/contact 
medium. The sample was frozen in liquid nitrogen, in order to fracture the fibers with a cooled knife 
inside the MED020. Subsequently, the sample sublimated for 3 min. and sputter was coated with 
platinum (coating thickness of 5 nm).  
Critical micelle concentrations 
The critical micelle concentration (CMC) of the different surfactants in MES-HBSS was determined 
according to the method described by Dominguez et al.
40
. Briefly, BZA was added to a final 
concentration of 0.14 mM, together with varying concentrations of each of the surfactant (TC, GC, 
TDC, GDO, Triton X-100, SDS and BC) in 10 mM MES-HBSS pH 6.5. A total volume of 200 µl was 
added to a clear flat-bottomed 96-well UV-transparent plate (Corning Incorporated, Corning, NY, 
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USA), and absorption was measured at 313 nm at 37°C using a Safire
2
 plate reader (Tecan Group Ltd., 
Männedorf, Switzerland).  
Contact angle  
The contact angle between FSP-Ins fibers and aqueous solutions of surfactants (6 mM TC, Triton X-
100, SDS or BC in 10 mM MES-HBSS, pH 6.5) was measured using an optical tensiometer (Theta, 
Attension, Finland) with a highspeed camera (3000 fps, MotionXtra N3, IDT, USA). A volume of 7.5 
µl of buffer was deposited on the fiber surface, and images were immediately recorded with 59 frame 
per sec the first 3.4 sec, and thereafter 1 frame per second until 34 sec. The contact angle was derived 
from the images as the angle between the tangent to the drop at the surface-liquid interface and the 
fiber. The contact angle, calculated as the mean of the left and right contact angle, was plotted as a 
function of time, and the initial contact angle was found by extrapolation these measurements. 
Confocal microscopy  
FSP-Ins fibers were placed in 10 mM MES-HBSS pH 6.5 with and without surfactants (6 mM TC, 
Triton X-100 or BC) and incubated for 3 h. After 2 h, ANS was added to a final concentration of 25 
µM and incubated for 1 h. The fibers were transferred to a coverslip and images were obtained using a 
laser scanning confocal microscope (Zeiss LSM 780, Jena, Germany), using excitation at 405 nm and 
emission measured at 489 nm. 
Statistics 
Statistical analysis was performed using GraphPad (GraphPad, La Jolla, CA, USA). Unpaired Student’s 
t test was used for assessment of statistically significant differences. 
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Results and discussion 
Release of insulin from FSP-Ins fibers was affected by surfactants in solution 
Insulin release from FSP-Ins fibers was studied at in MES-HBSS in the absence or presence of 
surfactants (Figure 1). The chosen surfactants are divided into four groups, i) biologic anionic 
surfactants (TC, TDC, GC, GDC), ii) synthetic anionic surfactant (SDS), iii) cationic surfactant (BC) 
and iv) neutral surfactant (Triton X-100) (for the chemical structures see Supplementary information 
S3). The release was studied at increasing surfactant concentrations, up to 6 mM, and the presence of 
bile salts increased the release of insulin in a concentration-dependent manner (Figure 1 A – D). No 
additional effect on release rate and amount was observed with bile salt concentrations higher than 6 
mM (data not shown). The fibers were physically stable in the buffer during long periods of time, as no 
change in internal structure was observed even after 2 months of incubation (Supplementary data S4), 
and the fibers remained non-dissolved even longer. To investigate if the effect on the insulin release 
could be caused by surfactants in general, insulin release upon exposure to synthetic surfactants (SDS, 
BC and Triton X-100) was analyzed in a similar manner, Figure 1 E-H. SDS induced a similar behavior 
as the bile salts, with increasing SDS concentrations leading to increased insulin release. However, 
fibers that were exposed to high concentrations of SDS were degraded, as observed visually, and 
accordingly the release of insulin continued to increase, contrary to what was observed for the bile 
salts. The synthetic SDS is a well-known denaturing agent, and as a rule of thumb it takes 1.4 g SDS/g 
protein to denature a protein to an unfolded structure (saturation). Although the FSP-fibers were not 
saturated with SDS at 6 mM SDS, degradation of the fibers occured. A further increase in SDS 
concentration up to 18 mM led to complete release of entrapped insulin, due to extensive fiber 
degradation (data not shown). Complete drug release allowed for quantification of the insulin 
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encapsulation efficiency, which was found to be 98.6 ± 2.9 % (n = 3)
36
. Insulin release in 3 mM SDS 
was similar to the release in MES-HBSS, but noticeable, when lowering the SDS concentration to 1.5 
mM SDS, insulin released decreased. The presence of the neutral surfactant, Triton X-100, did not alter 
the insulin release profile as compared to that observed in the MES-HBSS (Figure 1F), and no 
concentration-dependency was observed. Interestingly, almost no insulin was released from the FSP-
Ins fibers upon incubation with the cationic surfactant BC (Figure 1 G). Approximately 1 % of the 
encapsulated insulin was released in the 3 mM and 6 mM BC solution as burst release, but after 2 h no 
insulin was detectable. The strength of the interactions between BC and FSP-Ins fibers was 
investigated by transferring the FSP-Ins fibers to 12 mM SDS, after five h of incubation in 3 mM BC, 
and surprisingly no insulin was released after addition to the SDS solution (data not shown). This 
indicated that the interaction between BC and the FSP-Ins fibers resulted in a significant stabilization 
of the fiber structure, preventing insulin release. The differences in the way the surfactants affected 
insulin release, suggested that i) the surfactants interacted with the FSP-Ins fibers, and ii) the 
interaction, and the results of the interaction, strongly depend on the properties of the surfactants. The 
CMC of the surfactants in MES-HBSS was determined to investigate if there was any relation between 
the CMC and the effect on release (Figure 1 H), however no correlation to the CMC was found in 
relation to the effect of the surfactants on the drug release, which indicated that the CMC did not affect 
the behavior of the surfactants with respect to fiber interactions. In our previous study the simulated 
intestinal fluid also contained lipids, however the lipids were found not to affect insulin release (data 
not shown). Bovine serum albumin (BSA) is a common protein in the human body, and for that reason 
the effect of BSA on insulin release was briefly touched upon. Boegh et al. have developed a biosimilar 
mucus, which contained 3.1 % BSA, and with that amount of BSA in the MES-HBSS buffer, release of 
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insulin was increased (Supplementary information S5), indicating that interaction with fibers and 
thereby alterating fiber properties is not limited to surfactants.  
 
Figure 1. Insulin release from FSP-Ins fibers in vitro in MES-HBSS with varying concentrations of TC (A), TDC (B), GC (C), 
GDC (D), SDS (E), Triton X-100 (F) and BC (G,H); 0 mM (black), 1.5 mM (green), 3 mM (blue) and 6 mM (red). Data represent 
mean ± SD, n ≥ 3.  
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Fiber porosity was affected by interactions with surfactant 
In vitro release of a compound encapsulated in insoluble fibers has previously been correlated to the 
porosity of the fibers
19,20,41
. From those studies it was found that the release was facilitated by a two-
step mechanism; desorption of the compound from the nanoporous surface of the fibers, as the rate 
limiting step, followed by diffusion from the fiber matrix into the buffer. As a result, only compounds 
situated at the surface of the fibers were released, as long as the fibers were intact. Modulating the 
porosity, and thus the surface area, for instance by addition of porogens, such as poly(ethylene glycol), 
or varying the polymer nature, concentration or molecular weight, modified the maximum released 
amount, and also the compound release profile 
19,41,42
. In Figure 1the maximum release changed 
according to the type and the amount of surfactant present in the MES-HBSS buffer. To investigate if 
the observed tendencies were associated to changes in fiber porosity, the inner structure (cross-
sections) of the FSP-Ins fibers after incubation in MES-HBSS, MES-HBSS with 6 mM TC or MES-
HBSS with 6 mM BC, was analyzed with cryo-SEM, and compared to the inner structure of the fibers 
before incubation (Figure 2). Before incubation in a buffer, a small degree of porosity was observed 
throughout the fibers, and in some fibers the porosity in the core was increased, which most likely is 
caused by fast evaporation of the solvent (Figure 2D). After incubation in MES-HBSS and MES-HBSS 
with TC (Figure 2 A and B) the inner structure of the FSP-Ins fibers became more porous, whereas the 
fibers that had been exposed to BC became dense (Figure 2C). The trend in porosity correlated with 
insulin being released in MES-HBSS and MES-HBSS with TC, whereas release in MES-HBSS 
containing BC was negligible. The fact that the burst release in BC was almost nonexistent (Figure 1 
G), suggested that BC instantaneously interacted with the surface of the fibers, and induced a 
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stabilizing effect thus precluding insulin release and causing the inner fiber structure to become dense. 
The inner structure of fibers exposed to Triton X-100 or SDS were also investigated (data not shown), 
and porosity was observed in both cases. As with MES-HBSS in the presence and absence of TC, 
porosity after exposure to Triton X-100 and SDS correlated with insulin being released from FSP-Ins 
fibers in both Triton X-100 and SDS solutions. It was not possible to study a potential connection 
between extend of insulin release and degree of porosity, since the porosity made the fibers fragile and 
sensitive to beam damage, which resulted in partly closing of the pores, which thereby prohibited 
quantitative analysis of the porosity.  
 
Figure 2. Cryo-SEM images of FSP-Ins fibers after incubation in MES-HBSS (A), MES-HBSS with 6 mM TC (B), MES-HBSS 
with 6 mM BC (C) and before incubation (D). Scale bars are 1 µm. 
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Interactions between surfactants and FSP-Ins fiber led to changes in the contact angles 
The interactions between surfactants (TC, SDS, Triton X-100 and BC) in MES-HBSS and FSP-Ins 
fibers were further evaluated by contact angle measurements (Figure 3). MES-HBSS without 
surfactants displayed a large contact angle of 110 ± 8 degr., which indicated that the FSP-Ins fibers 
were hydrophobic. Addition of SDS caused no significant change in the contact angle (117 ± 7 degr.), 
whereas addition of TC increased the contact angle to 130 ± 6 degr. The presence of BC decreased the 
contact angle to 84 ± 21 deg. And Triton X-100 decreased the value even further to 37 ± 13 degr. The 
decreased contact angle caused by Triton X-100 and BC suggested that interactions between Triton X-
100, or BC, and the fibers, facilitated increased surface hydrophilicity. The rate by which the liquid 
drop was absorbed into the fibers, varied in the order Triton X-100 > BC > SDS > TC > MES-HBSS. 
The differences in contact angle and time for complete liquid drop absorption emphasized that the 
surfactants interacted with the fibers in different ways, dependent on the properties of the surfactants. 
The effect of the surfactant concentration was investigated by comparing the contact angle for 3 mM 
ans 6 mM TC or SDS, but no dose-dependency was observed in this concentration range (Figure 3 B) 
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Figure 3. Contact angles between FSP-Ins and MES-HBSS with or without surfactants (A) and  comparison of contact angles 
between FSP-Ins fibers and MES-HBSS containing either 3 mM or 6 mM surfactant (B). Data represent mean value ± SD, n > 3. 
Representative images of a drop of buffer (MES-HBSS with or without surfactants) on FSP-Ins fibers (C).  
 
Surface properties of the FSP-Ins fibers were affected by interactions with surfactants 
The hydrophobic nature of the FSP-Ins fibers was studied by ANS fluorescence (Figure 4). ANS is 
widely used to visualize hydrophobic regions in e.g. fibrillar aggregates and fibers, as its fluorescence 
is enhanced when ANS interacts with hydrophobic environments
43,44
. Increase in fluorescence intensity 
can thus be ascribed to increased amounts of hydrophobic pockets. Figure 4 A shows the ANS 
fluorescence in fibers after incubation with MES-HBSS. The visualization of the FSP-Ins fibers by the 
application of ANS fluorescence verified that the surface of the FSP-Ins fibers were hydrophobic. The 
homogeneity of the fluorescence throughout the fiber matrix furthermore suggested that the properties 
of the surface were consistent, despite of the complexity of the FSP matrix. The presence of 6 mM TC 
in the MES-HBSS buffer did not alter the ANS fluorescence (Figure 4 B), indicating that a similar 
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amount of hydrophobic pockets were still available for interactions with ANS. Interesingly, esposure of 
the FSP-Ins fibers to 6 mM Triton X-100 or 6 mM BC caused a decrease in ANS fluorescence, as 
shown in Figure 4C and D, respectively. In both cases the ANS fluorescence decreased significantly, 
compared to fibers exposed to MES-HBSS without surfactants, indicating that the amount of accessible 
hydrophobic regions was decreased. This was in agreement with the contact angle measurements, 
where an increased hydrophilicity was caused by BC and Triton X-100, and hydrophobicity was 
observed for MES-HBSS in the presence and absence of TC. The loss in the amount of hydrophobic 
regions available for ANS binding can be explained by changes in the FSP-Ins fiber surface properties, 
and here we propose two possible explanations. In the electrospun fibers, the protein entanglements 
may cause the proteins to be in an energetically unfavorable state. Addition of surfactants to the buffer 
may cause a relaxation of the proteins, which results in small rearrangements in the protein structure, 
and thus shielding of hydrophobic regions. Another hypothesis rely on the strong interactions between 
surfactants and fibers, which will compete with and prevent the ANS molecules from interacting with 
the fibers. Irrespective of the exact mechanism, changes in the surface properties of the fibers upon 
incubation with neutral or cationic surfactants were evident. 
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Figure 4. Cross-sectional confocal images of fibers displaying ANS fluorescence after incubation with FSP-Ins fibers in  MES-
HBSS (A), MES-HBSS with 6 mM TC (B), MES-HBSS with 6 mM Triton X-100 (C) and MES-HBSS with 6 mM BC (D). All 
images were recorded with the same settings.  
Conclusion 
The results presented in this study clearly indicate that biorelevant compounds interact with electrospun 
fibers. The interactions between surfactants in solution and electrospun protein fibers were found to 
significantly influence the release of entrapped cargo, the fiber stability, porosity and the fiber surface 
properties. Anionic surfactants were shown to have a concentration-dependent effect on insulin release, 
whereas addition of Triton X-100 did not cause a significant change in the amount released, and in 
MES-HBSS with BC, only negligible amounts of insulin were released. Cryo-SEM images of the fibers 
after incubation with the surfactants showed a correlation between release of cargo and increased 
porosity of the fibers, in the sense that when insulin was released, fiber porosity was observed. Contact 
angle measurements revealed that the surfactants had a significant influence on wetting of the fibers; 
for anionic surfactants a small increase in the contact angle was observed, whereas the presence of the 
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cationic surfactant, and especially the neutral surfactant, decreased the contact angle considerably. 
Interactions between fibers and surfactants were further elucidated, by decreased levels of interactions 
with the hydrophobic pocket fluorophore, ANS, after fiber incubation with neutral or cationic 
surfactants, as compared to anionic or no surfactants. Overall, this study emphasizes the importance of 
taking into account biologically relevant components, such as bile salts and proteins, with which 
electrospun fibers may be exposed to when used for tissue engineering, wound healing, drug delivery 
and other biomedical applications.  
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S1: Preparation of FSP 
Fresh cod (Gadus morhua) was filleted and frozen at -30˚C. The frozen fillet was defrosted, chopped into 
approximately 1x1x2 mm sized pieces, placed into centrifuge tubes and centrifuged for 15 min, 18,000 g, 5˚C 
(4K15, Sigma Laboratory centrifuges, Osterode am Harz, Germany). The supernatant was transferred to a petri 
dish, frozen, freeze dried and stored at -60˚C. 
 
S2: Preparation of FSP-Ins fibers  
FSP (125 mg/mL) and insulin (20 mg/mL) were dissolved in HFIP, added to a syringe and placed in a syringe 
pump (New Era Pump Systems, Farmingdale, NY, USA). A 30 G needle (Proto Advantage, Ancaster, ON, 
Canada) was used. The syringe pump delivered the FSP-Ins solution with a flow rate of 0.04 mL/min. Using a 
high voltage power supply (Gamma High Voltage Research, Ormond Beach, FL, USA), an electric field of 25 
kV was applied between the spinneret of the syringe and a the 5×5 cm collector plate made of stainless steel 
covered by alumina foil. The distance between the syringe tip and the collector plate was 15 cm. For control 
experiments, FSP (125 mg/mL) was dissolved in HFIP, and electrospun under the same conditions. 
S3: Chemical structures of the surfactants. 
 
Figure 1. Chemical structures of the surfactants. 
 
S4 Stability of FSP-Ins fibers 
 
Figure 2. Structure of FSP-Ins after 2 months incubation in MES-HBSS with and without TC. 
 
S4: Release of insulin from FSP-Ins fibers in the presence of 3.1% BSA 
 
Figure 3. In vitro insulin release from FSP-Ins fibers in MES-HBSS with (orange) and without (black) BSA. Data represent mean ± SD, n 
≥ 3. 
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a  b  s  t  r  a  c  t
Macrostructures  based  on  natural  polymers  are  subject  to large  attention,  as  the application  range  is
wide within  the  food  and pharmaceutical  industries.  In  this  study  we  present  nanocomplexes  (NCXs)
made  from  electrostatic  self-assembly  between  negatively  charged  alginate  and  positively  charged  ﬁsh
sarcoplasmic  proteins  (FSP),  prepared  by bulk mixing.  A concentration  screening  revealed  that  there
was  a range  of  alginate  and  FSP  concentrations  where  stable  NCXs  with  similar  properties  were  formed,
rather  than  two exact  concentrations.  The  size  of the  NCXs  was  293  ± 3 nm, and  the  zeta  potential  was
−42 ± 0.3  mV.  The  NCXs  were  stable  in  water,  gastric  buffer,  intestinal  buffer  and  HEPES  buffered  glycose,
and  at  all  pH values  from  2 to 9 except  pH  3,  where  they  aggregated.  When  proteolytic  enzymes  were
present  in the  buffer,  the  NCXs  were  degraded.  Only  at high  concentrations  the  NCXs  caused  a decreased
viability  in  HeLa  and  U2OS  cell lines.  The  simple  processing  procedure  and  the  high  stability  of the  NCXs,
makes  them  excellent  candidates  for  use  in the  food and  pharmaceutical  industry.
© 2015  Elsevier  B.V.  All  rights  reserved.
1. Introduction
The search for novel “supramolecular” nanostructured materi-
als for use in biomedicine, pharmacy, food, biotechnology and other
ﬁelds entails to identify constituting biopolymers that are not only
biocompatible and biodegradable, but also are capable to confer the
needed physical properties and functionality. Polysaccharide and
proteins are natural “building blocks” of living systems, where they
perform key functions, such as providing physical structure, confer-
ring protection against pathogens, performing enzymatic reactions
and signaling, among many more specialized functions. Complexes
of polysaccharide and proteins can be classiﬁed as cognate or non-
cognate. In the former, proteins and polysaccharides can be found
in the same physiological environment and interact speciﬁcally as
for example, lysozyme and glycosaminoglycans in mammalians’
cartilages [1]. By contrast, non-cognate mixtures comprise pairs
∗ Corresponding author at: Technical University of Denmark, Søltofts Plads 227,
DK-2800 Kgs Lyngby, Denmark. Tel.: +45 45252716; fax: +45 45939600.
∗∗ Corresponding author at: Westfälische Wilhelms-Universität Münster, Schloss-
garten 3, D-48149 Münster, Germany. Tel.: +49 2518324864; fax: +49 2518323823.
∗  ∗ ∗Corresponding author at: Technical University of Denmark, Søltofts Plads 227,
DK-2800 Kgs Lyngby, Denmark. Tel.: +45 45252773; fax: +45 45939600.
E-mail addresses: kaste@food.dtu.dk (K. Stephansen),
goycoole@uni-muenster.de (F.M. Goycoolea), ioach@food.dtu.dk (I.S. Chronakis).
that are not necessarily interacting speciﬁcally. Hence, polysac-
charides and proteins are ideal candidate components to develop
new “soft” materials for biomedical, food, agriculture and biotech-
nological applications, particularly, when both macromolecules
are already approved ingredients or common constituents of
food.
Self-assembling (SA) refers to the process whereby components
of a desired material associate themselves into supramolecular
organized systems, obtained by non-covalent synthesis. Col-
loidal polyelectrolyte complexes comprising polysaccharides
and proteins formed by spontaneous electrostatic interaction in
aqueous medium, have been the focus of several studies [2–8].
The physicochemical properties of the constituent molecules
determine not only the interactions among them, but also the
supramolecular architecture of the resulting nanoassembly [9]. In
the case of proteins, the proportion of polar, charged, aromatic or
hydrophobic amino acids in the primary structure, along with the
type of protein folding, are at play. Whereas in polysaccharides,
the monosaccharide composition (e.g. charged versus non charged
residues, degree, and position of the substituent groups) as well as
their sequence in the chain (i.e. block, alternating, random) along
with their linkage geometry, chain ﬂexibility, and conformation in
solution have a direct inﬂuence on the physicochemical properties
such as the stability, particle size, phase equilibrium and structure
at varying levels [9].
http://dx.doi.org/10.1016/j.ijbiomac.2015.02.018
0141-8130/© 2015 Elsevier B.V. All rights reserved.
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Protein-polysaccharide systems have been applied in the
development of drug delivery biocompatible carriers [10], or as
self-assembled gelling complexes [11,12]. Polysaccharide/protein
colloidal complexes that remain stable in liquid phase, and attain
particle size dimensions in the sub-micron range, are here regarded
as nanocomplexes (NCXs). The key to the formation of stable NCXs
based on electrostatic SA of polysaccharide and proteins is to con-
trol the medium pH, as depending on the intrinsic pK (pKo) of the
polysaccharide and the pI of the protein, it is possible to assess a
condition in which the components are oppositely charged. Other
important parameters are the salinity, the molar ratio of charged
groups and their total concentration. Often, the optimal conditions
lie within a narrow range of composition or external conditions
that avoid the aggregation and precipitation of the complex [13].
The focus of the present paper is the NCXs formed between
sarcoplasmic proteins isolated from cod (FSP) and alginate, here
referred to as FSP-Alg. FSP accounts for 25–30% of the ﬁsh mus-
cle proteins. They are easily accessible, and comprise peptides
and proteins of up to ∼200 kDa in molecular weight. Fish protein
hydrolysates have been shown to comprise bioactive proper-
ties [14–16]. One example is inhibitory effects against dipeptidyl
peptidase-4 (DPP-IV) [17,18], an enzyme with an essential role
in glucose metabolism and linked to type 2 diabetes, and DPP-
IV inhibitors may  be used as a potential new treatment for type
2 diabetes [19,20]. Additionally, dietary cod proteins have been
shown to improve insulin sensitivity in insulin-resistant subjects
[21,22]. Based on the multiple documented bioactive properties
of FSPs, their inclusion in nanostructured materials is an inter-
esting strategy to explore. Alginate is a linear block co-polymer
constituted by homopolymeric (1→4)-linked poly-l- guluronate
(poly-G) and poly-d- mannuronate (poly-M) and by alternate
block of both residues. Its composition, summarized by the molar
ratio of d-mannuroate to l-guluronate residues (M/G ratio), along
with the molecular weight, are the main properties that dictate
the physicochemical, functional and bioactive properties of algi-
nate. Protein-polysaccharide complexes comprising alginate have
been reported, for example with bovin serum albumin [4,8,10] or
-lactoglobulin, whey protein isolate, or lysozyme [4,5,9,13]. How-
ever, so far, to the best of our knowledge, nanometric complexes
of alginate and a complex mixture of ﬁsh proteins have not been
documented. Hence, in this study, we have aimed to address the
formation of stable NCXs between these components, obtained by
electrostatic SA complexation. We  have established optimal con-
ditions for their preparation, characterized their major physical
properties and degradability, as well as their cytotoxicity in HeLa
and U2OS cell cultures.
2. Material and methods
2.1. Materials
Alginate (Manucol LKX 50DR) was purchased from FMC  Biopoly-
mers (Philadelphia, PA, USA). The M/G  ratio was 1.56 according
with manufacturer speciﬁcations and the Mw 451 kDa (as deter-
mined by SEC-HPLC with intrinsic viscosity and DRI detectors
and by use of a Universal Calibration curve of pullulan stan-
dards). Cod (Gadus morhua) from the North Sea was  obtained from
Hanstholm Fisk (Hanstholm, Denmark). All other reagents, unless
otherwise stated, were obtained commercially at analytical grade
from Sigma–Aldrich (St. Louis, MO,  USA), and used without further
puriﬁcation.
2.2. Preparation of FSP-Alg NCXs
2.2.1. FSP extraction and dialysis
Muscle tissue from a cod was stored vacuum packed at −30 ◦C
until use. The tissue samples were partly defrosted (30 min  at
room temperature) before extraction of the sarcoplasmic proteins.
The ﬁsh muscles were cut into small 25 g pieces. A total volume
of 250 mL  of ﬁsh buffer (50 mM Tris–HCl, pH 7.4, 1 mM EDTA)
was added. The mixture was  kept on ice and homogenized at
8000 × g for 3 × 30 s with 2 min  between each homogenization, fol-
lowed by centrifugation (11,200 × g, 20 min, 3 ◦C) and subsequently
the supernatant was dialyzed against water (Spectra/Por1 dialy-
sis tubing, 6–8 kDa MWCO). Dialysis was  performed for 48 h with
change of water four times. The dialyses solution was centrifuged
(11,200 × g, 20 min, 3 ◦C) and the supernatant freeze dried. The
freeze dried protein was stored at −20 ◦C until use.
2.2.2. Zeta potential determination of FSP and alginate at
different pH
The zeta potential () at varying pH was  measured for FSP
and alginate solutions in 0.1 M NaCl and titrated with dilute HCl
solutions. This was conducted by mixed laser doppler electrophore-
sis and phase analysis light scattering (M3-PALS) in a Malvern
Zetasizer NANO-ZS (Malvern Instruments, Worcestershire, UK)
equipped with a 4 mW He/Ne laser beam operating at  = 633 nm.
The titration was conducted using an MPT-2 autotitration unit that
enabled automatic addition of acid during the neutralization pro-
cess. The measurements were made on a ZEN1060 folded capillary
cell. Mean ± SD, n = 3 are reported.
2.2.3. NCX preparation and puriﬁcation
Alginate stock solution (1.93 mg/mL) was  stirred gently
overnight to allow complete dissolution of the polymer. FSP
stock solution (12.89 mg/mL) was  prepared on the day of parti-
cle preparation and was  ﬁltered (0.4 m ﬁlter) before use. The
stock solutions of alginate and FSP were diluted with deminer-
alized water to the desired concentrations, and pH was  adjusted
to 3.8. NCXs were formed in 24-well plates by rapidly mixing the
FSP solution into the alginate solution in the volume ratio cor-
responding to 1.5 (e.g. 720 L alginate solution and 1080 L FSP
solution), with a pipette. The particles were incubated for 30 min
at room temperature in the 24-well plate, before transfer to Eppen-
dorf tubes containing a glycerol bed (approximately 10% of the total
volume of NCXs) to enable subsequent re-suspension. NCXs were
puriﬁed by centrifugation (12,000 × g, 60 min, 25 ◦C), followed by
removal of the supernatant, and then resuspension of the pellet
in demineralized water. Particles were stored at 4 ◦C until further
analysis.
2.3. NCX characterization
2.3.1. Measurement of particle size and zeta potential
The particle size and size distribution (PDI) was analyzed by
dynamic light scattering with non-invasive back scattering (DLS-
NIBS) at an angle of 173◦ with automatic attenuator setting and the
zeta potential by mixed laser Doppler electrophoresis and phase
analysis light scattering (M3-PALS). Both measurements were con-
ducted in a Malvern Zetasizer NANO-ZS (Malvern Instruments,
Worcestershire, UK) equipped with a 4 mW He/Ne laser beam oper-
ating at  = 633 nm.  The NCXs were diluted before transferring to
the measurement cuvette (particle size: 20 L NCX and 980 L
water; zeta potential: 10 L NCX and 990 L water). All measure-
ments were performed at 25 ± 0.2 ◦C. Mean ± SD,  n = 3 are reported.
2.3.2. Colloidal stability of the NCXs
The colloidal stability of the NCXs against aggregation in the dif-
ferent solvents (demineralized water, gastric buffer (GF) (34 mM
NaCl pH 1.2)), intestinal buffer (IF) (50 mM KH2PO4 pH 6.8) or
HEPES buffered glycose (HBG) (5% glucose, 20 mM HEPES, pH 7.0),
and pH 2–9 was tested by adding an aliquot of NCXs to the solvent
and incubate it for a given period of time at 37 ± 0.2 ◦C. The NCXs
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were subsequently analyzed according to the method described in
the section above. Mean ± SD, n = 3 are reported.
2.3.3. NCX morphology investigations by transmission electron
microscopy
The NCXs were negatively stained with 1% phosphotungstic acid
on copper 200 mesh grids. The NCXs were imaged with a transmis-
sion electron microscope (TEM) CM100 (Philips, Eindhoven).
2.3.4. Determination of FSP and NCXs protein composition
Sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS–PAGE) was performed according to Laemmli [23], to deter-
mine the protein composition in FSP, FSP-Alg NCXs and the
supernatant after NCX formation. Samples were boiled for 2 min  at
98 ◦C in loading buffer (0.25 M Tris/HCl pH 6.8, 1% (w/v) SDS, 20% v/v
glycerol, 0.04% v/v bromphenol blue) before addition to tris–glycine
gels (4–20%, Novex®, Life technologies Ltd., Paisley, UK). Mark 12TM
unstained standard (Novex®, Life technologies Ltd., Paisley, UK)
was used as molecular marker. Gels were run at a constant volt-
age of 125 V in an XCell IITM chamber (Novex®, Life technologies
Ltd., Paisley, UK) and stained.
2.3.5. Determination of protein concentration
Protein concentration was determined according to the protocol
of the BCA protein assay kit (Pierce, IL, USA). Absorbance was mea-
sured using a microplate reader (Synergy 2 Multi-Mode Microplate
reader, BioTek®, VT, US). Mean ± SD, n = 3 are reported.
2.3.6. Determination of alginate concentration
Quantiﬁcation of alginate was performed using the 3-Phenyl-
phenol assay according to Blumenkrantz and Asboe-Hansen [24].
Brieﬂy, 20 L alginate containing sample was mixed with 1.2 mL
H2SO4/sodium tetraborate solution (12.5 mM sodium tetraborate
in concentrated H2SO4). Samples were heated to 98 ◦C for 5 min
and 20 L 3-phenyl-phenol solution (0.5% NaOH, 0.15% 3-phenyl-
phenol) was added to the cooled sample. Absorbance at 520 nm
was measured within 5 min. Mean ± SD, n = 3 are reported.
2.4. Enzymatic degradation of NCXs
For enzymatic degradation studies, NCXs (approximately
400 g FSP/mL) or pure FSP were incubated for 0 or 2 h on a
shaking table in either simulated gastric ﬂuid (SGF) (34 mM NaCl,
4.5 g/mL pepsin (activity of 3.260 units/mg protein), pH 1.2) or
simulated intestinal ﬂuid (SIF) (50 mM KH2PO4, 14.3 g/mL pan-
creatin (activity of 8× U.S.P. speciﬁcations), pH 6.8). t0 samples
were drawn immediately after the NCXs/FSP was  transferred to
the enzyme-containing solutions. Protein compositions of enzyme
treated samples were analyzed by SDS–PAGE.
2.5. Cytotoxicity of NCXs
The cytotoxicity of NCXs was evaluated using MTS assay
(CellTiter 96® AQueous Non-Radioactive Cell Proliferation assay,
Promega, Madison, WI,  USA). Cells (HeLa or U2OS) were seeded in
96-well plates at an initial density of 5000 cells per well. After 24 h
the cells were washed with PBS buffer before addition of 100 L
samples containing different concentrations of FSP, alginate, or
FSP-Alg NCXs. The samples were made by mixing different vol-
umes of FSP, alginate, or FSP-Alg NCX stock solutions with DMEM
without fetal bovine serum. Cells were incubated for 24 h with the
samples before addition of 20 L MTS  reagent to each well. The
metabolic activity was evaluated after incubation at 37 ◦C and 5%
CO2 for 1 h for HeLa cells, and 2 h for U2OS cells, by measuring
absorbance at 490 nm using a Wallac Victor3 plate reader (Perkin-
Elmer, Waltham, MA,  USA). Cytotoxicity was reported as percent
Fig. 1. Zeta potential as a function of pH for alginate (dashed, ) and FSP (full, ).
Both components were dissolved in 0.1 M NaCl and titrated with dilute HCl.
cell viability using untreated cells as 100% viability. Mean ± SD, n = 3
are reported.
3. Results and discussion
3.1. Determination of FSP-pI and alginate-pKa
To determine the optimal pH for electrostatic SA between
positively charged FSP and negatively charged alginate, the pH
dependence of the net charge of FSP and alginate was  investigated.
Fig. 1 shows the zeta potential as a function of pH for both compo-
nents. Notice that for FSP the zeta potential curve crosses zero at
pH 6.1. This point matches the mid-point of the sigmoidal titration
curve, and can accordingly be taken as the mean value of the FSP-pI.
In the case of alginate, the zeta potential curve also describes a sig-
moidal shape with a maximum inﬂexion centered at a pH value
of ∼2.9, which thus can be taken as the pKa of alginate. There-
fore, in the pH range ∼2.5–6.0 the net charge of FSP was  positive
charged while alginate was  negative, and pH 3.8 was  chosen for
NCX formation.
3.2. Determination of optimal FSP:alginate ratio for successful
NCX formation
To determine the optimal FSP:alginate ratio for the formation
of stable NCXs, a screening was  carried out, where FSP (concen-
trations between 0.35 and 1.36 mg/mL) were mixed with alginate
(concentrations between 0.44 and 1.06 mg/mL). The formation of
NCXs was recognized by a characteristic opalescence which was
easily judged by the naked eye. An overview of the results from the
screening tests is shown schematically in Fig. 2A. Mixing alginate
solutions (0.69–0.97 mg/mL) with FSP solutions (0.55–0.69 mg/mL)
resulted in spontaneous formation of stable NCXs. The NCXs were
characterized with respect to size and PDI (data not shown), which
eliminated the combinations marked dark grey in Fig. 2A, as the
size and PDI of the NCXs large and polydisperse. The remaining
candidates were further characterized with respect to particle size,
PDI and zeta potential. Surprisingly, it was  found that all candidates
gave rise to NCXs having similar properties. Therefore a represen-
tative candidate formulation was chosen (FSP:alginate mass ratio
0.69:0.97) for further characterization. Fig. 2B shows the particle
size distribution of the NCXs from the selected candidate, together
with a table summarizing particle size, PDI and zeta potential. The
main population had a mean Z-average diameter of 293 ± 5 nm.
A small peak corresponding to micron sized particles was also
detectable. This peak may  arise due to protein aggregates that
were not removed during the puriﬁcation; however since it was
a proportionally small population, the contribution to the overall
physical and biological properties was  regarded negligible. The
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Fig. 2. A) Phase diagram showing an overview of the screening for alginate and FSP NCXs, obtained by mixing both components at varying concentrations (water, pH 3.8,
room  temperature). White: no formation of NCXs; dark grey: formation of unfavorable NCXs, light grey: formation of favorable NCXs, light grey hatched: chosen candidate.
B)  Size distribution of NCXs from the chosen candidate. The measurements were carried out at room temperature (n = 3). The inset shows an overview of size, PDI and zeta
potential. C) TEM image of NCXs. Scale bar: 500 nm.
Fig. 3. A) Size distribution of NCXs after incubation in water for 1 and 72 h at room temperature. B) Table summarizing the z-average particle size of NCXs described in A),
mean  ± SD, n = 3. C–E) Size distribution of NCXs after incubation during 30 , 60 and 90 min in C) GF (pH 1.2), D) IF (pH 6.8) and E) HBG (pH 7.0), respectively, and F) table
summarizing the z-average particle size of NCXs described in C–E. Mean ± SD, n = 3.
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Fig. 4. (A) Z-average diameter and (B) zeta potential of FSP–Alg NCXs subjected to different pH, and (C) hypothesized particle structures at three different pH domains
(protein; neg.: blue, neut.: grey, pos.: red, alginate; neg.: green, neut.: yellow). (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the
web  version of the article.)
size distribution was large (PDI ≈ 0.35); however, given the very
complex mixture of proteins, and that no selection for particular
NCXs sizes was attempted a large size distribution was  expected.
The size of the NCXs was conﬁrmed by TEM (Fig. 2C), which also
conﬁrmed a spherical shape. The zeta potential was  −42 ± 0.3 mV,
which indicated that at the processing conditions the shell of the
NCXs was dominated by alginate.
To investigate the yield of production and the composition of the
nanoparticles, the proportional amount of FSP and alginate com-
plexed into NCXs were analyzed. Upon NCX formation 56 ± 3% of
the original amount of FSP and 82 ± 2% of the initial amount of algi-
nate were incorporated. Hence, the actual FSP:alginate mass ratio
in the NCXs was 0.4:0.8, which explains the pronounced negative
zeta potential of the NCXs.
3.3. Particle stability
3.3.1. NCXs stability in water during 72 h
The stability of FSP-Alg NCXs after 1 and 72 h incubation in water
was investigated by measuring changes in particle sizes over time
(Fig. 3A). A small decrease in particle size was observed after 72 h
in water. The alternated chemical environment, compared to the
processing conditions, may  have caused the FSP and alginate to
rearrange inside the NCXs, which in this case led to a small decrease
in particle size. The limited changes observed suggested that the
NCXs in general were stable.
3.3.2. NCXs stability in selected buffer systems
NCX stability in GF (pH 1.2), IF (pH 6.8), and HBG (pH 7.0)
were investigated by studying changes in particle size and PDI
of the NCXs after incubation for 30, 60 and 90 min  in the differ-
ent solvents. In GF (Fig. 3C) and IF (Fig. 3D), the size of the NCXs
Fig. 5. SDS–PAGE of protein composition in lane 1: marker, lane 2: FSP, lane 3: lane
NCXs: 4: Supernatant after NCX formation.
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Fig. 6. SDS–PAGE of FSP and NCX degradation products in SGF (A) and SIF (B). M:  Marker; E: SGF/SIF. t = 0 samples were drawn immediately after the NCXs/FSP was transferred
to  the enzyme-containing solutions.
remained constant throughout 90 min. In HBG (Fig. 3E) the size
of the NCXs was increased after 30 min, compared to the other
buffer systems, which indicate that reorganization inside the par-
ticles took place. However neither the particle size nor the PDI
changed during 90 min, suggesting that the NCXs were stable in
HBG. All together the results indicated that the NCXs were stable
in the timespan of the experiments in the various physiologically
relevant environments.
3.3.3. NCXs stability at different pH values
The stability of NCXs originally formed at pH 3.8, and subse-
quently incubated for 10 min  in different pH environments, was
evaluated by particle size and zeta potential measurements (Fig. 4A
and B). Fig. 4C shows a model of the hypothesized structure of
the NCXs at three pH domains; pH < 3.0, 3.0 < pH < 6.0 and pH > 6.0.
Between pH 3 and 6, alginate and FSP were fully oppositely charged,
causing the particles to remain stable. Fig. 4B shows that the zeta
potential in this pH range was negative, indicating that the shell
was dominated by the negatively charged alginate, and hence the
majority of the protein may  be in the core of the NCXs. At pH ∼ 3.0
the particles aggregated (size data point not shown), most likely
due to neutralization at the NCX surface. At pH 2, the zeta poten-
tial was positive. This may  be caused by protonation of protein side
chains peeping out through the alginate layer, resulting in a pos-
itive zeta potential. The positive surface caused the NCXs to repel
each other, thus avoiding aggregation. Above pH 6 both alginate
and FSP were negatively charged. The reason to particle stability
even above the favorable pH range (pH 3–6), may  be due to slow
kinetics of FSP deprotonation within the NCXs, causing some resid-
ual side chains to remain protonated, even at high pH values. The
slow deprotonation rate suggests that the NCXs are composed of a
dense network of alginate and FSP.
3.4. Protein composition of NCXs
The protein composition of FSP, NCXs and the supernatant after
particle formation was investigated with SDS–PAGE (Fig. 5). The
band patterns for the three samples were all similar, indicating that
the NCXs consisted of a mixture of all FSP proteins, rather than
speciﬁc proteins of either high or low molecular weight.
3.5. Degradability of NCXs by proteolytic enzymes
The enzymatic degradation of FSP and NCXs was  studied in SGF
and SIF by SDS–PAGE. The protein compositions for FSP and NCXs,
after exposure to pepsin for a few seconds, are seen in Fig. 6A.
Changes in the band patterns for both FSP and NCXs, compared to
the band pattern for FSP, indicated that degradation of the proteins
was initiated immediately after contact with pepsin. After 2 h, only
trace amounts of proteins were left for both NCXs and in FSP. In SIF
(Fig. 6B), the degradation was slower. The majority of the proteins
were still present after a brief contact with pancreatin, but after 2 h
the majority of the proteins were degraded, and only proteins, or
protein degradation products, with molecular weight around 6, 14
and 36 kDa, respectively, were not degraded by pancreatin in the
timespan of the experiment.
3.5.1. Cytotoxicity of NCXs
Cytotoxicity of NCXs, alginate and FSP were evaluated by the
MTS  assay in HeLa and U2OS cell lines (Fig. 7A and B) using the
MTS  assay. Individually, alginate and FSP did not compromise cell
viability; however, when combined into NCXs, as the concentration
of NCXs increased, cytotoxicity was  induced, and at 300 g/mL the
viability was  decreased to approximately 50%. This behavior was
evident in both cell lines. Vaitkuviene˙ et al. have previously shown
that glycerol has an effect on cell viability [25]. In the present study
glycerol was used in the puriﬁcation of the NCXs. To investigate
if glycerol had a similar effect on cytotoxicity on HeLa and U2OS
cells, the cytotoxicity of isolated FSP-Alg NCXs (in glycerol) were
compared to the cytotoxicity of non-isolated NCXs (Fig. 7A). For
the non-isolated NCXs (without glycerol), the dose needed for
inducing cytotoxicity was displaced (e.g. at 150 g/mL no toxicity
was observed in the absence of glycerol, while a 20% reduction on
cell viability was  observed at the same dose of isolated NCXs in
glycerol). The decrease in cell viability may  thus partly be induced
by glycerol. However, even without glycerol the viability was
decreased at high NCX concentrations. Most likely there was no
uptake of FSP or alginate as separate compounds by the cells, but
when complexed into NCXs, uptake took place. At high NCX con-
centrations there may  not have been enough capacity to hydrolyze
the components, which thus resulted in decreased viability.
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Fig. 7. Cytotoxicity test of NCXs on HeLa cell line (A) and U2OS cell line (B). FSP (),
alginate (), NCXs (), NCXs without glycerol ().
4. Conclusion
NCXs were made from FSP and alginate by bulk mixing, utiliz-
ing electrostatic SA interactions between the two  components at
pH 3.8. Screening different combinations of alginate and FSP solu-
tions revealed optimal conditions for NCX formation, but it also
showed that the NCX formation entail great stability with respect
to variations in processing concentrations, as changes in FSP and
alginate processing concentrations, within a certain concentration
range, did not affect particle properties. The zeta potential of the
NCXs at the processing conditions was −42 ± 0.3 mV,  and therefore
the shell of the NCXs was hypothesized to be dominated by algi-
nate, whereas FSP mainly was present in the core. The NCXs were
stable during 72 h in water and during 90 min  in GF, IF, and HBG,
besides at different pH value, however changing the pH value from
optimal conditions did affect the electrostatic interactions hold-
ing the particles together. The remained stability of the particles in
the timespan of all experiments indicated that the NCXs in general
were stable and composed of a dense network of alginate and FSP.
As separate compounds alginate and FSP did not compromise cell
viability, and only at high NCX concentrations cell viability in HeLa
and U2OS cell lines were affected. The ease, by which the NCXs were
formed, together with the distinct stability of the particles, makes
the use of NCXs in, for instance biomedical, food or biotechnological
applications, appealing.
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